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Stroke in young adults
Stroke is defined as a rapidly evolving neurological deficit caused by an occlusion or rupture 
of a cerebral blood vessel. Patients with a stroke may for example suffer from hemiplegia, 
aphasia or visual problems, which may very much influence daily functioning. Stroke can 
be subdivided into a transient ischemic attack (TIA), ischemic stroke and intracerebral 
haemorrhage (ICH), depending on the cause and duration of symptoms. 
Each year, 15 million people worldwide are affected by stroke and 10-14% of those are under 
the age of 50 years and are therefore called ‘young stroke patients’.1, 2 Incidence of stroke in 
this age group is increasing, which has been explained by an also increasing prevalence of 
traditional vascular risk factors, such as diabetes mellitus, hypertension and dyslipidemia.3, 4
After stroke, patients may develop various complications, such as post-stroke epilepsy and 
recurrent strokes or other vascular events. Especially for this younger age group, long-term 
information on the years after the stroke is of utmost importance, as these patients usually 
have a long life ahead of them. However, reliable long-term information after a stroke at 
young age is scarce.
Post-stroke epilepsy after stroke at young age
In elderly stroke patients up to 14% develop post-stroke epilepsy during the course of their 
disease.5-12 Due to its unpredictability, epileptic seizures very much influence daily living. In 
studies among elderly it has been shown that epileptic seizures negatively influence stroke 
recovery, functional outcome and mortality. 11, 13-16 However the results of those studies 
cannot necessarily be generalised to younger patients, as they often are in a different period 
of life with work that may be considered unsuitable or unsafe. In addition the necessity to 
use long-term antiepileptic medication might have a particular high impact given their active 
lives with work, young families or future pregnancies and many social activities. However, 
unfortunately information on the frequency of post-stroke epilepsy, its treatment and the 
association with outcome after a stroke at young age is not available. 
Recurrent vascular disease after stroke at young age
Information on the long-term prognosis of patients with a stroke at young age is becoming 
more and more available and it has become increasingly clear that patients remain at a 
substantial risk of recurrent vascular events.17 For clinicians it is indispensable to assess the 
risk of recurrent vascular disease at an individual level, both to inform patients on the long-
term course of their disease as well as to determine optimal secondary prevention strategies 
for the individual patient in the decades after the stroke. Only a few large studies on patients 
with a stroke at young age have tried to identify which particular risk factors were associated 
with recurrent vascular events18, 19, however follow-up in those studies was limited. 
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Another possible consequence of the higher burden of traditional vascular risk factors 
among young stroke patients might be the development of small vessel disease, such as 
lacunes, microbleeds and white matter hyperintensities (WMHs) of presumed vascular origin. 
In the elderly, the presence of small vessel disease has convincingly been related to vascular 
risk factors and accelerated cognitive and motor decline.20-22 Accordingly, apart from the 
stroke itself, coinciding small vessel disease might also contribute to post-stroke prognosis 
in young stroke survivors. So far, the prevalence of the full spectrum of small vessel disease a 
comparison with controls has never been investigated in patients with a stroke at young age.
Aim of the thesis and study design
The aim of this thesis was to investigate the long-term consequences of a stroke in patients 
aged 18-50 years, especially the epidemiology of post-stroke epilepsy and recurrent vascular 
disease. The studies presented in this thesis are based on the Follow-Up of Transient ischemic 
attack and stroke patients and Unelucidated Risk factor Evaluation (FUTURE) study, a 
prospective cohort study designed to investigate aetiologies and long-term consequences of 
a young stroke. The FUTURE study comprises 1005 consecutive patients with a TIA, ischemic 
stroke or ICH, aged 18-50 years, who were admitted to the Radboud University Medical 
Centre Nijmegen from January 1, 1980 until November 1, 2010. Patients with a traumatic 
hemorrhagic, haemorrhage in known cerebral metastasis or primary brain tumor, cerebral 
venous sinus thrombosis, subarachnoid haemorrhage or ICH attributable to known ruptured 
aneurysm, and retinal infarction were excluded.
An extensive follow-up investigation took place between November 1, 2010 and January 1, 
2012.
At follow-up, 147 control subjects were recruited among patients’ spouses, relatives, or social 
environment. They had to be at least 18 years old without a clinical history of TIA or stroke. 
The control group and patient group were matched for age, sex, and level of education. 
Outline of this thesis
In chapter 2 the rationale and design of the FUTURE study is described.
Part II describes the incidence of post-stroke epilepsy after a stroke at young age (Chapter 
3). Subsequently, we investigated whether post-stroke epilepsy after an ischemic stroke or 
TIA at young age was related to outcome. In chapter 4 we investigated the association with 
functional outcome and in chapter 5 we report the association of post-stroke epilepsy with 
cognitive performance. The association of post-stroke epilepsy after an ischemic stroke or 
TIA with mortality is shown in chapter 6. 
Part III describes the long-term vascular consequences after a first-ever ischemic stroke or 
TIA at young age. Chapter 7 describes the risk of recurrent vascular events. In addition risk 
factors associated with recurrent vascular events were identified. In chapter 8 the prevalence 
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of small vessel disease, including lacunes of presumed vascular origin, microbleeds and 
WMHs are reported and compared to controls.
Part IV describes the rational and design of a new prospective multicentre study on aetiology 
and prognosis after a stroke at young age, the Observational Dutch Young Symptomatic 
StrokE StudY (ODYSSEY) (chapter 9).
In the final part of this thesis (Part V), the main results are discussed (chapter 10) and 
summarized (chapter 11 and chapter 12). All findings are put into perspective and 
methodological aspects are discussed. In addition, implications for clinical practice and 
directions for future research are made. 

2.
Risk factors and prognosis of young stroke. 
The FUTURE study
Published as:
Risk factors and prognosis of young stroke. The FUTURE study: 
a prospective cohort study. Study rationale and protocol.
Loes C.A. Rutten-Jacobs, Noortje A.M.M. Maaijwee, Renate M. Arntz, Mayte E. van Alebeek, 
Pauline Schaapsmeerders, Hennie C. Schoonderwaldt, Lucille D. Dorresteijn, Sebastiaan 
Overeem, Gea Drost, Mirian C. Janssen, Waander L. Van Heerde, Roy P.C. Kessels, Marcel P. 
Zwiers, David G. Norris, Maureen J. van der Vlugt, Ewoud J. van Dijk, Frank-Erik de Leeuw. 
BMC Neurol, 2011; 11:109
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Abstract
Background and objective: Young stroke can have devastating consequences with 
respect to quality of life, the ability to work, plan or run a family, and participate in social 
life. Better insight into risk factors and the long-term prognosis is extremely important, 
especially in young stroke patients with a life expectancy of decades. To date, detailed 
information on risk factors and the long-term prognosis in young stroke patients, and more 
specific risk of mortality or recurrent vascular events, remains scarce.
Methods/Design: The FUTURE study is a prospective cohort study on risk factors and 
prognosis of young ischemic and hemorrhagic stroke among 1 006 patients, aged 18-50 
years, included in our study database between 1-1-1980 and 1-11-2010. Follow-up visits at 
our research centre take place from the end of 2009 until the end of 2011. Control subjects 
will be recruited among the patients’ spouses, relatives or social environment. Information 
on mortality and incident vascular events will be retrieved via structured questionnaires. In 
addition, participants are invited to the research centre to undergo an extensive sub study 
including MRI.
Discussion: The FUTURE study has the potential to make an important contribution to 
increase the knowledge on risk factors and long-term prognosis in young stroke patients. 
Our study differs from previous studies by having a maximal follow-up of more than 30 
years, including not only TIA and ischemic stroke but also intracerebral hemorrhage, the 
addition of healthy controls and prospectively collect data during an extensive follow-
up visit. Completion of the FUTURE study may provide better information for treating 
physicians and patients with respect to the prognosis of young stroke.
Risk factoRs and pRognosis of young stRoke. the futuRe study 
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Introduction
Up to 12% of all strokes occur in patients between 18-50 years (‘young’ stroke)23, affecting 
about 5000 patients each year in the Netherlands and about 2 million young people 
each year worldwide. In a substantial proportion of roughly one third the aetiology 
remains unelucidated. In terms of prognosis a ‘young’ stroke has a dramatic influence on 
independency and quality of life as it occurs in the period of life that people start to form 
families, make decisive career moves, and have an active social life. Uncertainty about long-
term prognosis affects choices and planning affiliated with these life events.
Whereas risk factors and prognosis in patients who develop a stroke at higher ages (usually 
over 70 years) are among the best studied topics in clinical medicine, this does not hold 
true for young stroke. At higher ages, almost all risk factors have atherosclerosis in their 
final common pathway. However, this cannot simply be extrapolated to young stroke as the 
underlying cause of stroke is usually different from that in elderly and may therefore also have 
a different prognosis both with respect to functional stroke outcome as to risks of recurrent 
stroke or other major vascular events. Even more, the identification of risk factors for young 
stroke so far has often been based on the occurrence of presumed risk factors in consecutive 
series of young stroke patients, without methodological sound comparison with controls.
The ‘long-term’ perspective in an on average over 70 years ‘old’ stroke patient differs from 
that of a 30 years ‘young’ stroke patient, and particularly studies with a long-term follow-up 
of more than 10 years are lacking in the young stroke field. Studies thus far, usually with a 
mean follow-up duration of less than 7 years, report highly variable post-stroke mortality 
and risk of incident vascular disease.2, 19, 23-26 These large differences across studies are well 
explained because young stroke is a heterogeneous disease and most studies were small, 
had different selection criteria, did not investigate patients in person but relied on telephone 
interviews and outcome assessments and follow-up planning was not uniform and often 
suboptimal. Although stroke includes both ischemic stroke and intracerebral haemorrhage 
(ICH), almost all studies have excluded the investigation of aetiology and prognosis of young 
hemorrhagic stroke.
Except for recurrent vascular disease and persistent motor and language impairments, post-
’young’ stroke quality of life will most likely also be determined by cognitive dysfunction, 
depressive symptoms, fatigue, and specific post-stroke complications such as epilepsy, 
because those determine the ability to (return to) work and to have a normal family and 
social life. Data on those aspects in the very long-term follow-up of young stroke patients are 
even more scarce.
Although the absolute number of young stroke is lower than stroke among the elderly, the 
total number of years that young stroke patients as a whole will live with the consequences 
of the stroke exceeds that of older stroke survivors due to far longer survival.
This justifies a properly designed and executed study on risk factors and prognosis of 
young stroke, compared with controls. We therefore set up the FUTURE study (Follow-Up of 
Transient ischemic attack and stroke patients and Unelucidated Risk factor Evaluation study), 
Chapter 2
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the largest single-centre prospective cohort study on risk factors and prognosis of young 
transient ischemic attack (TIA), ischemic stroke and ICH patients (n=1 006) and controls.
Methods/Design
The FUTURE study is a prospective cohort study that aims to investigate the causes and 
consequences of a young stroke. The Medical Review Ethics Committee region Arnhem-
Nijmegen approved the study.
Patients
The department of neurology has a long-standing interest in the aetiology and prognosis of 
young stroke and therefore maintains a prospective registry of all consecutive young stroke 
patients with a standardised collection of baseline and clinical characteristics (see baseline) 
since the 1970’ies.27 For the current FUTURE study, all consecutive TIA, ischemic stroke 
patients with presumed arterial origin or those with an ICH that sought medical attention for 
these disorders at the department of neurology of the Radboud University Nijmegen Medical 
Centre between 1-1-1980 and 1-11-2010 will be eligible for participation in the study.
Inclusion criteria
1. TIA, ischemic stroke of presumed arterial origin or ICH
2. Date of onset between 1-1-1980 and 1-11-2010
3. Age 18-50 at onset
Exclusion criteria
1. Traumatic hemorrhage
2. ICH in known cerebral metastasis or primary brain tumor
3. Ischemic/haemorrhagic stroke due to cerebral venous sinus thrombosis
4. ICH due to ruptured cerebral aneurysm
5. Any subarachnoid haemorrhage 
6. Retinal infarct
TIA was defined as a rapidly evolving focal neurological deficit with no other than a vascular 
cause lasting less than 24 hours. Stroke was defined similarly, but with symptoms lasting 
more than 24 hours. On the basis of radiological findings, stroke was further subdivided into 
ICH and ischemic stroke.
As the diagnostic process may have changed during more than 30-year period all initial 
diagnoses were reviewed by a panel of 2 experts from a pool of 4 (FEdL, EvD, RA, LJD) and in 
cases of disagreement a consensus meeting was held to adjudicate the event.
1006 patients who had sought medical attention at our University Medical Centre between 
1-1-1980 and 1-11-2010 fulfilled the inclusion and exclusion criteria. Characteristics of our 
baseline population (at the time of their qualifying event) are reported in table 1.
Risk factoRs and pRognosis of young stRoke. the futuRe study 
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Controls
Control subjects will be recruited among the patients’ spouses, relatives or social 
environment.
They have to be at least 18 years old without a history of any TIA or stroke before the age of 
50 at the moment of inclusion.
Baseline
At baseline (during the occurrence of the qualifying event for the study) a minimal dataset 
has been collected that consists of demographics, stroke subtype, risk factors and additional 
investigations (table 2). The completeness of the baseline dataset varies among patients due 
to changes in standard diagnostic procedures over the last 30 years.
Current common rating scales for the severity and cause of stroke did not exist at the time 
when a substantial proportion of our patients experienced their qualifying event. Therefore, 
a rating of both the severity (NIHSS) and cause (Trial of Org 10172 in Acute Stroke Treatment 
[TOAST]) was done for all cases retrospectively by a validated approach.28
Follow-up
Information on the vital status will be available either from hospital data or through 
coupling of patient records with data from the municipality registry. All patients alive will be 
approached for the follow-up assessment according to a 2-step approach.
First, all patients will be contacted by letter to inform them about the study; subsequently 
they will be contacted by phone. In case the patient has moved, the municipality register of 
the last known residence will be contacted to trace the patient. In cases of an invalid phone 
number, a second letter will be sent asking the patient to contact our centre to provide a 
correct phone number. Subsequently, when a patient does not respond to the second 
letter, the last known general practitioner will be contacted to provide us with updated 
Table 1. Baseline population characteristics
Total population Time of index event
1980-1989 1990-1999 2000-2010
n 1008 223 250 535
Male, n (%) 471 (46.7) 109 (48.9) 129 (51.6) 233 (43.6)
Age at index event, mean (SD) 40.2 (8.0) 39.2 (8.3) 39.7 (8.7) 40.8 (7.4)
Index event
TIA, n (%) 276 (27.4) 53 (23.8) 40 (16.0) 183 (34.2)
Ischemic stroke, n (%) 632 (62.7) 144 (64.6) 190 (76.0) 298 (55.7)
ICH, n (%) 100 (9.9) 26 (11.7) 20 (8.0) 54 (10.1)
Abbreviations: SD=standard deviation, TIA=transient ischemic attack; ICH=intracerebral haemorrhage
Chapter 2
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contact details. The patient will be considered lost to follow-up when known alive, but when 
untraceable via the procedure described above.
Subsequently, patients will be given the opportunity to participate in an extensive sub 
study. If they agree to do so, they will be invited to visit our research centre for additional 
investigations including a structured interview, cognitive assessment, physical and 
neurological examination, an extensive magnetic resonance imaging (MRI) protocol, an 
electrocardiogram (ECG) and an ultrasonography of the carotid arteries (Table 2). In addition, 
blood samples (serum/plasma/DNA) will be taken for future analysis. When patients are not 
able to visit our research centre the same investigations will be performed at their homes, 
except for the ultrasonography of the carotid arteries, ECG and MRI scan. Controls will 
undergo the same protocol as patients.
The follow-up has started at the end of 2009 and is planned to finish at the end of 2011. 
All these participants signed an informed consent.
Outcome events
The primary outcome of the study will be all-cause mortality and the composite endpoint 
of death from all vascular causes; non-fatal stroke, non-fatal (silent) myocardial infarction, 
cardiovascular procedures (coronary artery bypass grafting, percutaneous transluminal 
coronary angioplasty, carotid endarterectomy and other arterial revascularization 
procedures), whichever occurred first. We will perform separate analysis for the occurrence of 
fatal or non-fatal stroke. Causes of death will be categorized into ischemic stroke, intracerebral 
haemorrhage, cardiac causes, other vascular causes or non-vascular causes. If we cannot 
obtain information about the cause of death, the event will be classified as unspecified.
Secondary outcomes are seizures (classified according to the International League Against 
Epilepsy [ILAE])29 and dementia (according to DSM-IV).
Whenever an outcome event is suspected with the aid of a standardised, structured 
questionnaire, information retrieved will be verified and adjudicated by physicians from 
the appropriate specialty. In case a patient has died, this information will be retrieved from 
their general practitioner or a relative. If there is no information available, the event will be 
classified as a possible event.
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Table 2. Schedule of assessments in the FUTURE study
Baseline Follow-up
Assessment
Demographics
Ethnicity                       X
Education                       X
Marital status                       X
Social/living status                       X
Stroke Characteristics
Qualifying event X
Symptoms at onset X
Discharge date and destination X
TOAST X
NIHSS at admission and at discharge X
mRS at discharge X
Medical History
History of any cardiovascular disease X                       X*
Cardiovascular risk factors X                       X*
Family history of cardiovascular disease X                       X
Medication use X                       X*
Stroke related surgical procedures X                       X*
Epilepsy X                       X*
Neuropsychological examination
Global cognitive function
Mini Mental State Examination X                       X
Verbal memory function
Rey Auditory Verbal Learning Test                       X
Visuospatial memory
Rey’s Complex Figure Test                       X
Speed of information processing
Symbol-Digit Substitution Task                       X
Stroop test                       X
Working memory
Paper and Pencil Memory Scanning Tasks                       X
Executive functioning
Animal Fluency task                       X
Attention
Verbal series attention test                       X
Subjective cognitive failures
Cognitive failures questionnaire                       X
Depressive symptoms
Structured questionnaire depressive symptoms                       X*
Mini International Neuropsychiatric Interview                       X
Centre of Epidemiological Studies Depression Scale                       X
Hospital Anxiety and Depression Scale                       X
Chapter 2
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Table 2. Schedule of assessments in the FUTURE study (Continued)
Baseline Follow-up
Assessment
Physical examination
Length and weight X                       X
Waist circumference                       X
Blood pressure X                       X
Heart rate X                       X
Neurological examination
Babinsky sign X
Sensory system
Quantitative measurement by vibration tuning fork                       X
Muscle strength
Medical Research Council Scale                       X
Mobility and activities of daily living
Timed-up-and-go -test                       X
Exercise expressed in metabolic equivalent value                       X*
Tinetti test (body balance and gait)                       X
mRS X                       X
Barthel Index                       X
IADL                       X
Additional questionnaires
Fatigue
Checklist on Individual Strength                       X
Health related quality of life
Short Form 36                       X
EQ-5D                       X
Stroke impact scale 3.0                       X
Sleep disturbances                       X*
List of Threatening Experiences                       X*
Work                       X*
Radiological examination
Confirmation of index event (CT or MRI) X
Angiography X
MRI
T1 magnetization-prepared rapid gradient echo                       X
FLAIR pulse sequences                       X
Transversal T2* weighted gradient echo sequence                       X
Diffusion Tensor imaging                       X
Resting state imaging                       X
Time-of-flight angiography                       X
Ancillary investigation
Electrocardiogram X                       X
Ultrasonography of the carotid arteries X                       X
Abbreviations: mRS=modified Rankin Scale; TOAST= Trial of Org 10172 in Acute Stroke Treatment; NIHSS=National 
Institutes of Health Stroke Scale;  IADL=instrumental actitivities of daily living; CT=computed tomography; 
MRI=magnetic resonance imaging. * Variables were collected both for the period before and after the index event.
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Assessment of variables during follow-up
Demographics and life style
Standardised questionnaires on demographics, education (classified using 7 categories; 
‘1’ being less than primary school and ‘7’ reflecting an academic degree)30, marital status, 
living conditions, and life style habits (alcohol consumption, smoking, exercise) will be 
administered. Alcohol consumption will be defined as units per day and the age at which 
alcohol consumption had started (and ended if stopped) will be noted. Cigarette smoking 
behaviour will be defined as never, former and current. Subsequently, former and current 
smoking behaviour will be quantified as the number of pack-years, calculated as the number 
of packs of cigarettes smoked per day multiplied by the number of years a participant had 
smoked. Exercise will be expressed in the metabolic equivalent value according to accepted 
standards.31
Medical history
Structured, standardised questionnaires will be used to assess participants history of 
hypertension, diabetes mellitus, atrial fibrillation, TIA, stroke, myocardial infarction, 
coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, carotid 
endarterectomy and other arterial revascularization procedures 32-35, migraine with or without 
aura36, pregnancy and malignancy. Whenever a primary or secondary outcome event is 
suspected with the aid of this standardised, structured questionnaire, information retrieved 
will be verified and adjudicated by physicians from the appropriate specialty (see outcome 
events). The presence of a family history of myocardial infarction, cerebrovascular disease 
and diabetes mellitus in next of kin will be recorded.
Epilepsy
Each patient will be evaluated for a history of epilepsy by means of a standardised, 
structured questionnaire. Whenever epilepsy is suspected, information will be retrieved from 
the treating physician and verified and adjudicated by a neurologist (FEdL). Epilepsy will be 
classified according to the ILAE criteria.29 Post-stroke epilepsy will be subdivided into early 
(≤7 days post-stroke) and late (>7 days) post-stroke epilepsy.
Current medication
Current medication use and the age at which medication use started will be noted and 
classified according to the Anatomical Therapeutic Chemical classification system. (World 
Health Organisation Collaborating Centre for drug statistics and methodology, http://www.
whocc.no/atcddd/)
Neuropsychological assessment
We will administer an extensive neuropsychological test battery that encompasses items 
from other large-scale epidemiological studies covering the main cognitive domains.37, 38 
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Global cognitive function will be assessed using the Mini Mental State Examination.39 Verbal 
episodic memory function will be assessed by the 3-trial version of the Rey Auditory Verbal 
Learning Test (RAVLT) that also includes a delayed free-recall and recognition trial, a test used 
to evaluate the ability to acquire and retain new verbal information.40 Visuospatial episodic 
memory will be administered by the Rey Complex Figure Test, that consists of 3 trials: a copy 
trial, an immediate recall trial after 3 minutes and a delayed-recall trial after 30 minutes.41 To 
evaluate speed of information processing and executive function, 2 tests will be used; the 
abbreviated Stroop Color Word Test (3 subtasks, the interference trial measuring response 
inhibition)42 and the Symbol-Digit Substitution Task, which is a modified version of the 
Symbol Digit Modalities Test.43 A verbal fluency task in which as many animals as possible 
have to be named within 60 seconds will be used to test semantic memory and executive 
functioning (response generation). To assess working memory, the Paper and Pencil Memory 
Scanning Task (4 subtasks)44 will be used. To evaluate attention, the verbal series attention 
test (VSAT) will be used.45 To register subjective cognitive failures we will administer the 
modified Cognitive Failures Questionnaire.46 The assessments will be carried out under 
standard circumstances in quiet rooms.
A standardised structured questionnaire used in previous large-scale epidemiological studies 
will be used to assess the history of depressive symptoms; normal reactions to stressful events 
or normal grief will carefully be excluded.21 In case of a depressive episode, age of onset, 
the medical advice and medication use will be registered. We defined ‘depression’ as those 
depressive episodes that have required attention of a general practitioner, psychologist, or 
psychiatrist. This definition includes minor depression, as well as more severe depression 
syndromes such as major depression and bipolar depression.21
In addition, participants will be screened for current depressive symptoms by means of the 
Mini International Neuropsychiatric Interview, part A, which is a short diagnostic structured 
interview based on the DSM-IV.47 Additionally, presence of actual depressive symptoms will 
be assessed by 2 self report questionnaires, the Centre of Epidemiologic Studies Depression 
Scale48 and the Hospital Anxiety and Depression Scale.49
Physical and Neurological Examination
Height and weight will be measured without shoes in light clothing. The body mass index 
will be calculated as weight divided by height (in meters) squared. The maximal waist 
circumference will be measured without shirt, in standing position, between the lowest rib 
and the iliac crest, at the end of normal expiration.50 Blood pressure and pulse rate will be 
measured in triplicate in supine position after 5 minutes rest. Subsequently one measurement 
is performed after 1 minute in upright position.34
The strength of the biceps, hand grip, iliopsoas, quadriceps and foot extensor muscles on 
both sides will be scored according to the medical research council scale.
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The sensory system will be assessed by a quantitative measurement by vibration tuning fork 
(Rydel-Seiffer®) on both first toes and both medial malleolus, also registering ankle oedema 
and the ankle jerk reflex.
Gait and balance
We will use a widely used modified version of the original Tinetti test with 17 items: 9 for body 
balance (score 0-16) and 8 for gait (score 0-12), with a maximum score of 28.51 It grades balance 
while sitting, standing with eyes open and closed, nudging and turning, gait initiation, stride 
length and width and symmetry. Functional mobility will be classified by using the widely-
used timed-up-and-go-test which is a timed test during which the participant is asked to rise 
from a standard armchair, walk 3 m, turn, walk back and sit down again.52 Each participant 
will perform the test 3 times.
Functional performance
As a measure of disability the Barthel Index and modified Ranking Scale (mRS) will be used.53 
The activities of daily living will be assessed by the instrumental activities of daily living 
questionnaire (IADL).54
Additional self-report questionnaires
Several primary sleep disorders are addressed using a number of screening questions. The 
presence of possible sleep disordered breathing is based on a history of snoring, witnessed 
sleep-related apnoeas and non-restorative sleep. Non-REM and REM parasomnias are 
addressed based on a history of sleepwalking, dream-enacting behaviour. Excessive daytime 
sleepiness will be assessed based on the presence of continuous feelings of sleepiness, 
sleep attacks or a combination of both. Finally, the presence of sleep-onset and/or sleep-
maintenance insomnia is recorded. 
For the assessment of fatigue we will use the Checklist on Individual Strength.55 The overall 
health status (quality of life) will be assessed with the Short Form 3656, 57, the EQ-5D58, and the 
Stroke Impact Scale.59
Adverse life events will be assessed with the 12-item List of Threatening Events, 6 months 
before the index event and subsequently the period after the index event. 60
Patients will be asked for their employment status in the month before their index event, 
within the first year after their index event and at time of the follow-up visit. Each period 
includes a description of occupation, working hours a week, adjustments in tasks, use of 
supporting devices and reasons for not working.
Ancillary Investigations
MRI protocol
MRI scanning will be performed on a 1.5-Tesla Magnetom scanner (Siemens, Erlangen, 
Germany). The scanning protocol includes whole brain 3D T1 magnetization-prepared 
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rapid gradient-echo (MPRAGE) sequence (TR/TE/TI 2730/2.95/1000ms; flip angle 7°; voxel 
size 1.0x1.0x1.0mm); FLAIR pulse sequences (TR/TE/TI 12220/85/2200 ms; voxel size 
1.0x1.2x3.0mm; slice gap 0.6 mm); transversal T2-weighted turbo spin echo sequence (TR/
TE 7440/96ms; voxel size 0.9x0.9x3.0 mm; slice gap 0.6 mm); Multi-slab 3D time of flight 
angiography sequence (TR/TE 24/7ms; voxel size 0.8x0.5x1.0mm) will be made of the carotid 
arteries and the circle of Willis. Gradient echo susceptibility weighted imaging sequence (TR/
TE 49/40ms; voxel size 0.8x0.7x1.0mm); DTI (TR/TE 9100/98ms; voxel size 2.2x2.2x2.2mm; 7 
unweighted scans, 61 diffusion weighted scans, with non co-linear orientation of the diffusion-
weighting gradient, and b value 1000s/mm²) and resting state imaging using a gradient echo 
EPI (TR/TE 1870/35ms; voxel size 3.5x3.5x3.0 mm; slice gap 0.5mm). During resting state, 
participants will be told not to concentrate on any particular subject, but just to relax with 
their eyes closed. The complete scanning protocol takes approximately 60 minutes.
Electrocardiogram 
An ECG will be performed and evaluated by a standardised assessment by an experienced 
cardiologist, registering frequency, cardiac rhythm, cardiac ectopias, cardiac axis, conduction 
time over the PQ, QRS and QTC intervals, conduction disturbances, left ventricle hypertrophy, 
pathologic Qs, infarction, repolarisation disturbances and acute ischemia. A final diagnosis is 
defined as normal, abnormal without clinical significance, abnormal with clinical consequences 
or pathologic ECG with immediate consultation of a cardiologist when necessary.
Carotid ultrasound
A carotid ultrasound assessment will be performed at which the intima media thickness 
will be measured in the distal (near the bulbus) left and right common carotid artery. All 
measurements will be performed using a phased array real-time scanner (Philips i-u22, The 
Netherlands) with a 17-5 MHz broadband linear transducer. The intima media thickness will 
be automatically measured by QLab® qualification software (V. 4.2.1.) according to previously 
described procedures.61 All ultrasound measurements will be performed by three experienced 
and specific trained clinical neurophysiology technicians.
Vena puncture
Fasting blood samples will be taken. Immediate analysis will include glucose, creatinine, 
lipid profile and complete blood count. Additional serum, plasma and DNA will be stored 
(-80°C) for future biochemical and genetic analyses.
Statistical analysis
Cumulative risk of primary and secondary outcomes will be estimated with Kaplan-Meier 
analysis. In the analysis of vascular events, patients who had died from other than the defined 
fatal endpoints will be censored at the time of death. Cox proportional hazard models will be 
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used to calculate the risk of suffering from any of the primary or secondary outcomes in the 
follow-up period, with adjustments for the necessary covariates. The relative risk (hazards 
ratios) will be calculated with their corresponding 95% confidence intervals (CIs).
Cross-sectional analysis (for example in the comparison between patients and controls of 
data acquired during the follow-up) of continuous variables will be done with Student’s 
t-test or analysis of variance or in case of skewed distributions which cannot be normalized 
corresponding nonparametric tests will be used. Chi-squared test will be used for cross-
sectional analysis of categorical variables.
Discussion
Detailed information on risk factors and the long-term prognosis in young stroke patients, and 
more specific the risk of mortality and recurrent vascular events, remains scarce. These data 
are often derived from selected patients (often with the exclusion of TIA and haemorrhagic 
stroke patients) in small sized studies with short follow-up without in person assessment of 
risk factors and outcomes. We therefore performed the FUTURE study, designed to investigate 
risk factors and to prospectively assess prognosis in a large cohort of young stroke patients.
Strong elements of our study are the inclusion of both TIA and haemorrhagic and ischemic 
stroke patients, the very long follow-up (up to 30 years), its sample size of over 1 000 
potential participants and the availability of baseline data of all consecutive patients in a 
single university medical centre. In addition, the extensive investigation during a follow-
up visit, including advanced neuroimaging has the potential of major contributions to the 
field. Our study differs from many other young stroke studies due to the inclusion of controls 
that enable us to compare the frequency of some presumed, but also unknown, risk factors 
between patients and controls. Detailed risk factor analysis can be done, not only for 
commonly documented risk factors but also for those that are rarely documented in medical 
records, like physical inactivity and sleep disturbances. Moreover, the inclusion of healthy 
controls provides the opportunity to distinguish consequences of a young stroke from other 
factors like aging effects.
We feel that completion of our study may contribute to a better understanding of the 
aetiology of young stroke and may provide better information for treating physicians and 
patients with respect to the prognosis of young stroke.
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Abstract
Background: Little is known about the incidence and risk of seizures after stroke in young 
adults. Especially in the young seizures might dramatically influence prognosis and 
quality of life. We therefore investigated the long-term incidence and risk of post-stroke 
epilepsy in young adults with a transient ischemic attack, ischemic stroke or intracerebral 
haemorrhage.
Methods and findings: We performed a prospective cohort study among 697 consecutive 
patients with a first-ever transient ischemic attack, ischemic stroke or intracerebral 
haemorrhage, aged 18-50 years, admitted to our hospital between 1-1-1980 till 1-11-2010. 
The occurrence of epilepsy was assessed by standardised questionnaires and verified by a 
neurologist. Cumulative risks were estimated with Kaplan-Meier analysis. Cox proportional 
hazard models were used to calculate relative risks.
After mean follow-up of 9.1 years (SD 8.2), 79 (11.3%) patients developed post-stroke 
epilepsy and 39 patients (5.6%) developed recurrent seizures. Patients with an initial late 
seizure more often developed recurrent seizures than patients with an initial early seizure. 
Cumulative risk of epilepsy was 31%, 16% and 5% for patients with an intracerebral 
haemorrhage, ischemic stroke and transient ischemic attack respectively (log-rank test 
ICH and IS versus TIA p<0.001). Cumulative risk of recurrent seizures was 23%, 8% and 
4% respectively (log-rank intracerebral haemorrhage versus ischemic stroke p=0.05, 
intracerebral haemorrhage versus transient ischemic attack p<0.001, ischemic stroke 
versus transient ischemic attack p=0.01). In addition a high NIHSS was a significant 
predictor of both epilepsy and recurrent seizures (HR 1.07, 95% CI 1.03-1.11 and 1.08, 95% 
CI 1.02-1.14).
Conclusions: Post-stroke epilepsy is much more common than previously thought. 
Especially patients with an intracerebral haemorrhage and a high NIHSS are at high risk. 
This calls upon the question whether a subgroup could be identified which benefits from 
the use of prophylactic antiepileptic medication. Future studies should be executed to 
investigate risk factors and the effect of post-stroke epilepsy on quality of life.
IncIdence of post-stroke epIlepsy
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Introduction
The incidence of epilepsy after stroke in elderly ranges from 2% to 14%, depending on study 
population, stroke subtype and definitions of epilepsy.5-11 Post-stroke epilepsy has a negative 
effect on stroke recovery and quality of life.11, 13-15 However information on post-stroke epilepsy 
is only available from studies containing elderly stroke patients, which can not necessarily be 
generalised to the young. Especially in young patients with a long life expectancy, seizures 
might have a dramatic influence on quality of life and disability due to its negative effect on 
stroke recovery and unpredictability. Due to this unpredictability, work may be considered 
unsuitable or unsafe by employers, which could ultimately result in unemployment of these 
young patients. Thereby seizures may not only influence life of the individual patient, but 
may have an impact on family and community as well.62 In addition the necessity to use long-
term antiepileptic medication might have a particular high impact given their active lives 
with work, young families and many social activities. Surprisingly little is known about the 
long-term incidence and risk factors of post-stroke epilepsy after a stroke in young patients. 
The only studies performed so far were usually small, had a short follow-up and different 
definitions of post-stroke epilepsy. In addition those studies were not designed to investigate 
the risk of epilepsy and only included patients with an ischemic stroke and not those with a 
transient ischemic attack (TIA) or intracerebral haemorrhage (ICH).7, 23, 26, 63, 64
Quantification of post-stroke epilepsy frequency and risk factors is a first step in both 
informing young stroke patients and evaluating and developing treatment strategies. The 
aim of this study was therefore to investigate the long-term incidence and risk of post-stroke 
epilepsy and epilepsy with recurrent seizures in patients with a TIA, ischemic stroke or ICH at 
young age.
Methods
Patients and study design
This study is part of the “Follow-Up of Transient ischemic attack and stroke patients and 
Unelucidated Risk factor Evaluation”-study (FUTURE study), a prospective cohort study that 
investigates causes and consequences of stroke in young adults. Details of the study have 
been described elsewhere.65 The Medical Review Ethics Committee region Arnhem-Nijmegen 
approved the study.
The FUTURE study comprises all consecutive patients with a TIA, ischemic stroke or ICH, 
aged 18 – 50 years, admitted to the Radboud University Nijmegen Medical Centre from 1-1-
1980 till 1-11-2010. TIA was defined as a rapidly evolving focal neurological deficit, without 
positive phenomena such as twitches, jerks or myoclonus, with no other than a vascular 
cause lasting less than 24 hours. Stroke was defined as focal neurological deficit persisting 
for more than 24 hours.66, 67 On basis of radiological findings, stroke was subdivided into ICH 
and IS. Exclusion criteria were previous stroke or TIA, traumatic hemorrhaege, haemorrhage 
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in known cerebral metastasis or primary brain tumor, cerebral venous sinus thrombosis, 
subarachnoid haemorrhage or ICH due to known ruptured aneurysm and retinal infarction. 
For the present study only patients with a first-ever stroke were included and history of 
seizures was an additional exclusion criteria.
Patients were included prospectively between 1980 and 2010 with a standardised collection 
of baseline and clinical characteristics (including demographics, stroke subtype, vascular 
risk factors and a history of epilepsy). Furthermore all patients underwent neurological 
examination and brain imaging at the time of their index event.65 The assessment of stroke 
aetiology (Trial of Org 10172 in Acute Stroke Treatment [TOAST])68 and severity (National 
Institutes of Health Stroke Scale (NIHSS)69 and modified Rankin scale (mRS)70) was done for 
all cases retrospectively by a validated approach,28, 71 as these scales did not exist at the time 
when a substantial proportion of our patients experienced their qualifying event.
Follow-up
Information on the vital status was available either from the hospital or via the municipality 
registry. Patients alive were invited for follow-up assessment between 1-11-2009 and 1-1-
2012. All patients signed informed consent.
Post-stroke epilepsy
Primary outcome was the occurrence of epilepsy after stroke. Post-stroke epilepsy was 
defined according to the International League Against Epilepsy (ILAE), in which patients with 
a single seizure associated with an enduring condition that could cause epilepsy (for example 
stroke), met the criteria of epilepsy.72 Seizures were classified as partial (simple, complex and 
secondary generalised) or generalised.73 If it was not possible to classify a seizure, this was 
defined as not otherwise specified. Furthermore seizures were classified according to their 
time of onset. Seizures occurring within 1 week after stroke were classified as early seizures 
and seizures occurring thereafter were classified as late seizures.74 Onset seizures were 
defined as occurring within 24 hours of onset of stroke.6 To provide comparability with other 
studies the occurrence of recurrent seizures was included as a secondary outcome.
All patients alive underwent standardised, structured questionnaires. In case a patient had 
died, this information was retrieved from the general practitioner by the same structured 
questionnaires. If seizures were reported, information from the treating physician was 
retrieved, both for patients alive and patients who died. This information was verified and 
adjudicated by an experienced neurologist who was blinded for the index event. In addition 
when patients reported early or onset seizures, this information was verified by medical chart 
review or by retrieving information from other treating physicians. Information about date of 
seizure, number of seizures during follow-up and treatment were systematically recorded. 
Data on outcome were available for all patients.
IncIdence of post-stroke epIlepsy
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Statistical analysis
For comparison of continuous variables between groups, students-t-test or Mann-Whitney U 
test were used when appropriate. In case of categorical variables chi-square-test was used. 
Cumulative risks of post-stroke epilepsy and cumulative risk of recurrent seizures were 
estimated with Kaplan-Meier analysis, with the first post-stroke seizure as qualifying 
endpoint. Patients who died or did not reach the endpoint before follow-up ended were 
censored. Furthermore as patients with a recurrent stroke or TIA might have a higher risk of 
epilepsy, they were censored after their recurrent event. Differences between stroke subtype 
and gender in cumulative risks of post-stroke epilepsy and epilepsy with recurrent seizures 
were tested with the log-rank test. 
Average annual risks of epilepsy and epilepsy with recurrent seizures were calculated using 
the formula 1-[(1-], where Ic equals the cumulative risk of epilepsy or the cumulative risk 
of recurrent seizures at n years, obtained by the Kaplan-Meier method.75 Cox proportional 
hazard models were used to calculate hazard ratios (HRs) with their corresponding 95% 
confidence intervals (CIs) for gender, age at event, stroke subtype and NIHSS at admission.
Two-sided P values of less than 0.05 were considered to indicate statistical significance. SPSS 
18 was used for all statistical analysis.
Results
Study population
1006 patients fulfilled in- and exclusion criteria of the FUTURE study, after inclusion one more 
patient with an ICH was excluded because after careful re-evaluation this appeared to be 
on the basis of a cerebral venous sinus thrombosis, which was an exclusion criterion for our 
study. For the present study 697 patients were included in the analysis (Figure 1). Our study 
included 206 patients with a TIA (29.6%), 425 patients with an ischemic stroke (61.0%) and 66 
patients with an ICH (9.5%). Compared to participants, patients lost to follow-up more often 
had an ischemic stroke (76.5% versus 61.0 %, p=0.008) and less often a TIA (13.1% versus 
29.0%, p=0.002). Furthermore patients lost to follow-up were younger (38.1 versus 40.5 years, 
p=0.02) and less often had diabetes (2.5% versus 5.7%, p=0.006). Except for smoking there 
were no differences in baseline characteristics in patients who refused to participate and 
participants (53.1% versus 62.0%, p=0.05).
Participants’ mean age was 40.5 years (SD 7.8) and 47.1% was male. Median NIHSS at 
admission was 3 (IQR 1- 8.5). Of all patients 160 (23.0%) had died after a mean follow-up of 
9.1 years (SD 8.2). 
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Frequency of post-stroke epilepsy
79 patients (11.3%) developed post-stroke epilepsy during follow-up (Table 1). In 25 patients 
the first seizure was an early seizure and thus occurred within 1 week aft er stroke. In 53 
patients the first seizure was a late seizure. Patients with an ICH had the highest incidence 
of epilepsy (16.7%), followed by ischemic stroke (14.4%) and patients with a TIA (3.4%). 
Classification of the first seizure is shown in table 2.
39 Patients (5.6%) developed recurrent seizures during follow-up. Patients with an ICH more 
oft en developed recurrent seizures (10.6%), followed by ischemic stroke (6.6%) and TIA 
patients (1.9%). Patients with an initial late seizure, more oft en developed recurrent seizures 
than patients with an initial early seizure (Table 3).
Baseline study population  
n = 1005
Follow-up study population  
n = 877
Refusers: n = 153
Follow-up Survivors
 n = 537
Follow-up investigation
n = 697
BA
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W
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P
Deceased
n = 160
Exclusion history of TIA or stroke: 
n = 46
Lost to follow-up: n = 82
For present study
Exclusion history of seizures:        
n = 27 
Figure 1. Flowchart study design
Abbreviations: TIA=transient ischemic attack
IncIdence of post-stroke epIlepsy
39
Ch
ap
te
r 3
Treatment
12 out of the 25 patients with an early seizure did not start anti-epileptic drugs (AEDs) during 
follow-up. 10 Patients started directly after the initial early seizure and 3 patients started after 
recurrent seizures. Of the 54 patients with an initial late seizure, 7 were not treated with AEDs 
during follow-up. 37 Started directly after the initial late seizure, 8 started after recurrent 
seizures and in 2 patients it was unknown when AEDs were started.
Patients with an initial late seizure more often started with AEDs than patients with an initial 
early seizures (87% versus 52%, p<0.001). Patients with recurrent seizures more often received 
AEDs than those with a single seizure (94.9% versus 57.5%, p<0.001).
Risk of post-stroke epilepsy 
After total follow-up of maximum 30 years the cumulative risk of post-stroke epilepsy was 
14% (95% CI 10.3-16.6) for all stroke subtypes. Cumulative risk of post-stroke epilepsy was 
31%, 16% and 5% for patients with an ICH, ischemic stroke and TIA respectively (log-rank test 
ICH versus ischemic stroke and ischemic stroke versus TIA p<0.001). 
Cumulative risk of recurrent seizures was 7% (95% CI 5.0-10.0). Patients with an ICH (23%) or 
an ischemic stroke (8%) had a higher cumulative risk of developing recurrent seizures than 
patients with a TIA (4%) (log-rank ICH versus ischemic stroke p=0.051, ICH versus TIA p<0.001, 
ischemic stroke versus TIA p=0.013). Figure 2 shows the overal cumulative risk of epilepsy and 
recurrent seizures and stratified by stroke subtype and sex.
Average annual risk of post-stroke epilepsy and average annual risk of recurrent seizures was 
the highest during the first year after the index event (8% and 4% respectively), especially in 
patients with an ischemic stroke or ICH (Figure 3).
High NIHSS at admission and ischemic stroke or ICH as stroke subtype were significant 
predictors of post-stroke epilepsy, corrected for age and gender (Table 4). High NIHSS 
remained a significant predictor for recurrent seizures.
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Table 1. Baseline Characteristics
Post-stroke epilepsy
Total,  
n=697
Absent,  
n=618 (%)
Present,  
n=79 (%)
p-value
stroke subtype
TIA 206 (29.6) 199 (32.2) 7 (8.9)
Ischemic stroke 425 (61.0) 364 (58.9) 61 (77.2) <0.001*
ICH 66 (9.5) 55 (8.9) 11 (13.9) <0.001*
Mean age (SD) 40.5 (7.8) 40,7 (7.9) 39.2 (7.4) 0.03
Sex, male 369 (47.1) 334 (54.0) 35 (44.3) 0.10
Mean follow-up (SD) 9.1 (8.2) 9.0 (8.2) 10.5 (8.4) 0.09
NIHSS, median (IQR)‡ 3 (1-8.5) 3 (1-8) 8.5 (2-14) <0.001
TOAST-classification§
Large artery 161(25.5) 146 (25.9) 15 (22.1) 0.50
Cardio-embolism 84 (13.3) 69 (12.3) 15 (22.1) 0.03
Lacunar 60 (9.5) 60 (10.7) 0 0.005
Other determined 91 (14.4) 72 (12.8) 19 (27.9) <0.001
Multiple 17 (2.7) 15 (2.7) 2 (29) 0.89
Undetermined 218 (34.5) 201 (35.7) 17 (25.0) 0.08
Cardiovascular risk factors
Diabetes mellitus 40 (5.7) 38 (6.1) 2 (2.5) 0.19
Hypertension 145 (20.8) 136 (22.0) 9 (11.4) 0.03
Atrial fibrillation 12 (1.7) 11 (1.8) 1 (1.3) 0.74
Smoking‡ 396 (61.8) 346 (54.8) 50 (69.4) 0.12
Abbreviations: TIA=transient ischemic attack; ICH=intracerebral haemorrhage; SD=standard deviation; 
NIHSS=national institutes of health stroke scale; IQR=interquartile range; TOAST= Trial of Org 10172 in Acute 
Stroke Treatment
*Patients with ICH or Ischemic stroke compared to TIA both p<0.001. Patients with IS compared to ICH p=0.62.
‡In 0.6% of the patients NIHSS at admission and in 8% smoking status was missing
§Percentages TIA and Ischemic stroke patients
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Table 2. Classification of first post-stroke seizure
Classification of seizures Total 
n=79 (%)
TIA 
n=7 (%)
IS 
n=61 (%)
ICH 
n=11 (%)
Partial
Simple partial 25 (31.6) 3 (42.9) 19 (31.1) 3 (27.3)
Complex partial 4 (5.1) 1 (14.3) 3 (4.9) 0
Secondary generalised 21 (26.6) 2 (28.6) 19 (31.1) 4 (36.4)
Generalised
Tonic-clonic 25 (31.6) 1 (14.3) 16 (26.2) 4 (36.4)
Not otherwise specified 4 (5.1) 0 4 (6.4) 0 
Abbreviations: TIA =transient ischemic attack; IS=ischemic stroke; ICH=intracerebral heamorrhage
Table 3. Recurrence of seizures according to time of onset first seizure
Early seizures* (n=25) Late seizures‡ (n=54) 
No recurrence, 
n (%)
Recurrent 
seizures,  
n (%)
No recurrence, 
n (%) 
Recurrent 
seizures,  
n (%)
p-value§
Overall 17 (68.0) 8 (32.0) 23 (42.6) 31 (57.4) 0.036
Men 10 (76.9) 3 (23.1) 12 (38.7) 19 (61.3) 0.021
Women 7 (58.3) 5 (41.7) 11 (47.8) 12 (52.2) 0.555
Stroke subtype
TIA 1 (100.0) 0 3 (50.0) 3 (50.0) 0.350
Ischemic stroke 14 (70.0) 6 (30.0) 19 (46.3) 22 (53.7) 0.082
ICH 3 (75.0) 1 (25.0) 1 (14.3) 6 (85.7) 0.044
Abbreviations: TIA=transient ischemic attack; ICH=intracerebral haemorrhage
* early seizures are defined as occurring within the first week after the index event
‡ late seizures are defined as occurring after the first week after the index event
§ p-value represents difference in incidence of recurrent seizures between patients with an initial first seizure 
versus patients with an initial late seizure, compared with chi-square.
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Figure 2. Cumulative risks for post-stroke epilepsy and recurrent seizures
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This figure shows the cumulative risk of post-stroke epilepsy and the cumulative risk of recurrent seizure: (A) 
overall cumulative risk; (B) cumulative risk according to stroke subtype and (C) cumulative risk according to sex. 
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Figure 3. Average annual risk of post-stroke epilepsy and recurrent seizures
Abbreviations: IS=ischemic stroke; ICH=intracerebral haemorrhage; TIA=transient ischemic attack
This figure shows (A) average annual risk of epilepsy and (B) average annual risk of recurrent seizures
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Table 4. Cox proportional hazard 
Post-stroke epilepsy* Recurrent seizures
HR (95% CI) p-value HR (95% CI) p-value
Stroke subtype
TIA Ref Ref
Ischemic stroke 3.68 (1.42-9.51) 0.007 2.23 (0.74-7.75) 0.16
ICH 3.84 (1.20-12.28) 0.02 3.16 (0.79-12.67) 0.10
Male sex 0.72 (0.45-1.56) 0.18 1.28 (0.67-2.43) 0.46
Age at index event 0.98 (0.96-1.01) 0.23 0.98 (0.94-1.02) 0.24
NIHSS at admission 1.07 (1.03-1.11) <0.001 1.08 (1.02-1.14) 0.005
Abbreviations: TIA=transient ischemic attack; ICH=intracerebral haemorrhage; NIHSS=national institutes of 
health stroke scale; HR=hazard ratio; CI=confidence interval
* epilepsy is defined as the occurrence of at least 1 seizure with an enduring cause
Discussion
Our study is the first to investigate the incidence and risk of post-stroke epilepsy in young 
adults with a TIA, ischemic stroke or ICH. We found an incidence of 11.3% for post-stroke 
epilepsy and 5.9% for epilepsy with recurrent seizures after a mean follow-up of almost 10 
years. 
Strengths of our study were the prospective and single centre design, which allowed us to 
collect information systematically and to uniformly verify both the qualifying event as well 
as the outcome. Furthermore, our study has one of the longest follow-up ever reported 
and the largest cohort compared with other studies investigating epilepsy after a stroke in 
young adults. In addition, our study has a high external validity, when comparing baseline 
characteristics to other studies.19
However there are also a few limitations. Some selection bias may have occurred due to 
selective loss to follow-up. Those lost to follow-up more often had an IS and less often a TIA 
compared to participants. Potentially, this might have resulted in an underestimation of the 
overall risk of epilepsy in our cohort, as patients with an ischemic stroke exhibited a higher 
risk of post-stroke epilepsy. However, the severity of stroke did not differ between participants 
and those lost to follow-up, so we considered this loss of follow-up very unlikely to influence 
our results. Patients who refused to participate did not differ in baseline characteristic from 
participants except from smoking, making selection bias in this group for the same reason 
unlikely. 
As information on seizures was collected by structured questionnaires for all patients in the 
same way, it is unlikely that seizures are reported differently between the stroke subtypes, 
which makes information bias very unlikely. Furthermore the neurologist verifying the event 
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was blinded for the index event. Since the present study features a long inclusion period 
recall bias might have influenced our findings, especially when the index event or seizure 
occurred a longer time ago. However there were no differences in reporting seizures between 
patients who suffered their stroke a long time ago than those with a more recent stroke 
(9.0% in 2000-2010 versus 16.0% in 1990-1999 versus 11.6% in 1980-1989, p=0.055), making 
recall bias unlikely. In addition it might have been possible that less information would be 
available in patients who died, especially in those who died a longer time ago, resulting in an 
underestimation of epilepsy in this group. However we did not find a difference in frequency 
of epilepsy between patients who died a long time ago and those who died more recently 
(12.5% in 1980-1989 versus 16.3% in 1990-1999 versus 16.7 in 2000-2010, p=0.882), making 
this explanation unlikely. On top of this, information on patients who died before follow-up 
ended was collected in an identical manner as in patients alive.
Another source of bias might be misclassification of TIA patients. In some cases it might be 
difficult to distinguish a TIA from a seizure, especially for example in case of a limb-shaking 
TIA.76 Theoretically either the index event or the seizure could have been misclassified. In 
our study all qualifying events were verified by two independent neurologists, independent 
from the outcome. In addition, 5 out of 8 patients developed complex partial seizures or 
(secondary) generalised seizures, which can be easily distinguished from a TIA, so it is unlikely 
that those were misdiagnosed. 
Another source of bias to be considered is confounding. We tried to overcome this by making 
appropriate adjustments for potential confounders including age, stroke severity, gender and 
stroke subtype in our multivariate analysis. Furthermore we have adjudicated for recurrent 
stroke or TIA, by withdrawing patients after a recurrent event in the Kaplan-Meier analysis.
 Another possible confounding factor might have been the use of AEDs. In our study 10 out of 
25 patients with an early seizure and 37 out of 54 patients with an initial late seizure started 
directly after the first seizure with AEDs. It might be possible that the use of AEDs has reduced 
the risk of epilepsy with recurrent seizures after a single seizure. However as AEDs were not 
prescribed prophylactic, only the frequency of epilepsy with recurrent seizures might have 
been affected by the use of AEDs and not the incidence of the first seizure. In addition the 
impact of AEDs on epileptogenesis remains unclear. Furthermore during 30 years of follow-
up patients may have switched or stopped AEDs, which may have provoked or prevented 
occurrence of seizures as well. 
According to the definition of the ILAE patients already meet the criteria of epilepsy when a 
single seizure occurs with an enduring cause. Most other studies still use the former version 
in which patients meet the diagnosis of epilepsy when they have at least 2 (late) seizures. 
For reasons of comparability, we therefore compared the risks of seizures in previous studies 
with the risk of epilepsy in our study. We found a higher incidence of post-stroke epilepsy 
compared to other studies that investigated seizures stroke in young adults (6-10%).7, 23, 26, 63, 
64 This may be explained by the characteristics of our study. Except for IS and TIA patients we 
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included patients with an ICH who had a higher cumulative risk of post-stroke epilepsy and 
with recurrent seizures, whereas other studies only included ischemic strokes. For patients 
with an ischemic stroke incidence of post-stroke epilepsy was almost 15% in our study, while 
others reported incidences of seizures between 6-10%.7, 23, 26, 63, 64 This difference may, in part, 
be explained by the far longer follow-up of our patients, leaving them more time to develop 
epilepsy. However a higher risk was found especially during the first years after the index 
event.
Compared to other studies in elderly with more or less the same definitions we found a 
higher incidence of post-stroke epilepsy and recurrent seizures (3.4% to 10.4% and 2% to 5% 
respectively).5, 6, 8, 10, 14 Compared to the few studies in both young and elderly stroke patients 
which performed survival analysis, cumulative risk of post-stroke epilepsy and cumulative 
risk of recurrent seizures was higher after same follow-up.6, 7, 10, 26 
The higher cumulative risk of post-stroke epilepsy and recurrent seizures in our young cohort 
may presumably be due to mechanisms in young patients which makes them more vulnerable 
for the development of epilepsy. This is also suggested by few other studies among elderly 
who found a higher incidence of seizures in younger patients, after stratification in several 
age groups.77-79 It was suggested that the brain of elderly patients might have a weaker 
epileptogenicity78, however there is no proper explanation for this finding yet. 
Interestingly, in our study patients with a TIA had comparable risk of epilepsy than shown 
in studies among elderly TIA patients.5, 13, 79-81 Despite the potential of misclassification of TIA 
patients, TIA was diagnosed according to current clinical guidelines and patients with positive 
phenomena such as twitches, jerks or myoclonus were excluded in order to minimize this, 
the only way to assess the risk of epilepsy after TIA is by including these patients in a study 
and ours is the first to do so. 
Few studies found comparable incidences of early seizures5, 9-11, 82, however definitions of early 
seizures in those studies varied from 24 hours until 2 weeks, which obviously influences the 
incidence. In line with another study, we found that patients with initial late seizures more 
often developed recurrent seizures than those with initial early seizures. 14 One explanation 
might be the effect of survival, however there was no difference in survival between patients 
with an initial early and initial late seizure. In our opinion late seizures have a greater clinical 
importance, as those seizures very much influence daily life when patients are trying to 
rebuild their normal activities. In addition it has been suggested that pathophysiology of 
early and late seizures might be different. Early seizures might be related to non-cerebral 
disarrangements and thought to result from cellular biochemical dysfunction.8, 80, 83 Late 
seizures on the other hand are suggested to be a result of gliosis or hemosiderin remaining.80 
As in other cohorts higher cumulative risks of epilepsy and recurrent seizures were found 
in patients with an ICH. In addition a high NIHSS was a significant predictor of post-stroke 
epilepsy and recurrent seizures.6, 14, 26, 77, 79, 84
In conclusion, we showed that epilepsy is much more common after a stroke in young adults 
than previously described. Future studies should be executed to investigate risk factors and 
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the underlying pathophysiology. Besides this, these studies should also investigate the effect 
of post-stroke epilepsy on quality of life. Furthermore, the high cumulative risk of epilepsy 
is as high as the risk of recurrent stroke.19 This calls upon the question whether a subgroup 
could be identified, which would benefit from prophylactic AEDs, especially during the first 
years after stroke during which the risks are the highest.
IncIdence of post-stroke epIlepsy
49
Ch
ap
te
r 3

4.
Post-stroke epilepsy after a stroke at 
young age impairs functional outcome
Published as:
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Abstract
Objective: To determine the influence of post-stroke epilepsy on long-term functional 
outcome in young stroke survivors.
Methods: This study is a prospective cohort study among 537 stroke survivors with a first-
ever transient ischemic attac, ischemic stroke or intracerebral haemorrhage, aged 18-50 
years. After a mean follow-up of 9.8 (SD 8.4) years, we performed a follow-up assessment 
that included an evaluation for post-stroke epilepsy and functional outcome. Odds ratios 
for poor outcome on modified Rankin Scale (mRS>2) and Instrumental Activities of Daily 
Living (IADL<8) were calculated using logistic regression analysis.
Results: 40 Patients (12.7%) with ischemic stroke, 4 patients with TIA (2.2%) and 10 
patients (25.6%) with ICH developed post-stroke epilepsy. Ischemic stroke patients with 
epilepsy more often had a poor functional outcome than those without both on mRS and 
IADL (mRS>2: 27.5% versus 9.8%, p=0.001 and IADL<8: 27.8% versus 12.6%, p=0.02). Epilepsy 
was not related to functional outcome in TIA and ICH patients. Multiple regression analysis 
revealed that epilepsy was an independent predictor of poor functional outcome after 
ischemic stroke assessed by mRS (OR 3.38, 95%CI 1.33-8.60). In contrast there was no such 
relation for IADL.
Conclusions: Epilepsy after stroke in young patients is a common problem that negatively 
affects functional outcome, even more than 10 years after ischemic stroke.
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Introduction
Stroke in young adults (aged 18-50) is a devastating disease with lifelong consequences.85, 
86 Both the residual post-stroke deficit and post-stroke complications may decrease the 
ability to function independently. A common complication after a young stroke is post-stroke 
epilepsy.87 Although previous literature suggested that seizures under ischemic conditions 
may exacerbate secondary injury,88 their possible consequences on long-term functional 
recovery are unknown. 
There are contradictory findings on the effect of post-stroke epilepsy on short-term functional 
outcome in patients aged over 50 years.9, 14, 15, 89 Only two studies on this subject exist in young 
stroke patients. However, these were retrospective26 or did not control for confounding 
factors63 and follow-up was limited. Furthermore, they used modified Rankin Scale (mRS) to 
measure functional outcome, which is a commonly used but rather global scale and does not 
assess complex skills, which are relevant for independent performance in daily life. 
Especially for the young, the unpredictability of seizures and the necessity to use long-term 
antiepileptic medication might have a particular high impact given their active lives with 
work and young families. Long-term information on what to expect is of great importance 
for patients and their caregivers, especially once the stroke has become complicated by 
epilepsy. 
Therefore, our aim was to investigate the long-term influence of post-stroke epilepsy on 
functional outcome in young stroke patients.
Methods
Study population
This study is part of the “Follow-Up of Transient ischemic attack and stroke patients and 
Unelucidated Risk factor Evaluation”-study (FUTURE study), a prospective cohort study that 
investigates causes and consequences of a young stroke.65, 90 
In short, the FUTURE study comprises 1005 consecutive patients with a transient ischemic 
attack (TIA), ischemic stroke or intracerebral haemorrhage (ICH), aged 18 - 50 years, admitted 
to the Radboud University Nijmegen Medical Centre from January 1, 1980 till November 1, 
2010. For the present study, we included patients with a first-ever TIA, ischemic stroke or 
intracerebral haemorrhage without a history of seizures. To minimize bias due to changing 
diagnostic techniques, the World Health Organisation definition for stroke was used.67, 91 TIA 
was defined as a rapidly evolving focal neurological deficit, without positive phenomena 
such as twitches, jerks or myoclonus, with no other than a vascular cause lasting less than 24 
hours. Stroke was defined similarly, but with symptoms lasting more than 24 hours. Stroke 
was subdivided into hemorrhagic and ischemic stroke on the basis of radiological findings. 
Exclusion criteria were traumatic haemorrhage, haemorrhage in known cerebral metastasis 
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or primary brain tumor, cerebral venous sinus thrombosis, any subarachnoid haemorrhage 
or ICH due to known ruptured aneurysm and retinal infarction. 
Patients were identified through a prospective registry with a standardised collection of 
baseline and clinical characteristics (including demographics, stroke subtype and vascular 
risk factors). Furthermore, all patients underwent neurological examination and brain 
imaging at the time of their index event.90 We assessed stroke aetiology (Trial of Org 10172 
in Acute Stroke Treatment [TOAST])68 and severity (National Institutes of Health Stroke Scale 
(NIHSS)69 and mRS70) retrospectively by a validated approach28, 71, as these scales did not exist 
at the time when a substantial proportion of our patients experienced their qualifying event. 
Standard protocol approvals, registrations, and patient consents
The Medical Review Ethics Committee region Arnhem-Nijmegen approved the study. Written 
informed consent was obtained from all patients.
Follow-up
Information on the vital status was available either from the hospital or via the municipality 
registry. Patients alive received an information letter regarding the follow-up assessment and 
were subsequently approached by phone between November 1, 2009 and January 1, 2012. 
When a patient consented over the phone in participating, an appointment was made to visit 
our research centre for an extensive in-person follow-up examination, including functional 
outcome, epilepsy and recurrent stroke.17 If patients consented to participate, but were not 
able to visit our research centre, data were collected by means of standardised, structured 
questionnaires that was sent out by mail. All data were collected on systematic, structured 
way by researchers trained in stroke and seizures.
Outcome 
Primary outcome was functional outcome, measured by the mRS,70 in all stroke survivors 
(n=537) at the time of follow-up. Secondary outcome was quality of life measured by EQ-5D.58 
Information EQ-5D was missing in 14 patients (2.6%).
In patients who participated in all parts of the study (n=465) functional outcome was 
measured by Instrumental Activities of Daily Living scale (IADL),54 in addition to the mRS, 
which predominantly measures outcome based on motor function. The IADL complements 
this with the assessment of more complex tasks necessary for independent living in a 
community. Information on IADL was missing in 6 patients (1%). 
Assessment of post-stroke epilepsy 
We defined post-stroke epilepsy according to the most recent version of the International 
League Against Epilepsy (ILAE), in which patients with a single seizure associated with an 
enduring condition that could cause epilepsy (such as stroke), met the criteria of epilepsy.72, 
73 Post-stroke seizures were divided into early seizures (occurring within 7 days after stroke) 
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and late seizures (occurring thereafter).74 Both the patients with early and late seizures were 
included in this study. In addition, patients with post-stroke epilepsy were subdived into 
patients with a single seizure and patients with recurrent seizures. 
All patients alive underwent a standardised, structured questionnaire that included a 
question on whether they had ever experienced epileptic seizures, diagnosed by a physician. 
Whenever an epileptic seizure was suspected, medical records including description of signs 
and symptoms, results and interpretations from ancillary investigations, were retrieved from 
the patient’s treating physician and subsequently verified and adjudicated by an experienced 
neurologist. 
Statistical analysis
Baseline characteristics were compared between participants and non participants (those 
patients that refused and patients lost to follow-up) using Student’s t test, Mann-Whitney 
U test or chi-square-test whenever appropriate. Similarly, baseline characteristics were 
compared between participants and deceased patients. Poor functional outcome was 
defined as mRS >2 and IADL<8. We used a chi-square test for comparison of poor functional 
outcome in patients with and without epilepsy. By means of binary logistic regression 
analysis, we calculated Odds ratios (ORs) with their corresponding 95% Confidence Intervals 
(CIs) for the risk of a poor functional outcome on mRS and IADL for ischemic stroke patients 
with post-stroke epilepsy. Covariates in the model were sex, age at follow-up, follow-up 
duration, mRS >2 at discharge and recurrent stroke (ischemic stroke or ICH). This analysis 
was repeated after excluding patients with only early seizures. We excluded patients with 
missing IADL in the corresponding analysis. We performed a sensitivity analysis (worst case/
best case scenario), but this did not alter our conclusions. 
Two-sided P values of less than 0.05 were considered to indicate statistical significance. SPSS 
20 was used for all statistical analysis.
Results
Study population
Five hundred thirty-seven stroke survivors entered the present study (figure 1). Of them, 
315 patients (59%) had an ischemic stroke, 183 patients (34%) a TIA and 39 patients (7%) 
an ICH. There were no differences in baseline characteristics between participants and 
those patients who refused or were lost to follow-up. Patients who died were more often 
men (54.4% versus 44.9%), had a higher NIHSS (median 7 [IQR 2-14] versus 2 [0-7]) and were 
older than participants (42.4 [SD 7.0] versus 40.0 (SD 8.0) years). Table 1 shows the baseline 
characteristics of patients with and without epilepsy.
After mean follow-up of 9.8 (SD 8.4) years, 40 patients (12.7%) with ischemic stroke, 4 patients 
with TIA (2.2%) and 10 patients (25.6%) with an ICH developed post-stroke epilepsy. The 
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cumulative incidence of post-stroke epilepsy over time aft er ischemic stroke is shown in 
figure 2.
Among ischemic stroke patients with seizures, 11 patients (27.5%) had an initial early seizure 
and one of them had a recurrent seizure; 29 patients (72.5%) had only late seizures and of 
them 13 patients (44.8%) had recurrent seizures.
Neither severity nor location of the index stroke was associated with recurrent seizures.
The incidence of post-stroke epilepsy did not diff er between patients with ischemic stroke 
caused by antiphospholipid syndrome and those with another cause.
Among ischemic stroke patients that developed post-stroke epilepsy, 3 patients (8%) had 
received tissue plasminogen activator as part of the index stroke treatment. The proportion 
of ischemic stroke patients treated with tissue plasminogen activator did not diff er between 
patients with and without post-stroke epilepsy.
Baseline study population  
n = 1005
Follow-up study population  
n = 877
Refusers: n = 153
Follow-up Survivors
 n = 537
Follow-up investigation
n = 697
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Deceased
n = 160
Exclusion history of TIA or 
stroke: n = 46
Lost to follow-up: n = 82
Exclusion history of 
seizures: n = 27
TIA
n = 183
Ischemic 
Stroke
n = 315
ICH
n = 39
Figure 1. Study design
Abbreviations: TIA=transient ischemic attack; ICH=intracerebral haemorrhage
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Table 1. Baseline characteristics
Post-stroke epilepsy
Total (%) Absent (%) Present (%)
n, (% of total) 537 483 (89.9) 54 (10.1)
Mean age (SD) 40.0 (8.0) 40.2 (8.0) 38.1 (7.3)
Sex, male 241 (44.9) 213 (44.1) 28 (51.9)
Mean follow-up (SD) 9.8 (8.4) 9.6 (8.3) 11.8 (8.7)
>15 years FU 159 (29.6) 140 (29.0) 19 (35.2)
>20 years FU 89 (16.6) 80 (16.6) 9 (16.7)
NIHSS, median (IQR)a 2 (0-7) 2 (0-6) 8 (2-13)
TOAST
Large artery 116 (23.2) 110 (24.2) 6 (13.6)
Cardio-embolism 55 (11.0) 48 (10.6) 7 (15.9)
Lacunar 51 (10.2) 51 (11.2) 0
Other determined 79 (15.9) 61 (13.4) 18 (40.9)
Multiple 10 (2.0) 9 (2.0) 1 (2.3)
Undetermined 187 (37.6) 175 (38.5) 12 (27.3)
Cardiovascular risk factors
Diabetes mellitus 22 (4.1) 22 (4.6) 0
Hypertension 135 (25.1) 128 (26.5) 7 (13.0)
Atrial fibrillation 7 (1.3) 7 (1.4) 0
Smoking* 248 (47.8) 223 (47.6) 25 (49.0)
Abbreviations: SD=standard deviation; FU=follow-up; NIHSS=National Institutes of Health Stroke Scale; 
TOAST=Trial of Org 10172 in Acute Stroke Treatment.
a In 0.6% of the patients NIHSS at admission was missing, and in 3.4% smoking status was missing.
One TIA patient that developed seizures had both one early seizure and one late seizure and 
the other 3 TIA patients with seizures had late seizures with recurrent seizures. Among ICH 
patients who developed seizures, 2 patients (20%) had only an early seizure and no recurrent 
seizures; 7 patients (70%) had only late seizures and of them 6 patients (86%) had recurrent 
seizures; one patient had both one early seizure and one late seizure. 
During follow-up, 30 patients (75%) with ischemic stroke, all 4 patients with TIA and 8 
patients (80%) with ICH used anti-epileptic drugs (AEDs). At the time of follow-up assessment 
20 patients (50%) with ischemic stroke, 1 patient (25%) with TIA and 5 patients (50%) with ICH 
still used AEDs. Nine patients with ischemic stroke, 3 patients with TIA and 4 patients with ICH 
had recurrent seizures after starting AED treatment. Among patients that did not start AEDs, 
none of the ischemic stroke patients but one of the ICH patients had a recurrent seizure.
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Figure 2. Cumulative risk of epilepsy after ischemic stroke
This figure shows the cumulative risk of post-stroke epilepsy after an ischemic stroke with the corresponding 
95% confidence interval.
post-stroke epilepsy and functional outcome
59
Ch
ap
te
r 4
Modified Rankin Scale
Among patients with ischemic stroke, 11 patients (27.5%) with post-stroke epilepsy had a 
poor functional outcome on mRS (>2), compared to 27 patients (9.8%) without epilepsy 
(p=0.001). Of these 11 patients with epilepsy and a poor functional outcome, 8 patients had 
a late seizure and 3 an early seizure. In ischemic stroke patients with epilepsy, severity but 
not location of the index stroke was associated with poor functional outcome (p<0.001 and 
p=0.19 respectively).
Among patients with TIA and ICH, there were only patients without epilepsy that had a poor 
functional outcome (12 patients [6.7%] with TIA and 5 patients [17.9%] with ICH), whereas all 
10 patients with epilepsy had a good functional outcome (p=0.15). 
Ischemic stroke patients with epilepsy with a single seizure and those with recurrent seizures 
more often had a poor functional outcome on mRS than patients without epilepsy (Table 2). 
This relation was still present after excluding those patients with only early seizures (Table 3). 
Functional outcome did not differ between patients with and without AED treatment.
Multiple regression analysis revealed that epilepsy after ischemic stroke was independently 
associated with a poor functional outcome (OR 3.38 [95% CI 1.33-8.60]) (Table 4). After 
excluding those patients with early seizures, the association for epilepsy with functional 
outcome remained (OR 2.81 [95% CI 1.00-7.88]) (Table 5).
Instrumental Activities of Daily Living
Ischemic stroke patients with epilepsy more often had a poor functional outcome on 
IADL (27.8%) than those without epilepsy (12.6%) (Table 2). Post-stroke epilepsy was not 
independently associated with a poor functional outcome on IADL in multiple logistic 
regression analysis (Table 4).
Among patients with epilepsy, only one patient with TIA and no patient with ICH had a poor 
functional outcome on IADL. 
Quality of Life in stroke survivors
For patients with ischemic stroke, TIA and ICH, there were no differences between patients 
with and without post-stroke epilepsy with respect to their quality of life on the 5 items of the 
EQ-5D both in univariate and multiple regression analysis.
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Table 2. Functional outcome in ischemic stroke patients with and without epilepsy
Poor functional outcome
mRS>2 p-valuea IADL<8 p-valuea
Epilepsy
Absent, n (%) 27 (9.8) - 30 (12.6)
Present, n (%) 11 (27.5) 0.001 10 (27.8) 0.02
Frequency of seizures
No epilepsy, n (%) 27 (9.8) - 30 (12.6) -
Single seizure, n (%) 6 (23.1) - 6 (26.1) -
Recurrent seizures, n (%) 5 (35.7) 0.003 4 (30.8) 0.05
Abbreviations: mRS=modified Rankin Scale; IADL=instrumental activities of daily living.
Data are presented as numbers (%). Shown are the proportion of patients with and without epilepsy with a 
poor functional outcome on mRS and IADL. mRS was available in all participants (n=315). IADL was available 
in patients who visited the research centre to participate in all parts of the study (n=276) and was missing in 2 
patients.
aThe proportion of patients with a poor functional outcome was compared in patients with and without epilepsy 
using the χ2 test. 
Table 3. Functional outcome with respect to the occurrence of epilepsy in patients without only 
early seizures 
Poor functional outcome
mRS>2 p-valuea IADL<8 p-valuea
Epilepsy
Absent, n (%) 27 (9.8) - 30 (12.6)
Present, n (%) 8 (26.7) 0.006 7 (25.9) 0.06
Frequency of seizures
No epilepsy, n (%) 27 (9.8) - 30 (12.6) -
Single seizure, n (%) 3 (18.8) - 3 (21.4) -
Recurrent seizures, n (%) 5 (35.7) 0.008 4 (30.8) 0.13
Abbreviations: mRS=modified Rankin Scale; IADL=instrumental activities of daily living.
Proportion of patients with and without epilepsy with a poor and good functional outcome on mRS and IADL. 
mRS was available in all participants (n=305). IADL was available in patients who visited the research centre to 
participate in all parts of the study (n=267) and was missing in 2 patients.
a The proportion of patients with a poor functional outcome was compared in patients with and without epilepsy 
by means of chi-square-test. 
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Table 4. Estimation of relative risks for a poor functional outcome in ischemic young stroke 
patients
  Poor functional outcome
mRS>2 IADL<8
Risk factor OR (95% CI) p-value OR (95% CI) p-value
Sex, men 0.36 (0.16-0.82) 0.02 0.70 (0.32-1.52) 0.37
Age follow-up, per year 1.07 (1.01-1.14) 0.03 1.02 (0.97-1.08) 0.45
Follow-up time, per year 0.96 (0.89-1.02) 0.19 0.99 (0.92-1.05) 0.65
mRS>2 at discharge 16.00 (4.60-55.69) <0.001 2.26 (1.65-3.10) <0.001
Recurrent stroke 3.90 (1.52-10.00) 0.005 6.97 (2.73-17.80) <0.001
Epilepsy 3.38 (1.33-8.60) 0.01 1.52 (0.57-4.01) 0.40
Abbreviations: CI=confidence interval; IADL=instrumental activities of daily living; mRS=modified Rankin Scale; 
OR=odds ratio.
ORs were estimated by multiple logistic regression analysis, in which all covariates are entered simultaneously 
in the logistic regression model.
mRS was available in all participants (n=315). IADL was available in patients who visited the research centre to 
participate in all parts of the study (n=276) and was missing in 2 patients.
Table 5. Estimation of risk of a poor functional outcome in ischemic young stroke patients without 
only early seizures
  Poor functional outcome
mRS>2 IADL<8
Risk factor OR (95% CI) p-value OR (95% CI) p-value
Sex, men 0.29 (0.12-0.70) 0.005 0.50 (0.23-1.10) 0.08
Age follow-up, per year 1.07 (1.00-1.14) 0.04 1.02 (0.96-1.08) 0.50
Follow-up time, per year 0.96 (0.90-1.03) 0.25 0.99 (0.93-1.05) 0.71
mRS >2 at discharge 14.80 (4.23-51.85) <0.001 5.90 (2.34-14.87) <0.001
Recurrent stroke 3.79 (1.45-9.94) 0.007 4.78 (1.89-12.09) <0.001
Epilepsy 2.81 (1.00-7.88) 0.05 1.77 (0.63-4.98) 0.28
Abbreviations: mRS=modified Rankin Scale; IAD=instrumental activities of daily living; OR=odds ratio; 
CI=confidence interval.
Odds ratios are estimated by multiple logistic regression analysis, in which all covariates are entered 
simultaneously in the logistic regression model.
mRS was available in all participants (n=305). IADL was available in patients who visited the research centre to 
participate in all parts of the study (n=267) and was missing in 2 patients.
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Discussion
We showed that post-stroke epilepsy was associated with a poor functional outcome after 
a young ischemic stroke, even after a mean follow-up of 10 years. However, post-stroke 
epilepsy did not seem to affect post-stroke quality of life.
Strengths of our study include the long follow-up duration of a large cohort of young 
stroke patients. In addition, the prospective and single centre design allowed us to collect 
information systematically and to uniformly verify both the qualifying event as well as follow-
up information in all patients, which reduces the risk of information bias. Moreover, the 
neurologist who verified the seizures was blinded for the index event. 
We included patients with both early and late seizures. There is no evidence from older 
stroke studies that an early seizure is associated with a poor functional outcome. However, in 
theory an early seizure may be harmful to a recently damaged brain, in which an infarct core 
has not yet been demarcated and a penumbra is still at risk, due to an imbalance between 
oxygen demand and supply.88 Therefore, we believe that including also the patients with 
early seizures is relevant to answer the question whether epilepsy is associated with a poor 
functional outcome after stroke. In addition, we subdivided seizures into single and recurrent 
seizures. Recurrent seizures might cause accumulating brain damage, possibly leading to 
a synergistic negative effect on functional outcome. In addition, patients with recurrent 
seizures may experience a worse quality of life, due to fear of having another seizure, than 
patients who only had one seizure.
There are some limitations. First, selection bias may have occurred due to selective loss 
to follow-up. Potentially, those lost to follow-up were the ones with a more severe stroke 
and thereby poor functional outcome. However, there were no differences in baseline 
characteristics between participants and non-participants. In addition, patients who died 
were not included in our analysis, which may have lead to an underestimation of poor 
functional outcome. 
Second, since our study is a single-centre hospital-based study, rather than a community 
based study, it may be that we did not include all young stroke cases in our catchment area. 
However, patients who survive usually visit our university medical centre during the course 
of their disease, because our hospital is the only university medical centre in our region. 
Only those patients who experienced a fatal stroke, who were not admitted to our hospital, 
would not have been included in our study. Since the present study only includes stroke 
survivors, this would not have altered our conclusions. In addition, there are no restrictions 
to be admitted to our hospital, and we included all consecutive cases admitted. We therefore 
presume that our study population is a representative sample of Dutch patients with stroke 
aged 18 through 50 years, although formal data are lacking to prove this generalisability. 
Another source of bias to be considered is confounding. We have tried to overcome this 
by making appropriate adjustments for potential confounders in our multiple regression 
analysis. 
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Third, statistical power was limited for TIA and ICH patients because of only few cases of 
epilepsy, of which none had a poor functional outcome. Therefore, we could not perform 
multiple regression analysis in these groups.
We found a higher incidence of epilepsy than previous studies in young stroke patients.23, 26, 63, 
64, 92 This might be explained by different definitions we used. We used the most recent ILAE-
classification in which a patient already meets the criteria of epilepsy after only one seizure, 
in combination with the stroke. The other studies used the former definition of epilepsy, in 
which patients needed to have two seizures to meet the criteria. However, also compared 
with the incidence of one post-stroke seizure in previous literature, we still found a higher 
percentage. This might me due to the longer follow-up duration in our study. 
We found that post-stroke epilepsy after a young ischemic stroke was associated with a poor 
functional outcome, even more than 10 years after stroke. Although residual confounding 
of stroke severity still might play a role, this information may be of great importance 
when counselling patients and caregivers on the course of their disease, which is of major 
importance in this young working population, given their long life expectancy. The few short-
term follow-up studies in the young that addressed the question whether epilepsy has a 
negative influence on functional outcome did not find this association.26, 63 Few studies in 
elderly showed that epilepsy might have a negative effect on the very short-term functional 
outcome.14, 15, 93 
Interestingly post-stroke epilepsy affected outcome assessed with the “motor performance 
dominant” mRS, but not instrumental ADL-tasks. This poor functional (motor) outcome in 
patients with epilepsy after an ischemic stroke might be explained by the fact that seizures 
themselves might have a direct negative influence on recovery, by mechanisms not clearly 
understood yet. Seizures may worsen the state of insufficient oxygen and energy supply in 
already ischemic brain parenchyma, thereby increasing infarct size and impairing motor 
recovery.88 Secondly, the use of AEDs might have influenced functional outcome. However, 
functional outcome did not differ between patients with and without AEDs, but this may 
have been affected by confounding by indication. One study showed that AEDs might have 
a negative impact on motor recovery after stroke,94 but the use of AEDs might be a proxy for 
more severe seizures or stroke rather than the AEDs having an adverse effect themselves. It is 
well known that AEDs negatively influence cognition95, it might be that this in turn influences 
functional outcome. Contradictory, we did not find a difference on the IADL, which includes 
instrumental ADL-tasks that are more complex than the mRS. However the IADL is not a 
true cognitive screenings instrument and cognitive performance may still be influenced by 
epilepsy.
Despite an unfavourable functional outcome in young stroke patients with epilepsy, quality 
of life was not affected. Although the EQ-5D covers the whole aspect of quality of life, it only 
contains 5 items and subtle changes might have been missed. In the general population, 
epilepsy (without stroke) significantly influences quality of life.96 However, these studies used 
different measures to assess quality of life. It might be possible that in a stroke population, 
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stroke severity is a more important factor for quality of life than post-stroke epilepsy. There 
is only one other small (n=71) retrospective study among young stroke patients that showed 
a poorer quality of life in patients with post-stroke epilepsy than those without.64 However, 
after correction for stroke severity and other confounding factors, this relation disappeared.
We showed that post-stroke epilepsy is not only a common problem after stroke in young 
patients but may also have a negative impact on functional motor outcome, even after more 
than 10 years of follow-up. This is information is of great importance in this young working 
population with a long life expectancy. 
There is a need for future studies to investigate whether risk factors can be identified which are 
associated with post-stroke epilepsy and whether epilepsy influences cognitive performance 
as well. 
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Abstract
Objective: Post-stroke epilepsy is a common complication after stroke at young age 
and has been associated with poor functional outcome. However, daily functioning is 
also determined by cognitive performance. The aim of this study was to investigate the 
association between post-stroke epilepsy and cognitive performance after a stroke at 
young age.
Methods: We performed a prospective cohort study among 427 stroke survivors with a 
first-ever transient ischemic attack or ischemic stroke aged 18-50 years. After 10.2 (SD 8.3) 
years we performed a follow-up assessment, which included extensive neuropsychological 
testing and assessment of post-stroke epilepsy. Adjusted mean z-scores in seven cognitive 
domains were compared between patients with and without epilepsy using ANOVA. 
Logistic regression was used to calculate odds ratios for cognitive impairment for post-
stroke epilepsy.
Results: 427 patients were included (TIA n=157, ischemic stroke n=270), 38 patients (8.9%) 
developed post-stroke epilepsy. Patients with post-stroke epilepsy had a worse global 
cognitive performance than those without (group difference adjusted mean z-score: 0.324, 
95%CI 0.115-0.533, p=0.002). The domains processing speed and working memory were 
most affected. In addition, patients with epilepsy more often had a cognitive impairment 
than those without (45.9% versus 25.1%, p=0.006). Patients with epilepsy more often had 
an impaired processing speed than those without (OR 3.1 95%CI 1.4-7.2).
Conclusion: Post-stroke epilepsy is a common complication after a young stroke and is 
associated with a worse cognitive performance.
post-stroke epilepsy and cognitive performance
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Introduction
Post-stroke epilepsy is a common complication after stroke in patients aged 18-50 years and 
occurs in 1 out of 9 patients.87 Apart from the sudden, unexpected character of a seizure, 
post-stroke epilepsy is associated with a poor functional outcome.97 However post-stroke 
outcome is not only determined by functional performance, but even more so by cognitive 
performance which. Both post-stroke seizures and/or daily use of anti-epileptic drugs 
(AEDs) might negatively influence post-stroke cognitive performance. Especially for young 
patients, maintaining (or regaining) adequate post-stroke cognitive performance is of major 
importance for independent functioning and developing. 
There have been no studies after stroke in young adults, and only a few studies in elderly 
stroke survivors, that have investigated the influence of post-stroke epilepsy on cognitive 
performance. Although these studies showed that post-stroke epilepsy was associated with 
cognitive impairment they have some limitations.98, 99 In one study99 cognitive performance 
was only assessed by mini mental state examination, which is a global dementia screen, rather 
than a sensitive tool to detect cognitive impairment in stroke patients.100 To fully characterize 
the whole spectrum of cognitive impairment, it should be measured by neuropsychological 
tests covering different cognitive domains. Second, duration of follow up was limited. This 
is an important potential shortcoming as post-stroke epilepsy might especially influence 
cognition on the long-term, possibly by repeated seizures or long-term use of anti-epileptic. 
Therefore, the aim of this study was to investigate the association between post-stroke 
epilepsy and long-term cognitive performance in first-ever ischemic stroke and transient 
ischemic attack (TIA) patients aged 18 through 50 years.  
Methods
Study population
This study is part of the “Follow-Up of Transient ischemic attack and stroke patients and 
Unelucidated Risk factor Evaluation”-study (FUTURE study), a cohort study that investigates 
causes and consequences of a young stroke.65 
The FUTURE study comprises all consecutive patients with a TIA, ischemic stroke or ICH, aged 
18-50 years, admitted to the Radboud University Nijmegen Medical Centre from January 1980 
till November 2010. TIA and stroke were defined according to the World Health Organisation.67 
TIA was defined as a rapidly evolving focal neurological deficit, with no other than vascular 
cause lasting less than 24 hours. Stroke was defined similarly, but with symptoms lasting 
more than 24 hours, without haemorrhage on computed tomography (CT) or magnetic 
resonance imaging (MRI). For the present study only patients with a first-ever TIA or ischemic 
stroke, without a history of seizures were included. Exclusion criteria were cerebral venous 
sinus thrombosis and retinal ischemia.
Chapter 5
70
Patients were identified through a prospective registry between 1980 and 2010 with a 
standardised collection of baseline and clinical characteristics and brain imaging. The 
assessment of stroke aetiology (Trial of Org 10172 in Acute Stroke Treatment [TOAST] )101 
and severity (National Institutes of Health Stroke Scale (NIHSS)69 was done for all cases 
retrospectively by a validated approach71, as this scale did not exist at the time when a 
substantial proportion of our patients experienced their qualifying event. Lesion location 
was divided into left-hemispheric, right hemispheric infratentorial or bilateral stroke. 
Stroke-free controls were recruited among patients’ spouses, relatives, or social environment 
and were used as a reference group for cognitive performance (n=146). They had to be at 
least 18 years old without a history of TIA or stroke and were matched for age, sex, and level 
of education. 
Standard protocol approvals, registrations and patient consents
The Medical Review Ethics Committee region Arnhem-Nijmegen approved the study. Written 
informed consent was obtained from all participants.
Follow-up
Patients alive were invited to our research centre for an extensive in-person follow-up 
examination between November 2009 and January 2012. 
At follow-up examination, patients underwent standardised, structured questionnaires 
collecting information on current functional status (modified Rankin Scale [mRS]) and 
level of education. Level of education was scored with a widely-used Dutch scoring 
system (1=less than primary school; 7=university degree).102 During follow-up examination 
neuropsychological tests were administered. 
In addition, they underwent questionnaires on the occurrence of recurrent vascular events 
and seizures. If seizures or recurrent stroke were reported, information from the treating 
physician was retrieved. This information was verified and adjudicated by an experienced 
neurologist who was blinded for the index event (FEdL).65
Post-stroke epilepsy
Post-stroke epilepsy was defined according to the International League Against Epilepsy, as 
a paroxysmal disorder of the CNS with our without loss of consciousness or awareness and 
possible motor involvement.72 Post-stroke seizures were classified as early seizures (occurring 
within 7 days after stroke) and late seizures (occurring thereafter).74 Recurrent seizures were 
included as a determinant as well.
Cognitive performance 
The following cognitive domains were examined: Processing speed (Symbol-Digit Modalities 
Test, Abbreviated Stroop Color Word Test, parts I and II), Visuoconstruction (Rey-Osterrieth 
Complex Figure – Copy trial), Working memory (Paper and Pencil Memory Scanning Task), 
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Immediate memory (Rey-Osterrieth Complex Figure – Immediate recall and the total 
number of words immediately recalled in the three-trial version of the Rey Auditory Verbal 
Learning Test), Delayed memory (delayed recall on the Reu-Osterrieth Complex Figure and 
the Rey Auditory Verbal Learning Test), Attention (Verbal Series Attention Test) and Executive 
functioning (Verbal Fluency and Stroop Interference). The mean z-scores of all seven domains 
were averaged to calculate a compound score for global cognitive performance. Detailed 
information on the neuropsychological examination and calculation of domain-scores is 
described extensively elsewhere.65, 86 
Primary outcome was mean global cognitive performance and cognitive performances on 
the different cognitive domains. Secondary outcome was cognitive impairment (>1.5 SD 
below the age-adjusted mean of control subjects).103
Statistical analysis
For comparison of clinical and demographical characteristics between patients with and 
without epilepsy, students-t-test, Mann-Whitney U test or chi-square test were used when 
appropriate. 
All cognitive domains were compared by an ANOVA model between patients with and without 
post-stroke epilepsy. Covariates in the model were, age at follow-up, level of education, NIHSS 
and recurrent stroke or TIA. Mean adjusted z-scores with 95% CI were presented for patients 
with and without post-stroke epilepsy. Inspection of the data using Shapiro-Wilk-test and 
Q-Q plots indicated that the normality assumptions were satisfied. Sensitivity analysis was 
performed to determine the impact of outliers. Analyses were performed with and without 
outliers and results were compared. 
To compare early and late seizures, a univariate one-way ANOVA was used in which a factor 
for ‘no, early or late seizures’ was added. In addition, a univariate one-way ANOVA was used 
to compare single and recurrent seizures.
A Chi-square test was used for comparing the proportion patients with and without post-
stroke epilepsy with cognitive impairment. By means of binary logistic regression we 
calculated odds ratios (ORs) for cognitive impairment for patients with post-stroke epilepsy, 
adjusted for previous mentioned covariates. In addition, to assess the effect of stroke 
location, we performed a logistic regression analysis for global cognitive impairment with 
stroke location as covariate.
To adjust for multiple comparisons in all analyses a Bonferroni correction was applied 
(p-values <0.0071 were considered significant, since there were seven pair wise comparisons 
for each analysis). All p-values reported were two-sided. SPSS 20 was used for all statistical 
analyses.
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Results
Study population
427 Patients (TIA n=157, ischemic stroke n=270) were eligible for participation in the present 
study. Non-participants (refusers n=136, lost to follow-up n=72, participants of FUTURE but 
non-participants of neuropsychocological investigations n=79) less often had a TIA (27.6% 
versus 36.8%) and more often had an ischemic stroke (72.4% versus 63.2%) than participants. 
There was no difference in the occurrence of post-stroke epilepsy between participants and 
patients who did not underwent the neuropsychological investigations (38 [8.9%] versus 6 
[8.5%]).
Patients who died (n=133), more often had an ischemic stroke (82.7% versus 63.2%) and 
less often had a TIA (17.3% versus 36.8%), they were older (42.6 versus 40.3 years) and had a 
higher NIHSS (5 [IQR 2-12] versus 2 [IQR 0-6]). 24 (18%) of the patients who died developed 
post-stroke epilepsy during follow-up.
After mean follow-up of 10.2 (SD 8.3) years, 38 patients (8.9%) developed post-stroke epilepsy. 
Table 1 shows the clinical characteristics for patients with and without epilepsy. 
Cognitive performance
At follow-up patients with post-stroke epilepsy had a worse global cognitive performance 
than those without adjusted for confounders (group difference in adjusted mean z-score: 
0.325, 95%CI 0.117-0.534, p=0.002). Patients with epilepsy performed worse on the domains 
processing speed and working memory (group difference in adjusted mean z-score: 0.582, 
95%CI 0.213-0.950, p=0.002 and 0.488, 95%CI 0.172-0.804, p=0.003 respectively) (Figure 1). 
Exclusion of outliers did not change our results.
In 11 patients the first seizure was an early seizure and 27 patients had a late seizure. 2 Of 
the patients with an initial seizure developed late seizures as well. Patients with an initial 
late seizure had a worse global cognitive performance than patients without seizures 
(group difference mean z-score: 0.649, 95%CI 0.350-0.949, p<0.001). Patients with an initial 
late seizure performed worse on processing speed (group difference mean z-score: 0.953, 
95%CI 0.0.467-1.149, p<0.001), visuoconstruction (group difference mean z-score: 0.667, 
95%CI 0.190-1.144, p=0.006) and working memory (group difference mean z-score: 0.1.043, 
95% CI 0.620-1.465, p<0.001). Patients with an initial early seizure did not differ in cognitive 
performance from patients without seizures (Figure 2).
15 of the 38 patients with epilepsy developed post-stroke epilepsy with recurrent seizures. 
There were no differences in cognitive performance between patients with a single seizure 
and patients with recurrent seizures, however patients with recurrent seizures performed 
worse than patients with no seizures (Figure 3). During follow-up 30 (78.9%) patients with 
epilepsy used AEDs, whereas 24 patients (63.2%) still used AEDs at the moment of cognitive 
assessment. There were no differences in cognitive performance between patients who used 
AEDs at the moment of cognitive assessment and those who did not.
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Table 1 Clinical characteristics
Seizures
Present n=38 (%) Absent n=389 (%) p-value
Stroke subtype
TIA 3 (7.9) 154 (39.6) <0.001
Ischemic stroke 35 (92.1) 235 (60.4) <0.001
Sex, male 20 (52.6) 212 (54.5) 0.825
Mean age at index event (SD) 38.9 (7.3) 40.5 (7.9) 0.105
NIHSS at admission, median (IQR)a 6 (2.5-12) 1 (0-5) <0.001
TOAST-classification
Large artery 6 (15.8) 98 (24.4) 0.232
Cardio embolism 6 (15.8) 36 (9.3) 0.197
Small Vessel 0 45 (11.6) 0.023
Other determined 13 (34.2) 48 (12.3) <0.001
Multiple 1 (2.6) 7 (1.8) 0.303
Unknown 12 (31.6) 158 (40.6) 0.277
History of vascular risk factors
Hypertension 4 (10.5) 101 (26.0) 0.035
Diabetes mellitus 0 19 (4.9) 0.397
Smokinga 17 (47.2) 181 (47.6) 0.963
Alcohol 4 (10.5) 22 (5.7) 0.231
Stroke location 
Left hemispheric 14 (36.8) 165 (44.1) 0.389
Right hemispheric 19 (50.0) 124 (33.2) 0.038
Bilateral 3 (7.9) 1 (0.3) <0.001
Infratentorial 2 (5.3) 84 (22.5) 0.013
Follow-up duration (IQR) 8.4 (4.8-17.3) 6.7 (3.0-16.4) 0.231
Mean age at follow-up examination (SD) 50.1 (10.1) 50.6 (10.7) 0.559
Education, median (IQR) 5 (4-5) 5 (4-6) 0.355
mRS at follow-up, median (IQR) 1 (1-2) 1 (0-1) 0.008
Recurrent strokes 8 (21.1) 64 (16.5) 0.470
Abbreviations: TIA=transient ischemic attack; SD=standard deviation; IQR=interquartile range; NIHSS=National 
Institutes of Health Stroke Scale; TOAST= Trial of Org 10172 in Acute Stroke Treatment; mRS=modified Rankin 
Scale.
ain 0.5% NIHSS was missing and in 2.6% smoking status was missing
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Figure 1. Cognitive performance for patients with and without epilepsy
This figure shows adjusted mean composite Z-scores (95% CI) per cognitive domain for patients with and 
without post-stroke epilepsy (adjusted for age at follow-up, education, stroke severity and recurrent stroke). 
-2,5 
-2 
-1,5 
-1 
-0,5 
0 
0,5 
1 
1,5 
Do
m
ai
n 
co
m
po
sit
e 
Z-
sc
or
e 
No seizures 
Early seizures 
Late seizures 
Processing  
speed 
Visuo- 
construction 
Working  
memory 
Immediate  
memory 
Delayed  
memory 
Attention Executive 
functioning 
Global 
cognitive 
performance 
p<0.001 p<0.001 p<0.0001 p=0.006 
Number of patients 
No seizure           382                    376                     379                   386              382          367      386  379           
Early seizures      11                       11                       11                    11                       11                        9       10   11 
Late seizures       24                       26                       25                         27               26           24       26   26       
Figure 2. Cognitive performance according to onset of seizure
This figure shows mean composite Z-scores (95% CI) per cognitive domain for patients without seizures, early seizures 
and late seizures, measured by one-way ANOVA. p-value denotes the diff erence between late and no seizures.
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Figure 3. Cognitive performance according to seizure recurrence
This figure shows mean composite Z-scores (95% CI) per cognitive domain for patients without seizures, 
single seizure and recurrent seizures, measured by one-way ANOVA. p-value denotes the diff erence 
between recurrent and no seizures.
Cognitive impairment 
Global cognitive impairment was more frequent among patients with post-stroke epilepsy 
than among patients without (45.9% and 25.1% respectively, p=0.006) (Figure 4). 
Binary logistic regression showed that patients with epilepsy more oft en had an impaired 
processing speed (OR 3.1 95%CI 1.4-7.0, p=0.007) aft er adjustment for confounders than 
those without. 
To evaluate the eff ect of stroke location, a logistic regression model with stroke location 
as covariate was created. Aft er adjusting for stroke location, post-stroke epilepsy remained 
associated with cognitive impairment (OR 2.8, 95%CI 1.3-5.7, p=0.006). 
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Figure 4. Cognitive impairment for patients with and without epilepsy
This figure shows the proportion of patients with a cognitive impairment (>1.5SD below the average mean 
of controls) for patients with and without post-stroke epilepsy. P-values are based on chi-square.
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Discussion
We showed that aft er stroke at young age, patients with post-stroke epilepsy had a worse 
global cognitive performance than patients without, even aft er adjustment for stroke 
severity, education and recurrent stroke. Even up to 55% of the patients with post-stroke 
epilepsy had an impairment in one of the domains. Especially patients with an initial late 
seizure performed worse. 
To our knowledge, this study is the first to investigate the association between epilepsy aft er 
stroke in young adults and cognitive function. We were able to investigate the main cognitive 
domains with an extensive neuropsychological examination in a large sample aft er a long 
follow-up duration of more than 10 years. Other strengths of our study were the prospective 
single centre design, which allowed us to collect information in a systematic and uniform 
way. Strict instruction protocols were used for the assessment of cognitive performance and 
trained researchers were blinded for clinical data, hereby reducing information bias.
However, there are also a few limitations that need to be addressed. First of all, the present 
study only included patients who underwent the extensive neuropsychological examination, 
which may have lead to selection bias. Obviously, patients who died were not included in our 
analyses. Patients who died had a more severe stroke and a higher proportion of post-stroke 
epilepsy. In addition, we have previously shown that post-stroke epilepsy is associated with 
mortality104, this makes it likely that those who died and had post-stroke epilepsy are also 
the ones with a poor cognitive performance. This would have lead to an underestimation of 
our results. Furthermore, survivors who did not participate might have been the ones with a 
poor outcome. Even though there were no diff erences in stroke severity between those who 
participated in the present study and those who did not, data on cognitive performance is 
missing. 
To avoid misclassification between a TIA and seizures, all events were verified by two 
independent neurologists, independent from outcome. TIA was diagnosed according to 
clinical guidelines and patients with positive phenomena such as twitches and jerks were 
excluded.97 
Third, statistical power was limited when comparing patients with a single seizure with those 
with recurrent seizures, as the number of patients in each group was small. This may have 
resulted in not enough power to detect a diff erence between both groups.
Last, we have tried to overcome the problem of confounding bias by adjusting for the 
most important confounding factors such as age at follow-up, education, stroke severity 
and recurrent stroke. As stroke location (especially left  hemispheric stroke) and recurrent 
stroke may be very important for the cognitive reserve, a separate model to adjust for stroke 
location was created.
We have shown that post-stroke epilepsy aft er a stroke at young age has a widespread 
impact on cognitive function, aff ecting multiple domains. The domains working memory 
and processing speed were most aff ected, resulting in problems with use and storage 
of information and speed of information processing. Problems on those domains may 
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have large consequences when it comes to the hectic and demanding life in which young 
patients may find themselves. The availability of this information is of major importance to 
adequately inform patients, for example on what to expect when it comes to working careers 
and planning families. 
There are a few explanations for a poor cognitive performance in patients with post-stroke 
epilepsy. First of all, seizures themselves on top of the post-stroke cognitive deficit, might 
have a negative influence on cognition. Based on data derived from the general epilepsy 
population, it has been suggested that seizures could result in progressive neuronal damage, 
resulting in accumulating cognitive dysfunction.105 Other studies suggest that additional 
metabolic stress of seizures, on top of already vulnerable tissue, worsens neurological and 
functional outcome.88, 106 Second, patients with epilepsy might also experience inter-ictal 
discharges, which may influence cognitive performance. 
Finally, it is well known that AEDs influence cognitive performance.95 This might also be the 
reason that patients with late seizures have a worse cognitive performance, as those are 
usually treated with AEDs. However, we did not find a difference in cognitive performance 
between patients who used AEDs at the moment of the cognitive assessment and those who 
did not in our study. It should be noted that almost 80% of the patients with epilepsy used 
AEDs during a certain moment of follow-up and patients may have stopped and switched 
AEDs, which may have influenced cognition. We were not able to take this into account in our 
analyses. In addition, the number of patients with post-stroke epilepsy in our study might 
have been too small to detect a difference between patients with and without AEDs.
In conclusion, we showed that epilepsy after a stroke in young adults is associated with a 
worse cognitive performance affecting several domains. Future studies should investigate 
the role of AEDs and the effects on cognitive outcome in post-stroke patients.
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6.
Post-stroke epilepsy after a stroke at 
young age is associated with mortality
Published as:
Post-stroke epilepsy is associated with a high mortality after a stroke at young age. 
Follow-up of Transient ischemic attack and stroke patients and Unelucidated Risk factor 
Evaluation Study.
Renate M. Arntz, Loes C.A. Rutten-Jacobs, Noortje A.M.M. Maaijwee, Hennie C. 
Schoonderwaldt, Lucille D. Dorresteijn, Ewoud J. van Dijk, Frank-Erik de Leeuw
Stroke 2015; 46(8):2309-2311
Chapter 6
82
Abstract
Background and purpose: Post-stroke epilepsy is a common complication after a young 
stroke. We investigated the association between post-stroke epilepsy and mortality.
Methods: We performed a prospective cohort study among 631 patients with a first-ever 
TIA or ischemic stroke, aged 18-50 years. Survival analysis and Cox proportional hazard 
analysis were used to estimate cumulative mortality and hazard ratios for patients with 
and without epilepsy.
Results: After mean follow-up of 12.5 years (SD 8.6), 76 (12.0%) developed post-stroke 
epilepsy. Case fatality was 27.4% for patients with post-stroke epilepsy and 2.1% for those 
without. Post-stroke epilepsy was associated with 30-day mortality (HR 4.8 95% CI 1.7-14.0) 
and long-term mortality (HR 1.8, 95% CI 1.2-2.9).
Conclusions: Epilepsy is a common problem after a young stroke and is associated with an 
increased short-term and long-term mortality. 
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Introduction
Epilepsy is a common complication after stroke in young adults. Those with post-stroke 
epilepsy have an even more impaired functional outcome in their already compromised 
life than patients without epilepsy.97 There are no studies on the association between post-
stroke epilepsy and mortality in young adults. A large cohort study in elderly stroke patients 
showed that seizures were associated with case fatality and mortality at 1 year, in particular 
in patients with a less severe stroke16, while other showed conflicting results and usually did 
not take stroke severity into account and had a short follow-up.9, 11, 14 Long-term prognosis is 
of utmost importance, especially in young patients who usually still have a life expectancy of 
decades ahead. 
The aim of this study was therefore to investigate the relation between post-stroke epilepsy 
and the risk of short- and long-term mortality in patients with a transient ischemic attack 
(TIA) or ischemic stroke at young age.
Methods
Study population
This study is part of the “Follow-Up of Transient ischemic attack and stroke patients and 
Unelucidated Risk factor Evaluation”-study (FUTURE study). The Medical Review Ethics 
Committee region Arnhem-Nijmegen approved the study. Participants provided written 
informed consent.
The FUTURE study comprises all consecutive patients with a TIA, ischemic stroke or 
intracerebral haemorrhage, aged 18-50 years, admitted to the Radboud University Nijmegen 
Medical Centre from January 1980 until November 2010.65 To minimize bias due to changing 
diagnostic techniques, the World Health Organisation definition for TIA and stroke was used.67 
TIA was defined as a rapidly evolving focal neurological deficit with no other than a vascular 
cause lasting less than 24 hours. Stroke was defined similarly, but with symptoms lasting 
more than 24 hours. For the present study only patients with a first-ever TIA or ischemic 
stroke were included. Exclusion criteria were cerebral venous sinus thrombosis and retinal 
infarction. A history seizures was an additional exclusion criterion.
At baseline the assessment of stroke aetiology (Trial of Org 10172 in Acute Stroke Treatment 
[TOAST]) and severity National Institutes of Health Stroke Scale (NIHSS) was done for all 
cases retrospectively71, as these scales did not exist when a substantial proportion of our 
patients experienced their qualifying event. 
Post-stroke epilepsy
Follow-up took place between November 2009 and January 2012 and subsequently 
between August 2014 and January 2015. During both follow-up assessments, patients 
underwent standardised, structured questionnaires to evaluate the occurrence of seizures. 
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In case a patient had died, information on the occurrence of seizures was retrieved from the 
general practitioner by the same structured questionnaires. When patients (or their general 
practitioners) reported seizures, medical records were retrieved from their treating physician. 
This information was subsequently verified and adjudicated by an experienced neurologist 
who was blinded for the index event and outcome.
Post-stroke epilepsy was defined according to the International League Against Epilepsy as 
a paroxysmal disorder of the central nervous system with our without loss of consciousness 
and possible motor involvement.72 Early seizures were defined as those occurring within 1 
week after the index event, late seizures thereafter. 
Mortality
Primary outcomes were all-cause long-term mortality and case fatality (death within 30 
days after the index event). Information on the vital status was retrieved from the Dutch 
Municipal Personal Records database. Deaths were classified according to the International 
Classification of Diseases.107 Causes were categorized into stroke, cardiac, other vascular, 
malignancies, infections and miscellaneous. 
Statistical analysis
Cumulative case fatality and long-term mortality were estimated with Kaplan-Meier analysis 
for patients with and without epilepsy. In all analyses a time varying variable for post-stroke 
epilepsy was created, as patients develop post-stroke epilepsy during follow-up (and not 
fixed at baseline). For long-term mortality, survival plots were curtailed at 20 years to ensure 
reliable plots for all subgroups.
Cox proportional hazard models were used to calculate hazard ratios (HRs) for death with 
post-stroke epilepsy as a time varying variable. For case fatality, covariates in the model 
were sex, age at event and NIHSS. For long-term mortality, covariates included sex, age at 
index event, history of diabetes mellitus, history of hypertension, TOAST-classification and 
recurrent stroke. In addition analyses were stratified by stroke severity (mild: NIHSS 0-4; 
moderate: NIHSS 5-11; severe NIHSS≥12). 
A Cox proportional hazard model was constructed with age, sex and period of the qualifying 
event (1980-1989, 1990-1999, 2000-2010) to evaluate whether a cohort or period effect could 
have influenced or mortality results, because the present study features a long inclusion 
period.
Schoenfeld residuals from the Cox models were examined to assess possible departures from 
model assumptions. There were no indications that the proportional hazards assumption 
was violated.
post-stroke epilepsy and mortality
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Results
Study population
Baseline characteristics of participants (n=631) are shown in table 1. Stroke pathogenesis 
and comparison with non-participants is shown in table 2 and 3. After mean follow-up of 12.5 
(SD 8.6) years, 76 patients (12.0%) developed post-stroke epilepsy. In 27.6% the first seizure 
was an early seizure and in 72.4% the first seizure was a late seizure. In addition, 36 patients 
developed recurrent seizures. 
Cox proportional hazard models of mortality revealed no significant effect of the period in 
which patients experienced their qualifying event (1980-1989, 1990-1999 and 2000-2010), 
adjusted for age and sex.
Table 1. Baseline characteristics
Epilepsy
Absent, 
n=555 (%)
Present,  
n=76 (%)
Stroke subtype
TIA 198 (35.7) 8 (10.5)
Ischemic stroke 357 (64.3) 68 (89.5)
Mean age (SD) 40.8 (7.8) 40.4 (7.3)
Sex, male 255 (45.9) 39 (51.3)
Mean follow-up (SD) 12.5 (8.6) 12.5 (8.9)
NIHSS, median (IQR)* 2 (0-6) 8 (2-14)
TOAST
Large artery 146 (26.3) 15 (19.7)
Cardio-embolism 68 (12.3) 16 (21.2)
Lacunar 60 (10.8) 0
Other determined 68 (12.3) 23 (30.3)
Multiple 15 (2.7) 2 (2.6)
Undetermined 198 (35.7) 20 (26.3)
Vascular risk factors
Diabetes mellitus 36 (6.5) 3 (3.9)
Hypertension 164 (29.5) 19 (25.0)
Atrial fibrillation 11 (2.0) 1 (1.3)
Smoking† 273 (49.2) 40 (52.6)
Abbreviations: TIA=transient ischemic attack; SD=standard deviation; NIHSS=National Institutes of Health 
Stroke Scale; IQR=interquartiel range; TOAST=Trial of Org 10172 in Acute Stroke Treatment, 
*0.5% missing
†4.4% missing
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Table 2. Participants versus non-participants 
Participants,  
n=631 (%)
Non-participants, 
n=208 (%)
p-value*
Stroke subtype
TIA 206 (32.6) 51 (24.5) 0.027
Ischemic stroke 425 (67.4) 157 (75.5)
Mean age (SD) 40.8 (7.7) 39.2 (8.2) 0.022
Sex, male 294 (46.6) 91 (43.8) 0.476
Mean follow-up (SD) 12.5 (8.6) NA
NIHSS, median (IQR) † 3 (1-7) 3 (1-7) 0.685
TOAST
Large artery 161 (25.5) 50 (24.0) 0.670
Cardio-embolism 84 (13.3) 23 (11.1) 0.398
Lacunar 60 (9.5) 26 (12.5) 0.217
Other determined 91 (14.4) 36 (17.3) 0.314
Multiple 17 (2.7) 4 (1.9) 0.537
Undetermined 218 (34.5) 69 (33.2) 0.717
Vascular risk factors
Diabetes mellitus 39 (6.2) 8 (3.8) 0.204
Hypertension 183 (29.0) 47 (22.6) 0.072
Atrial fibrillation 12 (1.9) 3 (1.4) 0.665
Smoking‡ 313 (49.6) 116 (57.4) 0.195
Abbreviations: TIA=transient ischemic attack; SD=Standard deviation; NIHSS=National Institutes of Health 
Stroke Scale; IQR=interquartile range; TOAST=Trial of Org 10172 in Acute Stroke Treatment.
*p-value: significance between participants and non-participants of present study
†0.5% missing
‡4.4% missing
post-stroke epilepsy and mortality
87
Ch
ap
te
r 6
Table 3. Other determined stroke aetiologies
Epilepsy
Absent, n=68 (%) Present, n=23 (%)
Arteriopathy
Dissection 23 (33.8) 6 (26.1)
Vasculitis 3 (4.4) 1 (4.3)
Moyamoya 3 (4.4) 2 (8.7)
Migraine 4 (5.9) 1 (4.3)
Coagulopathy 14 (20.6) 4 (17.4)
Systemic disease 6 (8.8) 2 (8.7)
Genetic 2 (2.9) 0
Toxic 3 (4.4) 2 (8.7)
Post-surgery 4 (5.9) 4 (17.4)
Traumatic 3 (4.4) 1 (4.3)
Pregnancy related 3 (4.4) 2 (8.7)
This table shows the aetiologies of the ‘other determined’ category of the TOAST-classification stratified by the 
occurrence of post-stroke epilepsy.
Case fatality
A total of 21 Patients (3.3%) died within 30 days after the index event. Twenty-eight patients 
(4.4%) developed post-stroke epilepsy within these first 30 days. Cumulative case fatality 
was higher among those with post-stroke epilepsy than those without (27.4% versus 
2.1%, p<0.0001) (figure 1A). After adjusting for confounders, post-stroke epilepsy remained 
associated with case fatality (HR 4.8, 95% CI 1.7-14.0, p=0.004). Stroke was the major cause 
of death (Table 4).  
Long-term mortality 
At the end of follow-up 153 (24.2%) of all patients had died, 32.9% of the patients with and 
23.1% of the patients without post-stroke epilepsy. Figure 1B shows 20-years cumulative 
mortality for patients with and without epilepsy (56.5% and 32.6% respectively, p=0.007). 
There were no differences in cause of death (Table 4). Post-stroke epilepsy remained 
significantly associated with mortality after adjustment for confounders (HR 1.8, 95% CI 
1.2-2.9, p=0.009). In patients with a mild stroke, post-stroke epilepsy was associated with 
mortality, after adjustment for confounders (HR 2.5, 95% CI 1.2-5.3, p=0.012). Post-stroke 
epilepsy was not associated with mortality in the moderate and severe stroke groups.
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Figure 1. Cumulative mortality for patients with and without post-stroke epilepsy 
A.
B.
This figure shows (A) case fatality and (B) long-term mortality for patients with and without post-stroke 
epilepsy (p=0.004 and p=0.007 respectively).
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Table 4. Cause of death
Case fatality Overall mortality*
Epilepsy Epilepsy
Cause of death Absent (%) Present (%) Absent, (%) Present (%)
Stroke 13 (86.7) 5 (83.3) 32 (25.2) 7 (28.0)
Complications from initial stroke 13 (86.7) 4 (66.7) 16 (12.6) 4 (16.0)
Recurrent stroke 0 1 (16.7) 16 (12.6) 3 (12.0)
Cardiac 0 1 (16.7) 27 (21.3) 9 (36.0)
Other vascular 2 (13.3) 0 9 (7.1) 1 (4.0)
Malignancies 0 0 27 (21.3) 3 (12.0)
Infections 0 0 12 (9.4) 4 (16.0)
Miscellaneous 0 0 13 (10.2) 1 (4.0)
Cause of death among patients who died within 30 days after the index event and overall cause of death, 
stratified by the occurrence of post-stroke epilepsy.
*Cause of death was missing in 7 patients.
Discussion
Post-stroke epilepsy was associated with long-term mortality and case fatality in patients 
with a stroke at young age.
Strengths of our study were the prospective and single centre design. Furthermore, our study 
has one of the longest follow-up duration and largest cohort. 
There are also a few limitations. Selection bias may have occurred due to selective loss to 
follow-up. However, there was no difference in NIHSS, making this less likely.
Since our study features a long inclusion period, recall bias might have influenced our 
findings, especially when patients died a long time ago. However, we did not find a difference 
in incidence of epilepsy between patients who died a long time ago and those who died 
more recently. Furthermore, imaging techniques have changed over the past 30 years, which 
may have resulted in misclassification. We have tried to overcome this by using the clinical 
definitions of stroke and TIA according to the World Health Organisation.
Post-stroke epilepsy was associated with case fatality. An explanation might be that patients 
with post-stroke epilepsy have a more severe stroke. However, after adjustment for NIHSS, 
epilepsy remained associated with mortality. Nevertheless, since NIHSS assessment was 
done retrospectively as this scale did not exist when a large proportion of our population 
experienced their qualifying event, measurement error in stroke severity during this long 
inclusion period cannot totally be excluded.
In addition, we found that patients with post-stroke epilepsy had a higher long-term 
cumulative mortality, even after adjusting for confounders. Especially in patients with a less 
severe stroke epilepsy was associated with mortality. Probably in patients with more severe 
strokes, severity is more important for mortality than post-stroke epilepsy. In a large study 
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on stroke patients over 50 years, it was also shown that in patients with a less severe stroke 
epilepsy was associated with mortality16, however follow-up was limited.  
In conclusion we showed that post-stroke epilepsy is associated with both case fatality and 
long-term mortality. Future studies should investigate the role of antiepileptic drugs in post-
stroke epilepsy and the association with outcome.
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Part III│
Long-term vascular consequences after a 
stroke at young age

7.
Very long-term risk and predictors of 
recurrent ischemic events after a stroke at 
young age
Published as:
The very long-term risk and predictors of recurrent ischaemic events after a stroke at a 
young age: The FUTURE study.
Renate M. Arntz, Mayte E. van Alebeek, Nathalie E. Synhaeve, Jeske van Pamelen, Noortje 
A.M.M. Maaijwee, Hennie C. Schoonderwaldt, Maureen J. van der Vlugt, Loes C.A. Rutten-
Jacobs, Frank-Erik de Leeuw.
European Stroke Journal 2016; 1(4):337-345
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Abstract
Introduction: Patients who suffer a stroke at a young age remain at a substantial risk 
of developing recurrent vascular events and information on very long-term prognosis 
and its risk factors is indispensable. Our aim is to investigate this very long-term risk and 
associated risk factors up to 35 years after stroke.
 
Methods: Prospective cohort study among 656 patients with a first-ever ischemic stroke 
or transient ischemic attack, aged 18-50, who visited our hospital (1980–2010). Outcomes 
assessed at follow-up (2014-2015) included TIA or ischemic stroke and other arterial events, 
whichever occurred first. Kaplan-Meier analysis quantified cumulative risks. A prediction 
model was constructed to asses risk factors independently associated with any ischemic 
event using Cox proportional hazard analyses followed by bootstrap validation procedure 
to avoid overestimation.
Results: Mean follow-up was 12.4 (SD 8.2) years (8105 person-years). 25-years cumulative 
risk was 45.4% (95%CI 39.4-51.5) for any ischemic event, 30.1% (95%CI 24.8-35.4) for cerebral 
ischemia and 27.0% (95%CI 21.1-33.0) for other arterial events. Risk factors retained in 
the prediction model were smoking (HR 1.35, 95%CI 1.04-1.74), poor kidney function (HR 
2.10, 95%CI 1.32-3.35), history of peripheral arterial disease (HR 2.10, 95%CI 1.08-3.76) and 
cardiac disease (HR 1.84, 95%CI 1.06-3.18) (C-statistic 0.59 (95%CI 0.55-0.64).
 
Conclusions: Young stroke patients remain at a substantial risk for recurrent events; 
almost 1 of 2 develops a recurrent ischemic event and 1 of 3 develops a recurrent stroke 
or transient ischemic attack during 25 years of follow-up. Risk factors independently 
associated with recurrent events were poor kidney function, smoking, history of peripheral 
arterial disease and cardiac disease. 
long-term risk and predictors of recurrent ischemic events
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Introduction
Long-term prognosis after a stroke at a young age is significantly affected by occurrence of 
incident vascular events. It is already known that this risk is not only high in the first months or 
years after stroke, but patients remain at a substantial risk even 10 years after their initial stroke.17 
Reliable information thereafter is largely lacking, though important to know as after 10 years 
these patients are still young and can expect to live for many more decades. Providing young 
adults with reliable information on the course of their disease, including the risk factors 
associated with this prognosis, also after the first 10 years is therefore of utmost importance. 
Only a few large studies have tried to identify which particular risk factors were associated with 
recurrent vascular events. However in those studies mean follow-up did not exceed 5 years 
18, 19, or only the association between the etiologic subgroups based on TOAST-classification 
(Trial of Org 10172 in Acute Stroke Treatment) and recurrent events was taken into account 
rather than subgroups based on (potentially modifiable) risk factors.108 Also, prognosis has 
only been examined for the overall stroke population. Though this is important information 
from health care perspective, this does not always answer the question of individual patients 
who have a particular interest in their own, personalized prognosis. One study did develop a 
score for individual risk estimation of recurrent thrombotic events, with a moderate predictive 
value and follow-up duration of more than 3 years.18 Especially for younger patients, an 
individualized long-term risk assessment, after this first years, is also of great importance. 
Therefore, the aims of this study were to investigate the very long-term risk of recurrent 
vascular events up to 35 years after a stroke at a young age. In addition, we aimed to identify 
risk factors independently associated with the risk of recurrent vascular events on the long-
term. Subsequently, predictive performance of the resulting model was assessed.
Patients and methods
Study population
This study is part of the “Follow-Up of Transient ischemic attack and stroke patients and 
Unelucidated Risk factor Evaluation”-study (FUTURE study), a prospective cohort study 
on causes and consequences of a stroke in young adults.90 Detailed methods have been 
described previously.17 The Medical Review Ethics Committee region Arnhem-Nijmegen 
approved the study. All patients signed informed consent. 
In the present study we included all consecutive patients with a first-ever transient ischemic 
attack (TIA) or ischemic stroke, aged 18-50 years, admitted to the Radboud University 
Nijmegen Medical Centre from 1980 till 2010. The World Health Organisation definition for 
TIA and stroke was used.67 
Patients were identified through a prospective registry with standardised collection of 
baseline characteristics. Cardiovascular risk factors were defined as a history of a risk factor 
or detected during analysis of the initial event: hypertension as mean systolic blood pressure 
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≥135 mmHg or a diastolic blood pressure of ≥85 mmHg, measured after the first week of the 
index event85 or the use of antihypertensive medication; diabetes mellitus as random blood 
glucose level >200 mg/dL (11.1 mmol/L) or two consecutive fasting venous plasma glucose 
levels ≥6.1 mg/dL (7.0 mmol/L)109 or the use of antidiabetics; dyslipidemia as total cholesterol 
≥5.0 mmol/L, LDL ≥2.5 mmol/L or triglycerides ≥2.0 mmol/L17 or the use of statins; smoking as 
at least 1 cigarette per day in the year prior to the event; atrial fibrillation when identified on 
electrocardiogram (ECG) or during continuous electrocardiographic recording; excess alcohol 
consumption as consuming more than 200 g of pure alcohol per week. Kidney function was 
divided in estimated glomerular filtration rate (eGFR) <60, eGFR 60-120 and eGFR>120 mL/
min/1.73m2.110 In addition, a history of cardiovascular disease (myocardial infarction, cardiac 
intervention procedures and peripheral artery revascularization procedures) was collected.
The assessment of stroke aetiology (TOAST)68 and severity (National Institutes of Health 
Stroke Scale[NIHSS]69) was done for all cases retrospectively by a validated approach.71
Follow-up
Follow-up assessment took place from 2009 to 2012 and subsequently from August 2014 to 
January 2015. In case information from this last follow-up assessment was missing, follow-
up data from the previous follow-up (2009-2012) were used (n=28, 4.3%). Patients underwent 
structured questionnaires on the occurrence of recurrent events. In case a patient had died, 
information was retrieved by the general practitioner. All confirmed events were verified 
by a neurologist or cardiologist. TIA and ischemic stroke were defined similar to the index 
event, myocardial infarction was defined according to the universal definition of myocardial 
infarction.111 
Outcome
Primary outcome was the risk of any recurrent ischemic event, defined as the composite of 
cerebral ischemia (ischemic stroke or TIA) and other arterial events (myocardial infarction, 
coronary artery bypass grafting, percutaneous coronary intervention, carotid endarterectomy 
or peripheral artery revascularization procedures). Secondary outcomes were the risk of 
recurrent cerebral ischemia and the risk of other arterial events. 
Statistical analysis
Kaplan-Meier analysis was used to estimate cumulative risks of any ischemic event, cerebral 
ischemia and other arterial event, whichever occurred first. Person-years at risk were 
calculated for each patient from date of the index stroke until recurrent event, death or end 
of follow-up. Patients who died and/or did not reach an endpoint were censored. Survival 
plots were curtailed at 25 years to ensure that the provided survival plots were reliable for 
all subgroups112, all events were retained in subsequent analyses. Analyses were stratified 
by stroke subtype, age categories (18-29, 30-39 and 40-50 years) and TOAST-subtype with 
undetermined cause as reference.
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Annual risks were calculated from survival estimates obtained by Kaplan-Meier analysis. 
Mean annual risks were subsequently calculated for the periods 2-5 years, 6-10 years, 11-15 
years, 16-20 years and 21-25 years.
Missing data were handled using multiple imputation by the method of chained equations 
(eGFR 29.9% and dyslipidemia 20%).113, under the assumption that missing data was missing 
at random. 30 imputed datasets were created using predictive mean matching for eGFR and 
logistic regression for dyslipidemia. All variables considered in the subsequent regression 
analyses were included in the imputation model. Regression analyses were performed on 
each of the imputed datasets individually and subsequently the coefficients were pooled 
using Rubin’s rules.114 Restricting the analyses to only complete patients, yielded similar 
point estimates as obtained in the imputed datasets. Cox proportional hazard analysis was 
used to calculate hazard ratios (HRs) with their 95% confidence intervals (CIs) for baseline 
characteristics adjusted for age and sex for the risk of any ischemic event, cerebral ischemia 
and other arterial events.
A composite variable with number of traditional risk factors was used (diabetes mellitus, 
hypertension, smoking, dyslipidemia or atrial fibrillation). 
Finally we constructed a multivariable Cox regression model to predict recurrent ischemic 
events. All predictors were considered for entrance in the models irrespective of their 
univariable association with the outcome.  Subsequently, the model was simplified using a 
backward selection procedure (exclusion if p<0.20).
A bootstrap validation procedure (b=100) was performed to avoid overestimation in regression 
coefficients.115 A shrinkage factor was derived from this procedure and subsequently applied 
to the regression coefficients. Discriminative performance of the model was assessed by 
calculating the concordance (c) statics. Also the c-statistic was corrected for overoptimism by 
applying the bootstrap validation procedure. All p-values of less than 0.05 were considered 
as significant. IBM SPSS 20.0 and R version 3.2.1 software package (packages MICE version 
2.25 and RMS version 4.4-0) were used.
Results
Study population
656 patients entered present study, 209 (31.9%) patients with TIA and 447 
(61.7%) patients with ischemic stroke. Mean follow-up was 12.4 (SD8.6) years 
and 21.3% had a follow-up of more than 20 years. At the end of follow-up 167 
(25.5%) patients were deceased. Baseline characteristics are shown in table 1. 
There were no differences in baseline characteristics between participants and non-
participants (lost to follow-up n=73 and refusers n=139) except for age (39.1 years (SD8.2) 
versus 40.7 years (SD7.7) respectively).   
Chapter 7
100
Table 1. Baseline characteristics
Total 
n=656
TIA 
n=209 
Ischemic stroke 
n=447 
Mean age at time of event, years (SD) 40.7 (7.7) 40.6 (8.0) 40.8 (7.6)
Men, n (%) 309 (47.1) 94 (45.0) 215 (48.1)
Mean follow-up time, years (SD) 12.4 (8.6) 11.9 (8.1) 12.6 (8.8)
>15 years 217 (33.1) 56 (26.8) 171 (38.3)
>20 years 140 (21.3) 41 (19.6) 99 (22.1)
>25 years 73 (11.1) 26 (12.4) 47 (10.5)
Median NIHSS at admission (IQR)a 3 (1-7) 0 (0-1) 5 (2-10)
TOAST, n. (%)
Large artery disease 166 (25.3) 47 (22.5) 119 (26.6)
Cardio-embolic stroke 86 (13.1) 27 (12.9) 59 (13.2) 
Small vessel disease 65 (13.1) 11 (5.3) 54 (12.1)
Other defined 96 (14.6) 23 (11.0) 73 (16.3)
Multiple causes 17 (2.6) 2 (1.0) 15 (3.4)
Unknown cause 226 (34.5) 99 (47.4) 127 (28.4)
History of vascular risk factors, n (%)
Hypertension 231 (35.2) 71 (34.0) 160 (35.8)
Diabetes 54 (8.2) 13 (6.2) 41 (9.2)
Dyslipidemiaa 424 (80.8) 147(83.5) 277 (79.4)
Atrial fibrillation 15 (2.3) 5 (2.4) 10 (2.2)
Smokinga 324 (51.8) 83 (40.7) 241 (57.2)
Excess drinking 48 (7.3) 15 (7.2) 33 (7.4)
Number of traditional risk factorsb
0 72 (11.0) 26 (12.4) 46 (10.3)
1 243 (37.0) 82 (39.2) 161 (36.0)
2 238 (36.3) 71 (34.0) 167 (37.4)
≥3 103 (15.7) 30 (14.4) 73 (16.3)
History of cardiovascular disease, n (%)c 38 (5.8) 11 (5.3) 27 (6.0)
History of cardiac disease 29 (4.4) 9 (4.3) 20 (4.5)
History of peripheral arterial disease 21 (3.2) 7 (3.3) 14 (3.1)
Baseline kidney function, n (%)
eGFR 60-120 392 (85.2) 122 (88.4) 270 (83.9)
eGFR <60 29 (6.3) 7 (5.1) 22 (6.8)
eGFR >120 39 (8.5) 9 (6.5) 30 (9.3)
Abbreviations:  TIA=transient ischemic attack; SD=standard deviation;  IQR=interquartile rang; NIHSS, National 
Institutes of Health Stroke Scale; TOAST= Trial of Org 10172 in Acute Stroke Treatment; eGFR= estimated 
glomerular filtration rate.
aMissing data: NIHSS 0.5%; dyslipidemia 20%; smoking 4.7%; eGFR 29.9%.
bRisk factors included diabetes mellitus, hypertension, dyslipidemia, atrial fibrillation and smoking.
cSome patients both had a history of PAD and cardiac disease
long-term risk and predictors of recurrent ischemic events
101
Ch
ap
te
r 7
Cumulative risk of ischemic events
During 8105 person-years of follow up, 197 (30%) patients had at least one ischemic event of 
whom 67 (34.0%) had more than one event. 
25-years cumulative risk of any ischemic event was 45.4% (95%CI 39.4-51.5), 30.1% (95%CI 
24.8-35.4) for cerebral ischemia and 27.0% (95% CI 21.1-33.0) for other arterial events (Figure 
1A-C). There was no sex difference. Annual risks are shown in figure 2. 
There were no differences between patients with a TIA or ischemic stroke with regards to their 
25-years cumulative risk of any ischemic event (TIA 40.7% [95%CI 29.7-46.4] and ischemic 
stroke 47.1% [95%CI 40.0-50.8]), cerebral ischemia (TIA 27.8% [95%CI 23.0-37.0] and ischemic 
stroke 30.8% [95%CI 27.6-37.2]), or other arterial events (TIA 23.7% [95%CI 18.3-34.2] and 
ischemic stroke 28.5% [95%CI 24.9-35.8]).
There were no differences in 25-years cumulative risk of any ischemic event or cerebral 
ischemia by age category. Patients aged 40-50 years at the time of their qualifying stroke at a 
young age had a higher 25-years cumulative risk of other arterial events (38.2%, 95%CI 28.9-
47.6) compared to patients aged 30-39 years (15.5%, 95%CI 7.2-23.7) (log-rank p=0.004) and 
patients aged 18-29 years (7.8%, 95%CI 0.3-15.4) (log-rank p=0.002).
Figure 3 shows the cumulative risk of any ischemic event stratified by TOAST-subtype. For 
cerebral ischemia, patients with a cardio-embolic stroke (50.8%, 95%CI 25.8-75.7) or small 
vessel disease (37.5%, 95%CI 22.7-52.4) had a higher 25-years cumulative risk than patients 
with undetermined cause (22.9%, 95% 15.2-30.6) (log-rank p=0.02 and p=0.02 respectively). 
For other arterial events patients with a large artery stroke (48.5, 95%CI 37.8-59.2) or cardio-
embolic stroke (60.9, 95%CI 6.0-115.8) had a higher 25-years cumulative risk than those with 
undetermined cause (17.3, 95%CI 8.6-26.1) (log-rank p<0.001 and p=0.05 respectively). 
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Figure 1. Cumulative risks of ischemic events
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Figure 2. Annual risk of ischemic events
Data points represent mean annual risks for the periods 2 to 5 years, 6 to 10 years, 11 to 15 years, 16 to 
20 years and 21 to 25 years.
Figure 3. Cumulative risk of any ischemic event stratified by TOAST-subtype
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Patients with large artery (61.4%, 95%CI 51.1%-71.8%) or cardio-embolic stroke (62.7%, 95%CI 38.6%-
86.7%) had a higher cumulative risk of any ischemic event compared to undetermined cause (33.8%, 
95%CI 24.3%-43.2%) (log-rank p<0.001 and p=0.001 respectively).
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Risk factors
In age- and sex-adjusted univariable analyses, age (HR 1.03 per year increase, 95%CI 1.01-
1.05), diabetes mellitus (HR 1.62, 95%CI 1.03-2.57), hypertension (HR 1.36, 95%CI 1.02-
1.82), eGFR <60 (2.51, 95%CI 1.47-4.26, history of peripheral arterial disease (HR 3.44, 95%CI 
21.95-6.08) and history of cardiac disease (HR 3.33, 95%CI 2.01-5.52) were associated with 
any ischemic event. In addition, number of traditional risk factors was associated with any 
ischemic event (Table 2).
Kidney function (eGFR < 60) was associated with recurrent cerebral ischemia (HR 3.18, 95%CI 
1.74-5.80). Factors associated with other arterial event were age (HR 1.08 per year increase, 
95%CI 1.04-1.11), diabetes mellitus (HR 2.54, 95%CI 1.42-4.52), hypertension (HR 1.61, 95%CI 
1.06-2.43), smoking (HR 2.12, 95%CI 1.32-3.42), history of peripheral arterial disease (HR 6.87, 
95%CI 3.60-13.12) and cardiac disease (HR 4.99, 95%CI 2.70-9.21).
Table 3 shows the multivariable Cox proportional hazard model. Smoking (HR 1.35, 95%CI 
1.04-1.74), eGFR<60 (HR 2.10, 95%CI 1.32-3.35), history of peripheral arterial disease (HR 
2.10, 95%CI 1.08-3.76) and cardiac disease (HR 1.84, 95%CI 1.06-3.18) were independently 
associated with any ischemic event. Reported HRs have been shrunk by applying a shrinkage 
factor of 0.82 derived from the bootstrap validation procedure. C-statistic of the model was 
0.59 (95%CI 0.55-0.64) after correction for overoptimism.
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Table 3. Predictors of any ischemic event
  HR (95%CI) p-value
Age 1.02 (1.00-1.04) 0.06
Diabetes mellitus 1.39 (0.93-2.07) 0.11
Alcohol 0.73 (0.47-1.15) 0.18
Smoking 1.35 (1.04-1.74) 0.02
Baseline kidney function
eGFR 60-120 1
eGFR <60 2.10 (1.32-3.35) 0.002
eGFR >120 0.80 (0.42-1.52) 0.50
History of PAD 2.01 (1.08-3.76) 0.03
History of cardiac disease 1.84 (1.06-3.18) 0.03
Abbreviations: HR=hazard ratio;  eGFR= estimated glomerular filtration rate; CI=confidence interval.
Predictors of any ischemic events selected by backward LR (exclusion if p <0.200). C-statistic 0.59 (95%CI 0.55-
0.64). The regression coefficients were corrected for overfitting with a shrinkage factor of 0•82.
Discussion
We showed that patients who have suffered a stroke at a young age remain at a high risk of 
developing recurrent ischemic events, even decades after their stroke. Traditional vascular 
risk factors are common in these patients and are associated with this life-long risk. 
A unique and essential strength of our study is the large study population in combination 
with a very long-term follow-up duration up to 35 years. For patients who suffer a stroke at 
a young age, a long-term risk assessment is crucial, as patients are still young after only a 
few years of follow-up. Moreover, the single centre, prospective design, made it possible to 
uniformly collect data, making information bias less likely. 
However, some possible limitations need to be addressed. First of all selection bias might 
have occurred as patients who did not participate in the study might have been the ones with 
a more severe outcome. The number of patients who refused to participate and those lost to 
follow-up is rather high, which is probably due to the long follow-up duration, however there 
were no differences in baseline characteristics, making selection bias less likely.
Second, since our study features a long inclusion period, recall bias may have influenced our 
findings, especially when patients experienced their event a long time ago or died, however, 
this would only have resulted in an underestimation of cumulative incidence. In addition, 
we have tried to overcome this by collecting information in an identical way in patients who 
died and those still alive. Along the course of the inclusion period, specific young stroke 
investigations might have changed and secondary prevention strategies changed over 
time, which might have influenced risk of recurrent vascular events. However, these are 
unavoidable features of a long-term follow-up study. 
long-term risk and predictors of recurrent ischemic events
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We have previously shown that patients who suffer a stroke at a young age remain at a 
high risk of developing recurrent vascular events.17 Due to the extension of our follow up 
we were now able to show that even up to 25 years after a stroke at a young age the risk of 
recurrent events remains high. Moreover we found an even higher risk compared to other 
large cohorts2, 18, 19, 23, 26, 108, most likely due to the far longer follow-up duration and inclusion 
of TIA as an outcome event in our cohort. In addition, most other studies were small and/or 
retrospective.2, 19, 23, 26
To determine secondary prevention strategies and provide information on the course of the 
disease for individual patients, it is necessary to assess risk of recurrent events at an individual 
level and treatment decisions should ideally be based on clinical trials. As younger patients 
were usually underrepresented in trials on secondary prevention116, it remains uncertain 
how to treat these patients and information should be obtained from large cohorts.117 We 
therefore aimed to identify risk factors associated with recurrent vascular events. Poor kidney 
function, smoking and a history of PAD and cardiac disease were independently associated 
with recurrent ischemic events. However the prediction model only had a moderate 
discriminative ability. Possible reasons for this finding might include residual confounding 
which might have arisen from inevitable differences in measurement of risk factors during 
the course of an inclusion period spanning almost 30 years. Furthermore due to the long 
inclusion period in our cohort, secondary prevention strategies changed, which may have 
influenced the prediction model as well. 
Two previous studies also tried to identify risk factors associated with recurrent vascular 
events. One study found age, heart failure, previous TIA and diabetes mellitus to be 
important predictors19 while the other prospective study found especially discontinuation 
of medication, antiphospholipid antibodies, family history, migraine with aura and any 
increase in traditional vascular risk factors to be associated with recurrent events18. However, 
follow-up in those studies was shorter and they had a smaller number of events to include 
in the analyses. Differences in study design and inclusion criteria between the studies could 
have contributed to the variation in associated risk factors. Patients in our study and the 
Finnish study were older (41.5 years) than in the Italian stroke project (36.8 years), which 
may have resulted in a higher incidence of traditional risk factors. In addition, it may be 
possible that due to the longer follow-up duration, traditional vascular risk factors become 
more important as patients are longer exposed to the risk factors. In addition, the Italian 
study developed a score for individual risk estimation, with a better predictive value than 
the prediction model in our study (c-statistic 0.66). Unfortunately, none of the models had a 
good discriminative ability, which may also indicate that there is considerable potential to be 
gained. Other unknown factors may contribute to the risk of recurrent events. For example, 
increasing evidence suggests that stroke at a young age has a stronger genetic basis than 
stroke occurring at older ages.118, 119 Genetic factors might also interact with vascular risk 
factors, possibly making patients who have suffered a stroke at a young age more vulnerable 
to traditional vascular risk factors.
Chapter 7
108
Furthermore we found that patients with a cardio-embolic stroke or large artery disease 
had a higher risk of any ischemic event or other arterial event. Another large study on the 
association between etiologic subgroups and recurrent events, also found large artery 
atherosclerosis and cardio embolism to be important predictors of recurrent events.108 
Moreover, in our study patients with small vessel disease or large artery disease had a higher 
risk of recurrent ischemia. This is probably explained by the fact that patients with these 
aetiologies of their stroke are more likely to have traditional risk factors than patients with an 
undetermined cause. Surprisingly, age was not associated with the risk of recurrent events, 
which indicates that even very young patients remain at a substantial risk of developing 
recurrent vascular events.
Our findings may indicate that risk factors for vascular diseases and a history of vascular 
diseases, such as peripheral artery or cardiac disease, should create awareness among the 
treating physician for risk of future recurrent events. Especially smoking is an important 
modifiable risk factor, which can be addressed more straightforward than pre-existing 
atherosclerosis in daily practice. Although prediction models are not perfect, traditional 
vascular (partly) modifiable risk factors do seem to play an important role in developing 
recurrent events. This might suggest that strict long-term secondary prevention strategies 
should be encouraged, even in very young patients, however it should be noted that the 
use and adherence of medication is not taken into account in this study. Therefore future 
research should especially aim at secondary prevention strategies in this specific age group.
In conclusion, we have shown that patients with a stroke at young age remain at substantial 
risk for developing recurrent vascular events, even decades after their initial event. Particularly 
young patients, with vascular risk factors that are usually prevalent at higher ages should 
raise the level of suspicion of their treating physicians as they are at the highest risk for future 
vascular events.
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Abstract
Objective: To study the long-term prevalence of small vessel disease after young stroke 
and to compare this to healthy controls. 
Methods: This prospective cohort study comprises 337 patients with an ischemic stroke 
or transient ischemic attack, aged 18-50 years without a history of transient ischemic or 
stroke. In addition 90 age and sex matched controls were included. At follow-up lacunes, 
microbleeds and white matter hyperintensity-volume were assessed using MRI. To 
investigate the relation between risk factors and small vessel disease, logistic and linear 
regression were used.
Results: After mean follow-up of 9.9 (SD 8.1) years, 337 patients were included (227 with 
an ischemic stroke and 110 with a TIA). Mean age for patients was 49.8 (SD 10.3) years 
and 45.4% were men, for controls mean age was 49.4 (SD 11.9) and 45.6% were men. 
Compared with controls, patients more often had at least one lacune (24.0% versus 4.5%, 
p<0.0001). In addition, they had a higher white matter hyperintensity-volume (median 1.5 
ml (IQR 0.5-3.7) versus 0.4 ml (IQR 0.0-1.0), p<0.001). Compared with controls, patients had 
the same volume of white matter hyperintensities on average 10-20 years earlier. In the 
patient group, age at stroke (β=0.03 (95%CI 0.02-0.04) hypertension (β=0.22, 95%CI 0.04-
0.39) and smoking (β=0.18, 95%CI 0.01-0.34) at baseline were associated with white matter 
hyperintensity-volume.
Conclusions: Patients with a young stroke have a higher burden of small vessel disease 
than controls adjusted for confounders. Cerebral aging seems accelerated by 10-20 years 
in these patients, which may suggest an increased vulnerability to vascular risk factors. 
prevalence of cerebral small vessel disease
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Introduction
Incidence of stroke at young age is increasing3, which has been explained by a high 
prevalence of traditional vascular risk factors.4 However, the prevalence of these risk factors 
is not only high in (young) stroke patients, but often equally high in the general population.120, 
121 Accordingly, most young individuals with these risk factors never experience a stroke. 
This may suggest that patients who do develop a stroke are more vulnerable to risk factors 
than those who do not. Consequently, they may also have a higher risk of developing 
other (cerebro)vascular diseases. A possible marker of the brain’s vulnerability to vascular 
risk factors is cerebral small vessel disease (SVD). In the elderly, SVD has convincingly been 
related to vascular risk factors and accelerated cognitive and motor decline.20-22 
The prevalence of the full spectrum of SVD (lacunes, microbleeds and white matter 
hyperintensity (WMHs) at variable intervals after stroke at young age, and its comparison with 
controls, has never been investigated. In addition, it is unknown whether the same risk factors 
in elderly are associated with SVD in patients with a stroke at young age. We hypothesized 
that SVD as a marker of early ageing, would be more frequent after stroke in young adults, 
compared with controls.
The aim of this study was to examine prevalence and risk factors of SVD as a marker of the 
brain’s vulnerability to vascular risk factors in patients with a first-ever transient ischemic 
attack (TIA) or ischemic stroke aged 18-50 years, after long-term follow-up and to compare 
this with controls. 
Methods
Study population
This study is part of the “Follow-Up of Transient ischemic attack and stroke patients and 
Unelucidated Risk factor Evaluation”-study (FUTURE study), a prospective cohort study that 
investigates causes and consequences of a young stroke.65 We used the same methodology 
as the one employed in previous studies.65  
The FUTURE study comprises all consecutive patients with a TIA or ischemic stroke, aged 18 
- 50 years, admitted to the Radboud University Nijmegen Medical Centre from 1980 till 2010.65 
For the definition of stroke and TIA the World Health Organisation definition was used67, 91, 
in which stroke was defined as a rapidly evolving focal neurological deficit, with no other 
than vascular cause lasting more than 24 hours.65 For TIA the same definition was used, but 
lasting less than 24 hours.65 Exclusion criteria were cerebral venous sinus thrombosis and 
retinal infarction.65 
Patients were identified through a prospective registry with a standardised collection of 
baseline and clinical characteristics and all patients underwent neurological examination 
and brain imaging at the time of their index event.65 The assessment of stroke aetiology (Trial 
of Org 10172 in Acute Stroke Treatment [TOAST])68 and severity (National Institutes of Health 
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Stroke Scale [NIHSS]69) was done for all cases retrospectively by a validated approach28, 
71, as these scales did not exist at the time when a substantial proportion of our patients 
experienced their qualifying event.65 
Standard protocol approvals, registrations and patient consents
The Medical Review Ethics Committee region Arnhem-Nijmegen approved the study. Written 
informed consent was obtained from all participants.
Controls
At follow-up stroke-free controls were recruited among patients’ spouses, relatives or social 
environment. They had to be at least 18 years old without a clinical history of TIA or stroke. 
The control group and patient group were matched for age, sex, and level of education.65 
Follow-up
Patients alive were approached by telephone and follow-up assessment was performed 
between 2009 and 2012. Subsequently patients were given the opportunity to participate in a 
sub study in which they were invited to our research centre for an extensive in-person follow-
up examination, including physical examination and an extensive magnetic resonance 
imaging (MRI) protocol.65 Patients with MRI contraindications or known claustrophobia were 
excluded from the present study. 
MRI scanning and processing
MRI scanning was performed on a 1.5- Tesla Magnetom scanner (Siemens, Erlangen, 
Germany). The scanning protocol included whole brain 3D T1 magnetization-prepared-rapid 
gradient-echo sequence (TR/TE/Tl 2730/2.95/1000ms; flip angel 7º; voxel size 1.0x1.0x1.0mm); 
FLAIR pulse sequences (TR/TE/Tl 12220/85/2200 ms; voxel size 1.0x1.2x3.0; slice gap 0.6mm); 
transversal T2-weigted turbo spin echo sequence (TR/TE 7440/96ms; voxel size 0.9/0.9x3.0 
mm; slice gap 0.6 mm) and gradient echo susceptibility weighted imaging (SWI) sequence 
(TR/TE 49/40ms; voxel size 0.8x0.7x1.0mm). All patients underwent MRI-scanning according 
to this standardised protocol.65 
Small vessel disease
SVD was defined according to the STRIVE-criteria.122 WMHs of presumed vascular origin were 
defined as hyperintense signal abnormalities in the white matter on FLAIR images, without 
cavitation.122 Hyperintensities in the subcortical grey matter or brainstem were also included 
in the analysis. Gliosis surrounding lacunar and territorial infarcts was not considered to be 
WMHs. WMH-volumes were determined using a validated in-house developed fully automated 
method.123 This computer aided detection system uses a supervised machine learning 
approach being trained on a dataset of more than 300 MR images with WMHs annotated 
on them. More than 20 features were utilized to describe for each voxel the intensities of 
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FLAIR and T1 modalities, location and the shape of the structure each voxel belongs to. 
The system has been evaluated on an independent dataset of 32 images and it was shown 
to be performing close to a human observer. All scans were checked by visual inspection. 
WMH-volumes were normalized to intracranial volume. Voxel-Based Morphometry toolbox 
within SPM8 was used for each T1 image to determine the volume of grey matter, white 
matter, and cerebrospinal fluid, in order to calculate intracranial volume.124 In addition, 
WMHs were manually rated according to the Fazekas score: 0=one or no hyperintensities, 
1=focal hypertensities, 2=beginning confluence and 3=confluent hyperintensities with diffuse 
involvement of the entire region.125
Lacunes of presumed vascular origin were defined as round or ovoid, subcortical, fluid-filled 
cavities, of between 3 mm and about 15 mm in diameter, consistent with a previous acute 
small deep brain infarct in the territory of one perforating arteriole.122
Cerebral microbleeds were defined as small areas less than 10 mm in diameter of signal void 
with associated blooming seen on SWI.122 Signal voids in areas of territorial infarcts were not 
considered to be microbleeds. For each participant the presence and numbers of lacunes 
and All MRI scans were analyzed by a trained rater blinded to clinical and demographic data. 
In a random sample of 10% the interrater reliability for the presence of lacunes yielded a 
kappa of 0.76 and intrarater reliability yielded a kappa of 0.80. For the Fazekas score interrater 
and intrarater reliability yielded a weighted kappa of 0.68 and 0.88 respectively. Interrater 
and intrarater reliability for the presence of microbleeds yielded a kappa of 1.0 and 0.92 
respectively.
Vascular risk factors at follow-up
At follow-up blood pressure was measured in supine position three times on both arms, 
of which the highest measurement was used to define hypertension. Hypertension was 
defined as a systolic blood pressure ≥135 mmHg or a diastolic blood pressure of ≥85 mmHg85 
or the use of antihypertensive medication. Hypertension was defined into 3 categories: 
treated but uncontrolled hypertension, hypertension controlled with medication, untreated 
hypertension. Diabetes mellitus was defined as random blood glucose level >11.1 mmol/L 
or two consecutive fasting venous plasma glucose levels ≥7.0 mmol/L109 or the use of 
antidiabetics (oral or insulin). Dyslipidemia was defined as total cholesterol ≥5.0 mmol/L or 
LDL ≥2.5 mmol/L or triglycerides ≥2.0 mmol/L17 or the use of statins. Whenever blood pressure, 
glucose levels or cholesterol levels were missing (0.2%, 2.3% and 3.3% respectively), a 
medical history of diabetes mellitus, dyslipidemia and/or hypertension was used. In addition, 
information on smoking was collected by a structured questionnaire. Current smoking was 
defined as smoking ≥1 cigarette per day in the year prior to follow-up (0.5% missing).
Statistical analysis
Baseline characteristics and the prevalence of SVD between patients and controls were 
compared using chi-square, student’s t-test or Mann-Whitney-U whenever appropriate. In 
Chapter 8
116
addition, the prevalence of lacunes, microbleeds and mean WMH-volume were stratified by 
age at MRI (20-39, 40-54 and 55-79 years).
By means of binary logistic regression the prevalence of lacunes and microbleeds were 
compared between patients and controls by calculating Odds ratios (ORs) with their 95% 
Confidence Intervals (CIs). Linear regression was used to compare WMH-volume between 
patients and controls, by calculating betas. WMH-volumes were natural log transformed 
because of skweness of the untransformed measure. As the data contained zeros (n=21), 
which cannot be log transformed, a constant number of 0.001 (which equalled the smallest 
volume in the dataset) was added to all data before transformation. Confounders in the 
logistic regression and linear regression model were age, sex, smoking, diabetes mellitus and 
hypertension at follow-up.
Within the patient group, by means of binary logistic regression and linear regression, we 
calculated ORs and betas of individual baseline variables with 95% CIs for the risk of lacunes, 
microbleeds and WMH-volume respectively. Each baseline risk factor was only adjusted for 
sex, age at event and follow-up duration. In addition, for WMH-volume independent betass 
with 95% CIs were calculated for vasculur risk factors using the the enter method. Variables 
in the model were sex, age at stroke, follow-up duration, hypertension, diabetes mellitus and 
smoking.
Finally, to compare WMH-volume between patients and controls, mean WMH-volume was 
stratified by age groups of 5 years. To investigate the vulernatiblity of the brain to ageing, 
the relation between age and WMH-volume was investigated for patients and controls 
seperately. WMH-volume seemed to be exponential related to age (R2=0.97) for patients and 
polynomial for controls (R2=0.96). We then calculated group differences in WMH-volume to 
establish estimates of the number of years of age necessary for controls to achieve the same 
mean WMH-volume value as patients.
SPSS 20 was used for all statistical analysis.
Results
Study population
337 patients (110 with a TIA, 227 with an ischemic stroke) and 90 controls were included 
in the present study (Figure 1). Table 1 shows baseline characteristics for patients who 
participated in the present study and those who did not. Non-participants less often had 
an undetermined cause of their stroke (31.9% versus 40.9%) and more often were smokers 
(55.3% versus 45.3%).
Mean age at index event was 40.0 (SD 7.9) years and 45.4% of them were men. After a mean 
follow-up of 9.9 (SD 8.1) years, mean age was 49.8 (SD10.3) years for patients and 49.4 (SD 
11.9) years for controls. Baseline and follow-up characteristics are shown in table 2. 
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Figure 1. Flowchart selection of patients
First-ever TIA / IS  
n = 868
FUTURE participants
n = 656
Participants with MRI 
at follow-up 
n=337
BA
SE
LI
N
E
FO
LL
O
W
-U
P
- Lost to follow-up n=73
- Refusers n=139
- Died n=145
- FUTURE participants but not able to 
visit research centre n=85 
- Participants who visited the research 
centre but did not underwent an MRI 
(n=89):
Exclusion criteria MRI n=51
No permission MRI n=33
Technical errors MRI n=5
Table 1. Baseline characteristics for patients included and excluded in the present study
Included in present 
study (n=337)
Excluded in present 
studya (n=386)
p-value
Index event, n (%)
TIA 110 (32.6) 129 (33.4)
Ischemic stroke 227 (67.4) 257 (66.6) 0.824
Age at index event, mean (SD) 40.0 (7.9) 39.9 (8.0) 0.617
Men, n (%) 153 (45.4) 166 (43.0) 0.518
NIHSS, median (IQR) 2 (0-6) 2 (1-6) 0.195
TOAST-classification
Large-artery atherosclerosis 77 (22.8) 93 (24.1) 0.694
Cardio-embolism 32 (9.5) 48 (12.4) 0.209
Small vessel occlusion 33 (9.8) 48 (12.4) 0.261
Other determined aetiology 51 (15.1) 66 (17.1) 0.474
Multiple aetiologies 6 (1.8) 8 (2.1) 0.776
Undetermined aetiology 138 (40.9) 123 (31.9) 0.011
Diabetes mellitus 16 (4.7) 23 (6.0) 0.472
Hypertension 97 (28.8) 118 (30.6) 0.600
Dyslipidemiab 232 (68.8) 252 (65.3) 0.984
Smokingb 149 (45.3) 208 (55.3) 0.008
Abbreviations: TIA=transient ischemic attack; SD=standard deviation;NIHSS=National Institutes of Health 
Stroke Scale; IQR=interquartile range; TOAST=Trial of Org 10172 in Acute Stroke Treatment
a Patients who refused to participate, were lost to follow-up or did not participate in the MRI sub study. 
b information on NIHSS was missing in 0.6%, information on dyslipidemia in 15.5%, and smoking status in 2.5%
Abbreviations: TIA=transient ischemic attack; IS=ischemic stroke; MRI=magnetic resonance imaging
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Table 2. Characteristics
Patients 
(n=337)
Controls  
(n=90)
p-value
Baseline
Age at index event, mean (SD) 40.0 (7.9) n/a
Men, n (%) 153 (45.4) 41 (45.6) 0.979
NIHSS, median (IQR)a 2 (0-6) n/a
TOAST-classification, n (%)
Large-artery atherosclerosis 77 (22.8) n/a
Cardio-embolism 32 (9.5) n/a
Small vessel occlusion 33 (9.8) n/a
Other determined aetiology 51 (15.1) n/a
Multiple aetiologies 6 (1.8) n/a
Undetermined aetiologies 138 (41.0) n/a
Use of Medication at baseline, n (%)
Antithrombotic therapy 294 (87.2) n/a
Oral antidiabetics 6 (1.8) n/a
Insulin therapy 12 (3.6) n/a
Blood pressure lowering agents 90 (26.7) n/a
Statin use 112 (33.4) n/a
Follow-up (MRI scanning)
Age at MRI scanning, mean (SD) 49.8 (10.3) 49.4 (11.9) 0.735
Follow-up duration, mean (SD) 9.9 (8.1) n/a
Cardiovascular risk factors, n (%)
Diabetes Mellitus 34 (10.1) 5 (5.6) 0.185
Hypertension 204 (60.5) 48 (53.3) 0.217
Treated uncontrolled 72 (21.4) 15 (16.7) 0.326
Treated controlled 50 (14.8) 4 (4.4) 0.008
Untreated 82 (24.3) 29 (32.2) 0.130
No hypertension 133 (39.5) 42 (46.7) 0.217
Dyslipidemia 313 (92.9) 73 (81.1) 0.001
Smoking ever 228 (67.7) 55 (61.1) 0.215
Smoking current 90 (26.7) 23 (25.6) 0.803
Medication use, n (%)
Antiplatelet drugs 243 (72.3) 8 (8.9) <0.001
Oral anticoagulants 35 (10.4) 0 0.001
Oral antidiabetics 19 (5.6) 1 (1.1) 0.070
Insulin use 10 (3.0) 1 (1.1) 0.320
Blood pressure lowering agents 122 (36.2) 19 (21.1) 0.001
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Statin 167 (49.6) 11 (12.2) <0.001
Migraine, n (%) 69 (20.5) 9 (10.0) 0.022
Alcohol (>2U/d) (%) 13 (4.0) 5 (5.6) 0.514
Drugs ever, n (%) 26 (7.7) 9 (10.0) 0.488
Drugs current, n (%) 6 (1.8) 2 (2.2) 0.786
Abbreviations: SD=standard deviation; IQR= interquartile range; NIHSS= National Institutes of Health Stroke 
Scale; TOAST= Trial of Org 10172 in Acute Stroke Treatment; MRI=magnetic resonance imaging; n/a= not 
applicable.
Missing data: 0.6% of NIHSS, 0.5% of smoking status, 0.2% of antiplatelet drugs, oral anticoagulants at follow-
up, migraine and data on drugs and 2.3% of alcohol use was missing.
Stroke in young adults versus controls
After mean follow-up of 9.9 (SD 8.1) years, 81 patients (24.0%) had at least 1 lacune versus 4 
controls (4.5%) (p<0.001). There was no difference in microbleeds between patients (n=44, 
13.1%) and controls (n=6, 6.7%). Patients had a higher WMH-volume than controls (median 
1.5 ml [IQR 0.5-3.7] versus 0.4 ml [IQR 0.0-1.0], p<0.001) (Table 3).
Logistic regression showed that patients remained at a higher risk for lacunes than controls 
after adjustment for confounders (age, sex, smoking, DM and hypertension at follow-up) (OR 
6.8, 95%CI 2.4-19.8, p<0.001). Linear regression showed a higher WMH-volume for patients 
compared to controls after adjustment for confounders (β=0.82 95%CI 0.63-1.01, p<0.001).
Table 4 shows the prevalence of lacunes and microbleeds and WMH-volume for patients and 
controls stratified by age at follow-up. 
For patients, the prevalence of microbleeds and lacunes and the volume of WMHs increased 
by age. In addition, beginning confluence and confluent WMHs were not present in patients 
aged 20-40, in contrast to the higher age groups. In all age groups WMH-volume was higher 
among patients than among controls. In addition, lacunes were more prevalent among 
patients compared to controls in the age groups 40-55 years and 55-79 years and not in the 
youngest age group. 
Figure 1 shows the relation between age at follow-up and WMH-volume both for patients and 
controls. Compared with controls, patients had the same volume of WMHs on average 10-20 
years earlier (Figure 3).
Baseline risk factors for SVD in patients with stroke at young age
Baseline risk factors associated with microbleeds were male sex (OR 2.0, 95%CI 1.0-3.9, 
p=0.043) and hypertension (OR 1.1, 95%CI 1.0-1.1 p=0.009). Male sex was also associated with 
lacunes (OR 2.3, 95% CI 1.3-3.9, p=0.002). Age at stroke (β=0.03, 95%CI 0.02-0.04, p<0.001) 
hypertension (β=0.22, 95%CI 0.04-0.39) and smoking (β=0.18, 95%CI 0.01-0.34, p=0.035) were 
associated with WMH-volume. (Table 4)
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In addition, age at stroke (β=0.03, 95%CI 0.02-0.04, p<0.001), follow-up duration (β=0.04, 
95%CI 0.03-0.05, p<0.004) and hypertension (β=0.20, 95%CI 0.02-0.38, p=0.029), were 
independently associated with WMH-volume adjusted for sex, diabetes mellitus and smoking 
(R-square=0.23).
Table 3. Prevalence of cerebral small vessel disease for patients and controls
Patients 
(n=337)
Controls 
(n=90)
p-value
Lacunes, n (%)a 81 (24.0) 4 (4.5) <0.001
0 lacunes 256 (76.0) 85 (95.5)
1-3 lacunes 73 (21.6) 4 (4.5)
≥4 lacunes 8 (2.4) 0
Microbleeds, n (%)a 44 (13.1) 6 (6.7) 0.100
0 microbleeds 293 (86.9) 83 (93.3)
1-3 microbleeds 28 (8.3) 6 (6.7)
≥4 microbleeds 16 (4.8) 0
Fazekas ≥1, n (%)a 275 (81.6) 51 (57.3) <0.001
0: ≤1 hyperintensities 62 (18.4) 38 (42.7)
1: ≥1 hyperintensities 259 (76.9) 50 (56.2)
2: beginning confluent hyperintensities 10 (32.9) 1 (1.1)
3: confluent hyperintensities 6 (1.8) 0
WMH-volume, median (IQR)a 1.5 (0.5-3.7) 0.4 (0.0-1.0) <0.001
Abbreviations: WMH=white matter hyperintensity; IQR=interquartile range
a In 1.1% of the controls lacunes, Fazekas and microbleeds were missing and in 1.5% of the patients and 2.2% of 
the controls WMH-volume was missing.
prevalence of cerebral small vessel disease
121
Ch
ap
te
r 8
Ta
bl
e 
4.
 P
re
va
le
nc
e 
of
 c
er
eb
ra
l s
m
al
l v
es
se
l d
is
ea
se
 st
ra
ti
fi
ed
 b
y 
ag
e 
at
 fo
ll
ow
-u
p
20
-4
0 
ye
ar
s
40
-5
5 
ye
ar
s
55
-7
9 
ye
ar
s
Pa
tie
nt
s  
(n
=5
7)
Co
nt
ro
ls
  
(n
=1
6)
Pa
tie
nt
s 
(n
=1
88
)
Co
nt
ro
ls
 
(n
=4
6)
Pa
tie
nt
s 
(n
=9
2)
Co
nt
ro
ls
 
(n
=2
8)
Pa
tie
nt
s 
p-
tr
en
db
La
cu
ne
s,
 n
 (%
)
11
(1
9.
3)
0
36
 (1
9.
1)
a
1 
(2
.2
)
34
 (3
7.
0)
a
3 
(1
0.
7)
0.
00
3
M
ic
ro
bl
ee
ds
, n
 (%
)
6 
(1
0.
5)
0
18
 (9
.6
)
3 
(6
.5
)
20
 (2
1.
7)
3 
(1
0.
7)
0.
01
5
Fa
ze
ka
s ≥
1,
 n
 (%
)
30
 (5
2.
6)
9 
(5
6.
2)
15
6 
(8
3.
0)
a
24
 (5
3.
3)
89
 (9
6.
7)
20
 (7
1.
4)
<0
.0
01
0
27
 (4
7.
4)
7 
(4
3.
8)
32
 (1
7.
0)
21
 (4
6.
7)
3 
(3
.3
)
8 
(2
8.
6)
1
30
 (5
2.
6)
9 
(5
6.
2)
14
9 
(7
9.
3)
24
 (5
3.
3)
80
 (8
7.
0)
19
 (6
7.
9)
2
0
0
5 
(2
.7
)
0
5 
(5
.4
)
1 
(3
.6
)
3
0
0
2 
(1
.1
)
0
4 
(4
.3
)
0
W
M
H
-v
ol
um
e,
 
m
ed
ia
n 
(IQ
R)
0.
5 
(0
.2
-1
.5
)a
0.
09
 (0
-0
.8
)
1.
3 
(0
.5
-2
.7
)a
0.
1 
(0
-0
.6
)
3.
8 
(1
.8
-7
.6
)a
1.
3 
(0
.4
-4
.8
)
n/
a
Ab
br
ev
ia
tio
ns
: W
M
H
=w
hi
te
 m
at
te
 h
yp
er
in
te
ns
ity
, I
Q
R=
in
te
rq
ua
rt
ile
 ra
ng
e
Th
is
 ta
bl
e 
sh
ow
s t
he
 p
re
va
le
nc
e 
of
 sm
al
l v
es
se
l d
is
ea
se
 st
ra
tif
ie
d 
by
 a
ge
 a
t f
ol
lo
w
-u
p 
fo
r b
ot
h 
pa
tie
nt
s a
nd
 co
nt
ro
ls
.
a  S
ig
ni
fic
an
t d
iff
er
en
ce
 b
et
w
ee
n 
pa
tie
nt
s a
nd
 co
nt
ro
ls
 w
ith
in
 th
e 
ag
e 
gr
ou
p 
(p
<0
.0
5)
.
b 
p-
va
lu
e 
re
pr
es
en
ts
 th
e 
di
ffe
re
nc
e 
ov
er
 th
e 
ag
e 
gr
ou
ps
 w
ith
in
 th
e 
pa
tie
nt
 g
ro
up
.
In
 1
.1
%
 o
f t
he
 co
nt
ro
ls
 la
cu
ne
s,
 F
az
ek
as
 a
nd
 m
ic
ro
bl
ee
ds
 w
er
e 
m
is
si
ng
 a
nd
 in
 1
.5
%
 o
f t
he
 p
at
ie
nt
s a
nd
 2
.2
%
 o
f t
he
 co
nt
ro
ls
 W
M
H
-
vo
lu
m
e 
w
as
 m
is
si
ng
.
Chapter 8
122
Figure 3. Stroke related brain ageing
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This figure shows the difference in age at which both controls and patients had identical WMH-volumes 
(Y-axis) and on the X-axis the age of the patient at follow up.
Volumes of WMHs were calculated for both patients and controls by age. The curved line indicates the 
difference in age between controls and patients at which both patients and controls have exactly the same 
mean WMH-volume. For example, the dotted line indicates WMH-volume of a 50 year old patient with a 
stroke at young age, which corresponds to WMH-volume of a control who is 12.8 years older (ie 62.8 years).
Figure 2. Relation between age at follow-up and WMH-volume for patients and controls
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This figure shows the mean WMH-volume for patients and controls stratified by age groups of 5 years. 
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Table 5. Baseline risk factors associated with small vessel disease in patients
Lacunes Microbleeds WMH-volume
OR (95% CI) p-value OR (95% CI) p-value Beta p-value
Sex, men 2.3 (1.3-3.9) 0.002 2.0 (1.0-3.9) 0.043 -0.03 (-0.19-0.14) 0.764
Age at stroke 1.0 (1.0-1.1) 0.240 1.0 (1.0-1.1) 0.441 0.03 (0.02-0.04) <0.001
Hypertension 1.5 (0.9-2.7) 0.131 1.1 (1.0-1.1) 0.009 0.22 (0.04-0.39) 0.014
Diabetes mellitus 0.7 (0.2-2.4) 0.527 2.4 (0.7-8.1) 0.162 0.16 (-0.22-0.53) 0.413
Dyslipidemia 0.8 (0.4-1.7) 0.599 0.8 (0.3-1.9) 0.595 0.01 (-0.21-0.23) 0.905
Smoking 1.6 (0.9-2.7) 0.101 0.8 (0.4-1.6) 0.597 0.18 (0.01-0.34) 0.035
Antithrombotic therapy, n (%) 1.7 (0.7-4.2) 0.224 1.5 (0.5-4.2) 0.471 -0.13 (-0.38-0.12) 0.293
TOAST-classification
Large artery 2.8 (1.4-5.7) 0.004 1.2 (0.5-3.0) 0.651 0.20 (-0.01-0.42) 0.067
Cardio-embolism 1.6 (0.6-4.8) 0.320 2.3 (0.7-7.2) 0.164 0.13 (-0.17-0.43) 0.406
Small vessel disease 7.5 (3.1-18.1) <0.001 2.4 (0.8-7.1) 0.124 0.53 (0.22-0.83) 0.001
Other determined 1.3 (0.5-3.2) 0.571 1.9 (0.7-5.3) 0.210 0.22 (-0.10-0.49) 0.118
Multiple causes 4.8 (0.8-30.3) 0.093 3.0 (0.3-29.9) 0.349 0.70 (0.03-1.36) 0.040
Undetermined - (Ref) - (Ref) - (Ref)
Abbreviations: TOAST= Trial of Org 10172 in Acute Stroke Treatment; OR=odds ratio; CI=confidence interval; 
WMH=white matter hyperintensity.
Missing data: 13.1% of dyslipidemia and 2.4% of data on smoking was missing.
This table shows the association between the individual baseline risk factors and lacunes, microbleeds and 
WMH-volume. Each baseline risk factor was only adjusted for sex, age at stroke and follow-up duration.
Discussion
We have shown that on average after 10 years of follow-up of patients with a stroke at 
young age, patients have a higher burden of lacunes and WMHs, than controls who did 
not experience a stroke at young age but had otherwise identical vascular risk factors. In 
addition, patients had already the same volume of WMHs on average 10-20 years earlier in 
life than controls. 
Strengths of our study include the large population of patients with a stroke at young age 
and the single-centre design, which made it possible to collect all data systematically and 
uniformly in all participants.85 In addition, a trained rater who analyzed the MRI scans was 
blinded to clinical and demographic data, making information bias less likely. Furthermore, 
the inclusion of a control group made it possible to compare the prevalence of cerebral SVD 
between patients with a stroke at young age and controls.
However, some limitations in our study need to be considered. First of all, it may be possible 
that selection bias occurred in our study due to selective loss to follow-up. Patients who did 
not participate in the present sub study more often were smokers compared to participants. 
Since smoking was associated with WMH-volume, this may have led to an underestimation 
of WMH-volume in patients. Second, baseline neuroimaging was performed according to 
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different clinical routines, for example due to the long inclusion period, therefore we were 
not able to determine incident SVD, but only its prevalence, which made it a cross-sectional 
study. Third, confounding may have influenced our results but we have tried to overcome 
this by adjusting for the most important confounders for SVD.
We have shown that patients with a stroke at young age have a significantly higher burden 
of lacunes and WMHs than controls, even after adjustment for confounders. Age at follow-up 
was an important factor associated with SVD. We found a higher prevalence of WMHs than 
two retrospective studies in patients with a stroke at young age, which reported a prevalence 
of WMHs of around 7%.126, 127 Another study on MRI characteristics in patients with a stroke 
at young age also reported a lower prevalence of 45% WMHs and 7% of microbleeds.128 
However, MRI in those studies was performed during the initial work-up directly after the 
index stroke. Due to our longer follow-up, patients were older at the time of the MRI scan and 
had a higher prevalence of vascular risk factors. In addition, WMHs in those studies was only 
rated by the Fazekas score and not quantitative. Due to the combination of a high prevalence 
of vascular risk factors and long follow-up duration patients may have been exposed to those 
risk factors for a longer period. However, 10 years after the stroke, patients in our study still 
were young and had a mean age of only 49.8 years and the prevalence of vascular risk factors 
was identical in our controls. 
An explanation for the high prevalence of SVD among stroke in young adults may be that 
patients are, for yet unknown reasons, more vulnerable to those vascular risk factors than 
others. A possible explanation might be that there is a genetic predisposition for developing 
cardiovascular diseases, however this has not been investigated. Another possibility might 
be that patients have been exposed to these vascular risk factors for already a longer period 
than controls. It has for example been shown that blood pressure is associated with subtle 
vascular brain injury such as a reduced cerebral integrity already very early in life.129 
Another explanation might be that that patients already had SVD due to their initial stroke. 
However, in only 10% the aetiology of the index event was SVD, which is comparable low 
to other studies on stroke in young adults and makes this an unlikely explanation.18, 130 
Obviously, with respect to the TOAST-classification patients with SVD as the cause of their 
initial stroke showed the most pronounced association compared to undetermined aetiology 
with the presence of lacunes and increased WMH-volume. This has also been found in elderly 
populations.131 However, also stroke due to large artery disease and multiple causes were 
associated with the presence of lacunes and increased WMH-volume. An explanation might 
be that large artery disease and SVD share underlying vascular risk factors including age at 
stroke and smoking which were associated with WMH-volume in the present study.
In addition, besides having a higher burden of SVD, another striking finding was that patients 
had already on average 10-20 years earlier in life the same volume of WMHs as controls, who 
have an identical traditional vascular risk profile. This may be an additional argument that 
these patients are very vulnerable to the deleterious effects of vascular risk factors, already 
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decades before their healthy peers. The suggested increased vulnerability supports the need 
for accurate identification of vascular risk factors at presentation and immediate treatment 
accordingly, even in these often young patients. Although this has never been investigated, it 
may be an argument for lifelong secondary prevention strategies.
Apart from gaining more insight in possible etiologic mechanisms, the occurrence of SVD 
may also have prognostic implications as well. In elderly patients SVD has been associated 
with depression and cognitive impairments20-22, independent of stroke. A large MRI study in 
patients with a stroke under the age of 55, found no association between depression and MRI 
characteristics of SVD.132 However, both MRI and assessment of depression took place within 
10 days after stroke. Patients may develop both SVD and depression during follow-up, which 
determines post-stroke functioning. Especially in young patients, this long-term follow-up is 
of utmost importance. 
We have shown that SVD is very prevalent in patients with a stroke at young age and is 
associated with age at follow-up. Cerebral aging seems accelerated by 10-20 years in these 
patients, which may indicate an increased vulnerability to vascular risk factors. 
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Abstract
Background: The proportion of strokes occurring in younger adults has been rising over 
the past decade. Due to the far longer life expectancy in the young, stroke in this group has 
an even larger socio-economic impact. However, information on aetiology and prognosis 
remains scarce.
Methods/design: ODYSSEY is a multicentre prospective cohort study on the prognosis 
and risk factors of patients with a first-ever transient ischemic attack, ischemic stroke 
or intracerebral haemorrhage aged 18 to 49 years. Our aim is to include 1500 patients. 
Primary outcome will be all cause mortality and risk of recurrent vascular events. 
Secondary outcome will be the risk of post-stroke epilepsy and cognitive impairment. 
Patients will complete structured questionnaires on outcome measures and risk factors. 
Both well-documented and less well-documented risk factors and potentially acute 
trigger factors will be investigated. Patients will be followed every 6 months for at least 
3 years. In addition, an extensive neuropsychological assessment will be administered 
both at baseline and 1 year after the stroke or transient ischemic attack. Furthermore 
we will include 250 stroke-free controls, who will complete baseline assessment and one 
neuropsychological assessment.
Discussion: ODYSSEY is designed to prospectively determine prognosis after a young 
stroke and get more insight into aetiology of patients with a transient ischemic attack, 
ischemic stroke and intracerebral haemorrhage in patients aged 18 to 49 years old in a 
large sample size.
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Background
Recent studies have shown that the proportion of strokes occurring in adults younger than 
50 years of age has increased from 13 to 19% over the past decade.2, 3 Due to the longer 
life expectancy in the young compared with a general elderly stroke patient, stroke in this 
younger group has a large impact on number of years lost to ill-health, disability or early 
death.85 This impact will not only be determined by the direct mortality and residual post-
stroke deficit, but may also be influenced by future vascular events, cognitive impairment 
or post-stroke epilepsy that may occur throughout their post-stroke lives.86, 87 Especially for 
young patients reliable information on this prognosis is of great importance as their stroke 
occurs in the period of life in which they would like to form families, have an active social life 
and make decisive career moves. However, it is exactly the prognosis of this younger group 
that remains unclear.
Previous studies on stroke in the young were mainly retrospective and included patients who 
had their index events at times with a completely different secondary prevention strategy. 
Most studies only aimed at prognosis in terms of mortality and vascular events, which are 
very important outcome measures. However, other important post-stroke complications, 
such as cognitive deficits, post-stroke epilepsy and post-stroke functioning were not taken 
into account. Furthermore previous studies have only included patients with an ischemic 
stroke, whereas studies in younger patients with a transient ischemic attack (TIA) or 
intracerebral haemorrhage (ICH) are scarce. There is growing evidence that despite the fact 
that TIA patients suffer from (by definition) transient neurological deficits, their cognitive 
or social deficits may last way longer.133-135 In addition, survival of patients with an ICH has 
improved substantially due to improved care resulting in longer post-stroke life expectancy. 
Information on prognosis after an ICH or TIA is consequently of great importance as well, both 
for patients and their health professionals when counselling their patients with information 
on the course of the disease.
Apart from uncertainties about prognosis and the major socio-economic impact of a young 
stroke, the explanation for the increased incidence of young stroke remains unclear. It 
has been suggested that an increased prevalence in traditional vascular risk factors, such 
as diabetes mellitus and obesity due to unhealthy life style and poor education, results in 
(more) atherosclerosis already at younger ages which may lead to stroke.136, 137 Furthermore, a 
rising incidence of substance abuse which may be more pronounced in the young might play 
a role.138 However, despite the use of ever increasing additional clinical investigations that 
take place in renowned specialized stroke centres, aetiology remains unknown in more than 
30% of the young stroke patients.139 An approach to get more insight into pathophysiological 
mechanisms of a young stroke is to identify potentially acute trigger factors that precede 
a young stroke. In studies on subarachnoid haemorrhage and ischemic stroke in elderly, 
several acute trigger factors already have been identified (including for example vigorous 
physical exercise, emotions and coffee consumption).140, 141
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The assessment of prognosis and aetiology is a first step in informing young stroke patients in 
terms of prognosis. We therefore will perform the Observational Dutch Young Symptomatic 
StrokE studY (ODYSSEY); a large multicentre prospective cohort study on prognosis and 
both traditional and other risk factors of patients with a TIA, ischemic stroke or ICH aged 18 
through 49 years.
Methods/design
Study design
ODYSSEY is a multicentre prospective cohort study that investigates prognosis and risk factors 
of patients with a TIA, ischemic stroke or ICH aged 18 through 49 years. Within this setting we 
will perform a case-crossover design on potential acute trigger factors. The Medical Review 
Ethics Committee region Arnhem-Nijmegen approved the study (NL41531.091.12) and all 
participants will be requested to sign an informed consent form.
Objectives
The main objective of our study is to determine the risk of mortality and recurrent vascular 
events in patients with a first-ever young TIA, ischemic stroke or ICH.
Secondary objectives are to determine the risk of post-stroke epilepsy, cognitive impairment 
and (vascular) dementia after a young stroke. The influence of a young stroke on functional 
outcome, quality of life and depressive symptoms will also be investigated. We will investigate 
the prevalence of traditional vascular risk factors and the relation between potential acute 
trigger factors and the occurrence of a young stroke. In addition we will identify baseline 
characteristics that are associated with our primary and secondary outcomes.
Study population
Patients
All consecutive patients with an acute first-ever young stroke or TIA admitted to the stroke 
unit or outpatient department of one of the participating centres will be asked to participate 
in the study. Participating study centres are the Departments of Neurology at the Haga 
Hospital Den Haag, St Franciscus Gasthuis Rotterdam, Tweesteden Hospital and St. Elisabeth 
Hospital Tilburg, Catharina Hospital Eindhoven, Amphia Hospital Breda, Medisch Spectrum 
Twente Enschede, Canisius Wilhelmina Hospital Nijmegen, Rijnstate Hospital Arnhem and 
Radboud University Medical Centre Nijmegen.
The following Inclusion criteria will be applied:
 1.   First-ever stroke (ischemic stroke or ICH) or TIA with corresponding lesion and/or 
  evidence of acute arterial occlusion on computed tomography (CT)/ angio-CT - or 
  magnetic resonance imaging (MRI)/angio-MRI scan.
 2.  Age 18 through 49 years
 3.  Onset of symptoms within 14 days prior to inclusion.
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TIA is defined as a rapidly evolving focal neurological deficit, without positive phenomena 
such as twitches, jerks or myoclonus, with no other than vascular cause lasting less than 
24 hours. Acute stroke is defined similar, but with symptoms persisting for more than 24 
hours. On the basis of neuro-imaging stroke is further divided into ICH and ischemic stroke. 
Hemorrhagic transformation of an ischemic stroke will be classified as an ischemic stroke.
Exclusion criteria
 1. History of TIA or stroke.
 2. Traumatic ICH. 
 3.  Any subarachnoid haemorrhage.
 4.  ICH due to a known ruptured aneurysm.
 5.  ICH in a known cerebral malignancy (either primary brain tumor or metastasis).
 6.  Transient monocular blindness or retinal infarction.
 7.  Cerebral venous sinus thrombosis.
 8.  Not permanently living in the Netherlands.
Controls
Controls will be recruited among patients’ spouses, relatives or social environment. Controls 
have to be aged 18 through 49 years and will be matched for mean age, sex and level of 
education. A history of TIA, ischemic stroke or ICH is an exclusion criterion, which will be 
confirmed by a validated questionnaire for verifying stroke-free status.142
Procedures
All eligible patients will be recruited during the evaluation of their TIA or stroke. Patient 
recruitment is planned over a 3-to-4 year period and we intend to include 1500 patients. 
After informed consent and written approval of the participants patients will formally enter 
the study. If the patient is unable to provide informed consent, consent is provided by the 
patient’s legally acceptable representative. During admission or visit to the outpatient 
department, patients will undergo a baseline assessment. In addition, patients will undergo 
an extensive baseline neuropsychological investigation 6–8 weeks after the index event. The 
same neuropsychological assessment will be administered 1 year after the TIA or stroke. 
After baseline assessment, patients will be followed every 6 months for at least 3 years by 
telephone interview. See Figure 1 for the flowchart of the study design. In addition we intend 
to include 250 controls who will undergo a baseline assessment on demographics and a 
neuropsychological assessment.
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Sample size and power calculation
Sample size is based on the least frequent endpoint aft er young stroke. According to 
previous literature cumulative incidence of post-stroke dementia is approximately 1% per 
year. To adjust for the most important confounders (age, sex, stroke severity, education and 
depression) in our Cox proportional hazard analysis, at least 40 cases are needed. To detect 
a cumulative incidence of 1% per year and a follow-up of 3 years with a power of 80%, results 
in a sample size of at least 1500 patients.
Control subjects are included to compare cognitive tasks between patients and healthy 
subjects. Our pilot studies showed that ‘attention’ is the cognitive task which diff ers the least 
between patients and healthy subjects (impaired in 14% versus 8% respectively). To identify 
this diff erence with a power of 80% and alpha 0.05 in previous mentioned 1500 patients, 265 
healthy control subjects need to be included.
Measures-baseline
Medical history
At baseline all participants (patients and controls) will undergo standardised structured 
questionnaires on demographics, level of education (scored using seven categories in 
accordance with the Dutch educational system: 1 = less than primary school; 7 = university 
degree)102, marital status and employment.
The presence of cardiovascular risk factors will be assessed by standardised, structured 
questionnaires and classified according to the current guidelines of the American 
Heart Association.143 Non-modifiable risk factors include age, sex and a family history of 
cardiovascular diseases in the next of kin. Well-documented and potentially modifiable 
risk factors will include cardiovascular diseases (valvular heart diseases, myocardial 
infarction, coronary artery bypass graft ing, percutaneous transluminal coronary angioplasty 
and peripheral revascularisation procedures). Furthermore well-documented potential 
modifiable risk factors will included diabetes mellitus, hypertension, dyslipidemia, smoking 
and atrial fibrillation.
Less-well documented, potentially modifiable risk factors included a history of migraine, 
acute infections, the use of oral contraceptives, alcohol consumption and the use of 
recreational drugs. Patients will be screened for migraine with the MISS questionnaire, a 
screening instrument regularly used in Dutch hospitals containing questions about migraine 
in terms of diagnosis, frequency, aura and concomitant symptoms. Definitions of both well-
documented and less-well documented, potentially modifiable risk factors are shown in 
Additional files.
In addition to the assessment of risk factors, patients will be asked about a history of 
epilepsy, pregnancies and complications, pulmonary embolism, deep vein thrombosis and 
current medication use. Furthermore functional performance prior to the index event will be 
assessed by modified Rankin scale.
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Potential trigger factors
In addition to the questionnaires on cardiovascular risk factors, patients will be requested 
to fill out a standardised structured self-reported questionnaire on acute factors that might 
trigger stroke. For each trigger factor, patients will be asked to report their usual exposure 
during the past year and the exposure during a predefined period before the onset of 
stroke; the hazard period. Hazard periods are based on the estimated duration of the effect 
of each potential trigger factor as used in previous studies investigating trigger factors of 
cardiovascular events.140, 141, 144 In addition to exposure in the hazard period, patients will be 
asked about the last exposure before stroke. In this case-crossover design, each patient will 
serve as his or her own control.145
Potential trigger factors that will be investigated include smoking, consumption of alcohol, 
recreational drugs (cocaine, heroin, methadone, amphetamine, cannabis, XTC, anabolic 
steroids, hallucinogens and EPO), caffeine containing drinks (coffee and cola), valsalva 
manoeuvre, fever, positive and negative emotions, physical exercise and sexual activity. Table 
1 shows the hazard periods for the different potential trigger factors. To investigate the effect 
of valsalva manoeuvre as stroke trigger, patients will be asked about sneezing, coughing, 
nose-blowing and heavy lifting. The exposure to positive and negative emotions will be 
measured using the PANAS scale, a 5 level scale which contains 9 positive and 9 negative 
affects.146 Whenever patients report a mean score of ≥3.5 on the negative affects, they will 
be considered exposed to negative emotions. Anger will be measured using the anger scale, 
consisting of 7 levels of anger.147 Patients are considered exposed to anger if they report a 
peak level of anger ≥4 (very angry, furious or enraged). Physical exercise will be expressed in 
the metabolic equivalent value according to accepted standards.31 The exposure of vigorous 
to extreme exercise (metabolic ecquavalent ≥ 6) will be reported.144 Consumption of alcohol, 
recreational drugs, coffee, cola and smoking will be reported in units per day.
Table 1. Hazard period for potential trigger factors
Hazard time 
Smoking 1 hour
Alcohol consumption 24 hours
Recreational drugs 4 hours
Consumption of coffee 1 hour
Consumption of cola 1 hour
Valsalva manoeuvre 1 hour
Fever 24 hours
Positive and negative emotions 1 hour
Anger 1 hour
Physical exercise 1 hour
Sexual activity 2 hours
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Clinical evaluations
Physical examination and additional investigations
Baseline standard clinical evaluation will be performed during admission or visit to the 
outpatient departments. Clinical signs, symptoms and duration of stroke and TIA will be 
reported. Stroke severity will be assessed by the National Institutes of Health Stroke Scale 
(NIHSS)69 and modified Rankin scale (mRS)70, both measured at admission and at discharge.
Furthermore standard clinical evaluation will include a physical examination and laboratory 
measures. Table 2 shows an overview of all investigations. Additional investigational DNA 
will be stored for future genetic analysis. Patients must consent for storage of the DNA and 
future analysis.
Classification of TIA or stroke: aetiology and neuro-imaging
Aetiology of ischemic stroke and TIA will be classified according to the TOAST-criteria (Trial of 
Org 10172 in Acute Stroke Treatment)68, Causative Classification System of ischemic stroke148 
and ASCO (Atherosclerosis Small vessel disease Cardiac source Other cause)149. Aetiology of 
ICH will be classified as hypertensive (deep or infratentorial haemorrhage in combination with 
hypertension), arteriovenous malformation, cavernous angioma, coagulopathy (iatrogenic or 
bleeding disorder), central nervous system infection, septic embolism, vasculitis, substance 
abuse or unknown (cryptogenic, multiple causes and incomplete evaluation).17 Aetiology will 
be based on neuro-imaging, medical history and the use of medication.
All patients will undergo neuro-imaging and additionally CT-angiography, MR-angiography 
or ultrasound will be performed according to standard clinical care. CT- and MRI-scans will 
be reviewed centrally in the Radboud University Medical Centre. TIA and ischemic strokes 
will be classified according to arterial territory and addition will be classified as lacunar or 
territorial. Whenever hemorrhagic transformation of an ischemic stroke has occurred this 
will be documented.
ICH will be classified as infratentorial (brainstem or cerebellar) or supratentorial haemorrhage 
(lobar, deep or ventricular) with or without ventricular involvement. Lobar haemorrhage will 
be further subdivided into frontal, temporal, parietal or occipital. In addition hematoma 
volume will be calculated according to the A*B*C/2 method.150
Course of the disease
Furthermore the course of the disease during admission will be reported, including medication 
use, (intra-venous or arterial) thrombolysis or other treatments and complications. Whenever 
a patient develops a recurrent vascular event (ischemic stroke, ICH, TIA, myocardial infarction) 
or post-stroke epilepsy this will be reported. In addition the course of stroke severity during 
admission will be assessed by mRS and NIHSS.
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Measures - follow up
All patients will be followed every 6 months by telephone interview. Patients will undergo 
standardised structured questionnaires on the occurrence of post-stroke epilepsy and 
recurrent vascular events (TIA, ischemic stroke, ICH, myocardial infarction, coronary artery 
bypass grafting, percutaneous transluminal coronary angioplasty and other revascularization 
procedures). In addition they will be asked about well-documented potentially modifiable 
vascular risk factors (diabetes mellitus, hypertension, dyslipidemia and smoking), the use 
of medication and pregnancies. In case a patient has died, this information will be retrieved 
from the general practitioner.
As measure of functional outcome mRS and Barthel Index151 will be administered and 
patients will be asked about their occupation or education. Occupation will be categorized 
Table 2. Neuropsychological assessment
Domain Test/Questionnaire
Cognitive assessment
Global cognitive functioning Mini Mental State Examination
Episodic memory Rey Auditory Verbal Learning Test
Speed of information processing Stroop Color Word Test
Letter-Digit Substitution Task
Visuoconstruction Rey Complex Figure Test - Copy
Executive functioning Animal Fluency test
Stroop Interference score
Brixton Spatial Anticipation Test
Neglect Star Cancellation
Language deficits Short Token Test
Attention and working memory Digit Span Test
Paper and Pencil Memory Scanning Task
Subjective cognitive complaints Cognitive failures questionnaire
Mood and functional outcome
History of depression
Anxiety and depression Mini International Neuropsychiatric Interview
Fatigue Checklist on Individual Strength 
Quality of life EQ-5D
Health Status Stroke Impact Scale
Short Form Health Survey 12
Functional outcome Modified Rankin Scale
Barthel Index
Instrumental Activities of Daily Living
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into 4 skills levels (ranging from first = primary education only to fourth = tertiary education 
with university degree or equivalent), according to the ISCO-88 (International Standard 
Classification of Occupations). 
Neuropsychological investigation
An extensive neuropsychological investigation will be administered in all patients six weeks 
and 1 year after the index event (using parallel versions for some tests that are susceptible to 
test-retest effects). Controls will be assessed only once at baseline.
The cognitive assessment includes tests used in other large scale epidemiologic studies 
covering the main cognitive domains.37, 38 Table 3 shows an overview of all cognitive 
tests performed. Global cognitive functioning will be assessed by the Mini Mental State 
Examination.39 Episodic memory will be measured using the 3-trial version of the Rey 
Auditory Verbal Learning Test40, which includes a delayed recall and a delayed recognition 
trial, assessing the acquisition and retention of new verbal information. To assess speed of 
information processing, Parts I and II of the Stroop Color Word test152 and the Letter-Digit 
Substitution Task (an adaptation of the Digit-Symbol Substitution Test153 will be used. 
Visuoconstructive ability will be assessed by the copy trial of the Rey Complex Figure Test.41 
With respect to executive functioning, verbal fluency (animal naming, 60 sec) will be used 
to test response regeneration, the Brixton Spatial Addition Task153 will be administered as a 
measure of concept shifting and rule detection, and the Stroop Interference Score152 will be 
included as a measure of response inhibition. Furthermore participants will complete the 
Star Cancellation of the Behavioural Inattention Test, a short screening battery to assess the 
presence of a visual neglect.154 Participants will be tested for language deficits by means of the 
short version of the Token Test, validated for the Dutch language.155 To evaluate attention and 
working memory we will assess the Digit Span subtest from the Wechsler Adult Intelligence 
Scale - Fourt Edition156 and the Paper and Pencil Memory Scanning Task (4 subtasks)157. 
Subjective cognitive complaints will be assessed by the Cognitive Failure Questionnaire.46 
The cognitive assessment will be performed in quiet rooms and administered by trained 
investigators.
In case cognitive impairment is suspected on the basis of the cognitive screening, relatives 
will be interviewed on the influence of cognitive performance on daily functioning by means 
of the IQCODE.158
In addition to the cognitive screening, questionnaires on mood and functional outcome will 
be administered. Participants will be screened for a history of depressive symptoms with a 
standardised questionnaire used in previous large-scale epidemiological studies21, in which 
normal reactions to stressful events or normal grief will be excluded. A history of depression 
is defined as those episodes that require attention of a medical caregiver, including both 
minor depression and major depressive syndromes as defined by the Research Diagnostic 
Criteria.159 Current anxiety and depression will be evaluated by means of the Mini International 
Neuropsychiatric Interview47, which is a short diagnostic structured interview based on 
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Table 3. Overview of investigations
Standard
Physical examination Neurological examination 
NIHSS X
mRS X
Blood pressure X
Oxygen saturation X
Heart rate X
Body temperature X
Body Mass Index X
Additional investigations ECG X
Laboratory measures X
Fasting glucose X
Cholesterol levels X
Blood count X
Sedimentation rate X
DNA storage X
Other specific laboratory measures on indication 
(young stroke laboratory measures) 
Echocardiography on indication
Imaging Neuro-imaging1 X
CT 
MRI
Vascular imaging2 X 
Angio-CT
Angio-MRI
Ultrasound
Abbreviations: NIHSS=National Institutes of Health Stroke Scale; mRS=modified Rankin Scale; 
ECG=electrocardiogram; CT=computed tomography; DNA= deoxyribonucleid acid ; MRI=magnetic resonance 
imaging
1 All patients will undergo neuro-imaging, either CT or MRI scanning.
2 All patients will undergo either angio-CT, angio-MRI or ultrasound according to standard clinical care. 
the DSM-IV. Functional outcome will be assessed by mRS, Barthel Index and Instrumental 
Activities of Daily Living54.
Furthermore participants will fill out validated self-report questionnaires on fatigue by 
means of the Checklist on Individual Strength55 and quality of life by means of the EQ-5D58. 
Health status will be assessed by means of the Stroke Impact Scale59 and Short Form Health 
Surveys-12160.
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Outcome
Primary outcome will be all cause mortality. Depending on date and location of death 
information on cause of death will be available either from the hospital (in-hospital mortality) 
or the general practitioner. Secondary measures of outcome will be the composite endpoint 
of any recurrent vascular event. Vascular events will include TIA, fatal or non-fatal stroke 
(ischemic or hemorrhagic), myocardial infarction, CABG, PTCA and other revascularization 
procedures, whichever occurs first. Stroke and TIA will be defined similar as the index event. 
Myocardial infarction will be defined by ischemic symptoms with electrocardiographic, 
cardiac biomarker, or pathological evidence of infarction according to the universal definition 
of myocardial infarction111.
In addition, the occurrence of post-stroke epilepsy and dementia will be noted as secondary 
outcome. Epilepsy will be classified and defined according to the International League Against 
Epilepsy, in which patients with a single seizure associated with an enduring condition that 
could cause epilepsy, meet the criteria of epilepsy.72, 73 Dementia will be defined according to 
DSM-5. Finally, tertiary outcome measures will include functional outcome, quality of life and 
mood disorders.
Whenever an outcome event is suspected with the aid of standardised structured 
questionnaires, information from the treating physician will be retrieved. This information 
will be verified and adjudicated by two independent experienced neurologists or, in case of a 
myocardial infarction, by a cardiologist, who will be blinded for the index event.
Analysis
Cumulative risk of mortality, vascular events and epilepsy will be estimated by Kaplan-Meier 
survival analysis. In the analysis for epilepsy and vascular events, patients who have died 
will be censored. Cox proportional hazard analysis will be used to calculate hazard ratios 
(HRs) for previous mentioned primary and secondary outcome measures adjusted for the 
necessary covariates. For the outcome measures vascular events and epilepsy, additional 
competing risk analysis will be performed in which death will be considered as a competing 
risk as suggested by Fine and Gray.161, 162
For the analysis containing cognition, raw test scores of each test will be calculated and 
converted to Z-scores using the mean and standard deviation of the controls. Z-scores of 
tests assigned to the same cognitive domain will be averaged and used in all subsequent 
analyses as composite Z-score, or domain score. ANCOVA models will be used to compare 
means of different variables on each cognitive domain adjusted for the necessary covariates. 
Linear regression will be used to explore the effect of different variables on each cognitive 
domain and results will be reported as beta coefficients.
For the analysis including acute trigger factors, a case-crossover design as previous described 
will be used in which each patient will serve as his or her own control.145 The ratio of the 
observed exposure frequency in the hazard period to the expected frequency based on the 
control period will be used to estimate relative risks.
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HRs, beta coefficients and relative risks will be calculated with their corresponding 95% 
confidence intervals (CIs). Comparisons of continuous variables will be done by Student’s t 
test or analysis of variance or, in case of skewed distributions which cannot be normalized, 
corresponding nonparametric tests will be used. Chi-squared test will be used for comparison 
of categorical variables.
Discussion
ODYSSEY aims to investigate the prognosis after a first-ever young TIA, ischemic stroke or 
ICH in terms of mortality, recurrent vascular events, post-stroke epilepsy and cognitive 
impairment. Furthermore we intend to determine the prevalence of vascular risk factors 
in young stroke patients and to relate potential acute trigger factors to the occurrence of a 
young stroke.
Strong elements of the study are the multicentre prospective design with multiple follow-
up assessments. Due to the multicentre approach we will be able to include a large sample 
size, covering a vast part of the Netherlands including both academic and regional hospitals. 
The prospective design allows us to obtain an accurate evaluation of the prognosis of young 
stroke patients, unlike previous small retrospective studies. Furthermore, most previous 
studies only included patients with an ischemic stroke while we will include patients with 
a TIA and ICH as well. This allows us to study a large part of the spectrum of stroke in 
young adults. Since patients will only be eligible for inclusion in our study when they have 
positive brain imaging corresponding with their neurological deficits, ODYSSEY will have a 
clearly defined population without misclassification. In retrospective studies often a clinical 
diagnosis was used for defining stroke, leading to a more heterogeneous study population.
Only few small studies among young stroke patients investigated cognitive performance 
after a young stroke. To our knowledge we are the first to investigate cognitive performance 
both at baseline as well as 1 year after follow-up. This enables us to describe the course of 
cognitive performance and potential further decline after an initial assessment. On top of 
this we will include healthy matched control subjects which will allow for a comparison of 
cognitive performance with a healthy group.
In addition, this study is the first investigating potential acute trigger factors preceding a stroke 
or TIA in a non-selected young population. In studies on subarachnoid haemorrhage and 
ischemic stroke in the elderly, several acute trigger factors already have been identified.140, 
141 Due to the case-crossover design we hope to identify possible acute trigger factors, which 
may give us more insight in the underlying pathophysiological mechanisms of a young 
stroke. As some of those trigger factors are potentially modifiable, the assessment of acute 
trigger factors might lead to new prevention strategies in high risk patients.
The estimation of aetiology and prognosis is a first step in informing young stroke patients in 
terms of prognosis. The estimates of recurrent vascular events risks may be used to design 
future intervention studies on start and withdrawal of secondary prevention in these young 
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patients, as the current prescription of these drugs is based on extrapolated findings from 
stroke trials in which young patients have been underrepresented or excluded.
In conclusion, ODYSSEY is designed to prospectively determine prognosis after a young 
stroke and get more insight in aetiology of patients with a TIA, ischemic stroke and ICH in 
patients aged 18 through 49 years old in a large sample size.
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Additional files
Definition of well-documented and less-well documented modifiable risk factors
Well-documented potentially modifiable risk factors: Myocardial infarction will be defined by 
ischemic symptoms with electrocardiographic, cardiac biomarker, or pathological evidence 
of infarction according to the universal definition of myocardial infarction.111 Smoking will 
be defined as at least 1 cigarette in the 6 months prior to the event. Overweight will be 
defined as Body Mass Index=25-29 and obesity as Body Mass Index≥30.163 On the basis of 
laboratory findings diabetes mellitus will be defined as a random blood glucose level ≥ 200 
mg/dL (11.1mmol/L) or 2 consecutive fasting venous plasma glucose levels of ≥ 126 mg/dL 
(7.0 mmol/L)109, 164 or the use of antidiabetics. Dyslipidemia will be defined by either total 
cholesterol level ≥5.0 mmol/L or low-density lipoprotein level ≥2.5 mmol/L or high-density 
lipoprotein level <1.0 mmol/L or the use of lipid-lowering drugs. Hypertension will be defined 
as a systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 (measured at least 24 
hours after stroke, with 2 independent measures)165, 166 or the use of antihypertensive drugs. 
Less-well documented potentially modifiable risk factors: Excess alcohol consumption will be 
defined as consuming more than 200 g of alcohol per week. Furthermore migraine will be 
defined according to the international classification of headache disorders.167
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Patients with a stroke at young age may experience various complications during their post-
stroke life. As patients in this specific age category usually have a long life expectancy with 
an attendant long exposure time to post-stroke complications, information on the long-term 
is of utmost importance. Therefore the general aim of this thesis was to investigate the long-
term consequences of a stroke at young age. The goal was to assess the risk of post-stroke 
epilepsy and recurrent vascular disease and their long-term consequences. The studies 
described in this thesis are based on the FUTURE study. The FUTUREstudy comprises all 
consecutive patients with a transient ischemic attack (TIA), ischemic stroke or intracerebral 
haemorrhage (ICH) aged 18-50 years, who visited the neurology department of the Radboud 
University Nijmegen Medical Centre. 
In this chapter, we will discuss the most important methodological considerations and main 
findings of the thesis. In addition, potential implications for clinical practice will be discussed 
and recommendations for future research will be given. 
Methodological considerations
Study design
The studies in this thesis are based on a prospective cohort of all consecutive patients with a 
TIA, ischemic stroke or ICH, aged 18-50 years who visited the neurology department between 
1980 and 2010. This longitudinal design made it possible to investigate changes over time 
with respect to incident vascular events, incident post-stroke epilepsy and its association 
with mortality. However the studies regarding the association between post-stroke epilepsy 
and functional outcome or cognition and the study on small vessel disease (SVD) are based 
on outcome measured at one time point. Therefore it is not possible to accurately assess 
whether the associations found in those studies are causal. However the long-term follow-up 
duration is unique element of our study and the prospective evaluation of the occurrence of 
post-stroke epilepsy and recurrent vascular events, gives us more insight in risks over time.
Internal validity 
The validity of a study is determined by the degree of errors in a study, which can be systematic 
or random.168 Three forms of systematic errors can be distinguished, which account for the 
internal validity of a study: selection bias, information bias and confounding. 
Selection bias arises when the relation between the determinant and the outcome is different 
for participants and non-participants.168 Whenever selection for the study is dependent of 
the risk factor or outcome under study, selection bias may occur. Especially in the studies 
regarding post-stroke epilepsy and the association with cognitive performance and functional 
outcome and our study on SVD, selection bias may have occurred as only those patients 
who visited the research centre or underwent a magnetic resonance imaging (MRI) scan were 
included. Possibly patients who did not participate in this sub study most likely were the 
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ones with either a poor or good outcome. In addition, patients who died obviously were not 
included, which may have lead to an underestimation of poor outcome. Although baseline 
characteristics did not markedly differ between participants and non-participants and there 
was no difference in stroke severity, formal information on outcome in non-participants is 
missing. For the studies on incident vascular events and post-stroke epilepsy, there were also 
no differences in baseline characteristics between participants and to lost to follow-up or 
those who refused to participate, making selection bias less likely.
Information bias may occur due to a measurement error of the determinant or outcome, 
which leads to misclassification.168 Information bias may occur whenever researchers are not 
blinded for outcome or index event. In addition, in the studies concerning post-stroke epilepsy 
it might be difficult to distinguish a TIA from a seizure, especially for example in the case 
of a limb-shaking TIA.76 Theoretically either the index event or the seizure could have been 
misclassified. To minimize misclassification TIA was diagnosed according to current clinical 
guidelines and patients with positive phenomena such as twitches, jerks or myoclonus were 
excluded. In addition, all index events were verified by two independent neurologists and 
outcome was assessed blinded from index event. Furthermore, imaging techniques have 
changed over the past 30 years. This could have led to more misclassification of the index 
event for patients who had a stroke or TIA a long time ago. We have tried to overcome this by 
using the clinical definitions of stroke and TIA according to the World Health Organisation.67, 
91
In addition, information bias may arise whenever an outcome is not clearly defined. In the 
described studies outcome measures were clearly defined and information on outcome was 
collected in an identical manner by structured, vascular questionnaires for all patient. In the 
study on SVD, MRIs were evaluated by a trained rater with a high inter- en intrarater reliability.
Recall bias is another possible type of information bias and may occur due to the long follow-
up duration in the FUTURE study. The occurrence of incident vascular events or incident 
post-stroke epilepsy could have been underestimated due to the use of self-reporting 
questionnaires, especially whenever the event occurred a longer time ago. However there 
were no differences in 5 years risk of vascular events or epilepsy, for the different inclusion 
periods. Moreover, we have tried to overcome this by verifying information on vascular events 
and post-stroke epilepsy retrieved from the treating physician by a neurologist. 
Confounding bias occurs whenever an association between a determinant and outcome is 
determined by another variable or confounder that correlates with both the determinant 
and the outcome.168 In the studies regarding post-stroke epilepsy and outcome an important 
confounder is stroke severity. In the studies on the association between post-stroke epilepsy 
and outcome, stroke severity could be correlated to the occurrence of post-stroke epilepsy 
and a higher mortality, poor functional outcome or worse cognitive performance. Therefore 
we adjusted for stroke severity and other confounders in the multivariate models. In addition, 
important confounders for the occurrence of SVD are vascular risk factors and age, which we 
adjusted for.
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Precision affects the reproducibility of a measurement and is reflected by the degree of 
random error that occurs.168 The amount of random error can be minimized by including a 
large sample size. Although the FUTURE study includes a large sample size, the study regarding 
SVD and the study including patients with an ICH are smaller, therefore results need to be 
interpreted with caution. In addition, random error might have occurred due to outcome 
measures that may be different or fluctuating over time, in this thesis this especially accounts 
for cognitive performance. To prevent this type of error, validated neuropsychological tests 
were used and covered the main cognitive domains, which were previously applied in large-
scale epidemiological studies in cerebrovascular disease.37, 38 In addition, for the study on 
SVD, imaging data were collected using a single scanner and two trained raters independently 
assessed 10% of all scans, with high inter-rater variability. 
External validity
External validity involves the extent to which the results of the study can be generalised 
beyond the study population.168 We presume that the study population of the FUTURE study 
is a representative sample of patients with a stroke at young age for several reasons. First of 
all, we have included a large study population of all consecutive patients who visited our 
Neurology department. Although all subjects were seen in a university hospital, patients with 
a stroke at young age usually visit our university medical centre during the course of their 
disease, since our hospital serves as the only referral centre in the region. In addition there 
are no restrictions to be admitted to our hospital. Second, baseline characteristics and stroke 
characteristics with respect to aetiology of patients in our study are more or less comparable 
to other studies concerning patients with a stroke at young age.18, 130 However, we have a 
relatively high proportion of women compared to other studies.
Although formal data on generalisablity are lacking, for those reasons we feel that our results 
can be generalised to a general young stroke population.
General discussion of main findings
Post-stroke epilepsy
This thesis shows that post-stroke epilepsy after a stroke at young age is not only a common 
problem, but it is also associated with a poor outcome. Almost 12% of all patients developed 
post-stroke epilepsy, of whom 30% had an initial early seizure (occurring within 1 week after 
the stroke) and 70% developed late seizures (occurring after the first week after stroke). 
Particularly, patients with an ischemic stroke or ICH with a high NIHSS had a high risk of 
developing seizures. In addition post-stroke epilepsy after an ischemic stroke or TIA was 
associated with mortality, functional outcome and cognitive performance. 
Pathophysiological mechanisms for epileptogenesis may be different for acute seizures 
and late seizures. In the acute phase of stroke the threshold for seizures may be lowered 
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by cytotoxic changes of neuronal cells and altered neurotransmitter release during acute 
ischemia.169-171 As these changes resolve over time, it may be expected that the risk of seizures 
decreases, however seizures may also develop over time. These late onset seizures may be 
caused by the persistent changes in neuronal excitability due to gliotic scarring.169, 171 Possibly, 
the macroscopic visible structural damage seen on MRI is not the only explanation for the 
epileptogenesis. It might be that microscopic changes, such as structural integrity of the 
brain and/or cortex also contribute to this process. Similar as found in loss of hippocampal 
structural integrity after a stroke at young age124, other structures of the brain and cortex may 
also be disrupted and thereby cause seizures. 
The association between post-stroke epilepsy and a poor outcome may be explained 
by an additional negative effect of seizures on recovery. Seizures may worsen the state of 
insufficient oxygen and energy supply in already ischemic brain tissue and thereby increasing 
infarct size and impairing recovery. This may be caused by a massive release of glutamate, 
causing excessive activation of glutamate receptors and may thereby be responsible for 
secondary neuronal injury.172, 173 Finally, the use of anti-epileptic drugs (AEDs) may have 
influenced outcome, in particular cognition95 and functional outcome.94 
Long-term vascular prognosis
This thesis shows that patients with a stroke at young age remain at a high risk of developing 
recurrent ischemic events. During 25 years of follow-up 1 out of 2 developed a recurrent 
ischemic event and 1 out of 3 developed a recurrent stroke or TIA. In addition, this thesis 
shows that patients have a higher burden of SVD than controls, despite having the same 
vascular risk factors. Patients already had on average 10-20 years earlier in life the same 
volume of white matter hyperintensities as controls.
Few other studies in the young have investigated risk factors associated with recurrent 
vascular events, with a short follow-up.18, 19 However, none of the developed prediction 
models, including the one in the FUTURE study, have obtained a good predictive value yet. 
This may suggest that other unknown factors contribute to the risk of recurrent vascular 
events. Increasing evidence suggests that stroke at a young age has a stronger genetic basis 
than stroke occurring at older ages.118, 119 It might be possible that genetic factors may also 
interact with vascular risk factors, possible making patients with a stroke at young age more 
vulnerable for those risk factors. An argument for this hypothesis may come from our study 
on the prevalence of SVD after a stroke at young age. Despite having the same cardiovascular 
risk profile, patients with a stroke at young age have a higher burden of SVD already early in 
life. This also suggests that patients with a stroke at young age might be more vulnerable for 
those vascular risk factors. As not every patient with vascular risk factors develops a (young) 
stroke, this may suggest a genetic predisposition.
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Clinical relevance
Post-stroke epilepsy
During post-stroke life patients with a stroke at young age may encounter various 
complications which may interfere with daily living. So far, the incidence of post-stroke 
epilepsy has received little attention. The information on the association between post-
stroke epilepsy and a long-term poor outcome is important for patients, their caregivers 
and physicians to provide them with information on the course of their disease. Especially 
for younger patients information on the long-term is crucial, as patients still have an active 
life ahead of them in which they start to form families and make a career. Moreover, the 
unpredictability of seizures or the necessity to use medication can make jobs unsuitable for 
them. 
Given the high incidence of seizures after a stroke at young age and its association with a 
poor outcome, it might be suggested that a subgroup could benefit from prophylactic 
AEDs. Unfortunately, we were not able to take the role of AEDs on the occurrence of post-
stroke epilepsy and its association with outcome into account in this thesis. Only a few 
studies have tried to investigated the role of primary prevention of AEDs after stroke.173 In 
a small randomized trial on the effect of valproate after an ICH, valproate did not prevent 
the occurrence of seizures, however National Institutes of Health Stroke Scale (NIHSS) scores 
improved in patients treated with valproate.174 Another study tried to perform a trial aimed 
at preventing the development of post-stroke seizures after an ischemic stroke or ICH using 
levetiracetam. Due to too few participants no conclusions could be drawn.175 
Although we showed in this thesis post-stroke epilepsy is associated with a poor outcome, 
in our opinion currently patients should not be treated prophylactic with antiepileptic drugs 
(AEDs). AEDs are known for their various side effects, which may also even contribute to the 
poor (cognitive) outcome and it remains unclear whether treatment improves this outcome. 
Obviously, it is widely accepted that patients with (repeated) late post-stroke seizures, 
should be treated we AEDs. How to treat patients with early seizure is more difficult. As we 
have shown patients with early seizures less often tend to develop recurrent seizures and 
early seizures less often are associated with a poor long-term functional outcome, on the 
other hand seizures in the first 30 days after stroke are associated with a higher case fatality, 
independent of stroke severity. Therefore, an alternative suggestion would be to treat 
patients with an initial early seizure with AEDs only for the first few months after the stroke.
Vascular consequences
Patients with a stroke at young age remain at a high risk for developing recurrent vascular 
events, even decades after their initial stroke. This raises the question how to incorporate 
secondary prevention strategies in this specific age group. Currently information on how 
to treat patients with a stroke at young age is extrapolated from studies in which younger 
patients were underrepresented our excluded. As it remains unclear when to start and stop 
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secondary prevention in young patients, future clinical trials should aim at this and how long 
secondary prevention should be used. Especially in patients without traditional vascular risk 
factors or an undermined cause of their stroke. As patients with a cardio embolic stroke or 
large artery disease as a cause of their stroke remain at a high risk even decades after their 
stroke, secondary prevention should be continued lifelong and patients should be followed 
carefully.
Although prediction models do not seem to be perfect, traditional (partly) modifiable risk 
factors also at younger ages seem to play an important role in developing recurrent ischemic 
events. In addition, patients with a stroke at young age seem to be more vulnerable for 
vascular risk factors, as they already develop a stroke and SVD early in life, despite having the 
same vascular risk factors as control subjects. This may be additional arguments for stricter 
secondary prevention protocols in the younger patient too, especially in those with vascular 
risk factors. 
As the causes of the stroke in younger patients are more heterogeneous than in older patients, 
it is more difficult to inform patients about their prognosis and counselling a patient should 
be even more on an individual base. A first step in this personalized medicine is to develop 
a prediction model with risk factors associated with recurrent vascular events. However no 
studies have developed a model with good predictive value yet. It might be possible that 
the young stroke group is too heterogeneous, which makes it hard to develop a uniform 
prediction model for all stroke aetiologies together.
Future directions
This thesis has shown that post-stroke epilepsy frequently occurs after stroke in young adults 
and is associated with serious complications such as mortality, poor functional outcome and 
cognitive impairment. The role of AEDs in the development of post-stroke epilepsy and its 
association with outcome remains unclear. Therefore future studies should investigate this. 
Possibly a subgroup at high risk of developing post-stroke epilepsy, could be identified that 
could benefit from prophylactic AEDs.
In addition, patients with a stroke at young age remain at a high risk of developing recurrent 
vascular events and prevalence of SVD is high. However, information on how to treat an 
individual patient remains unclear, which implies that there is also considerable potential to 
be gained in this area. To determine secondary prevention strategies at an individual level, 
future studies should aim at identifying risk factors associated with recurrent vascular events. 
Therefore we started the ODYSSEY study, a prospective multicentre study with a large sample 
size. In the ODYSSEY study both well-documented, less well-documented risk factors and 
potentially acute trigger factors will be investigated. Moreover, the use and (dis)continuation 
of secondary prevention will be documented. The risk estimates of recurrent vascular events 
may be used to design future intervention studies on start and withdrawal of secondary 
prevention in these young patients.
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Incidence of stroke at young age is increasing, which has been explained by an accompanying 
increase in the prevalence of traditional vascular risk factors. Especially for this younger 
age group, long-term information on the years after the stroke is of utmost importance, 
as these patients usually have a long life ahead. However, reliable long-term information 
on complications after a stroke at young age is scarce. Therefore we investigated the long-
term risk of post-stroke epilepsy and its association with outcome and the long-term risk of 
vascular disease after a stroke at young age. 
The studies described in this thesis are based on the FUTURE study, a prospective cohort 
study on causes and consequences of patients with a  transient ischemic attack (TIA), 
ischemic stroke or intracerebral haemorrhage (ICH) aged 18-50 years old. All consecutive 
patients who were admitted to the Radboud University Medical Centre between 1980 and 
2010 were included in the study. An extensive follow-up assessment took place between 
2010 and 2012 and between 2014 and 2015. The design of the FUTURE study is described in 
Chapter 2. 
Post-stroke epilepsy after a stroke at young age
In part II the occurrence of post-stroke epilepsy after a stroke at young age and its association 
with outcome is described. Chapter 3 reports the incidence of post-stroke epilepsy. After a 
maximum follow-up of 30 years, cumulative risk of post-stroke epilepsy was 14% and 7% for 
recurrent seizures. Patients who had an initial late seizure more often developed recurrent 
seizures than patients with an initial early seizure. Patients with an ICH or ischemic stroke 
had a 4 times higher risk of developing seizures than patients with a TIA. In addition a higher 
National Institutes of Stroke Scale (NIHSS) was independently associated with a higher risk 
of post-stroke epilepsy.
In chapter 4 we investigated the association of post-stroke epilepsy with functional 
outcome in young stroke survivors. Ischemic stroke patients with post-stroke epilepsy more 
often had a poor functional outcome than those without both on modified Rankin Scale 
(mRS) and Instrumental Activities of Daily Living (IADL) after more than 10 years of follow-
up; almost 30% of the patients with post-stroke epilepsy had a poor outcome compared to 
10% of the patients without. This effect was independent from for sex, age, stroke severity, 
follow-up duration and recurrent stroke. For patients with a TIA or ICH there was no such 
relation. In chapter 5 we investigated the association of post-stroke epilepsy with cognitive 
performance after a TIA or ischemic stroke. After mean follow-up of 10 years we investigated 
seven cognitive domains. Patients with post-stroke epilepsy had a worse global cognitive 
performance than those without after adjustment for age at follow-up, education level, stroke 
severity and recurrent stroke. Especially the domains processing speed and working memory 
were more affected. In addition, 46% of the patients with post-stroke epilepsy had a cognitive 
impairment compared to 25% of the patients without, this difference was independent of 
previous mentioned confounders. There was no difference in cognitive performance between 
patients who used anti-epileptic drugs (AEDs) at the moment of cognitive assessment. 
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However patients have stopped and switch AEDs during follow-up which could not be taken 
into account in our analyses.
Chapter 6 describes the association of post-stroke epilepsy with mortality after a TIA or 
ischemic stroke at young age. We found that patients with post-stroke epilepsy had a higher 
cumulative case fatality (death within 30 days after the initial stroke) than patients without 
(27% and 2% respectively), after adjustment for age, sex and stroke severity. In addition, 
20-years cumulative mortality was 57% or patients with post-stroke epilepsy and 33% for 
those without; this difference was independent of sex, age, history of hypertension, history 
of diabetes mellitus, TOAST-classifications and recurrent stroke. There was no difference in 
cause of death between the two groups. 
Long-term vascular consequences after a stroke at young age
Part III describes the long-term vascular consequences of a TIA or ischemic stroke at young 
age. In chapter 7 the very long-term risk of recurrent ischemic events was determined 
and risk factors associated with the risk of recurrent events were identified. We found that 
patients with a stroke at young age remain at a substantial risk of developing recurrent 
vascular events after their initial stroke. After 25 years of follow-up the cumulative risk of 
any vascular event was 45%; 30% for a recurrent stroke or TIA and 27% for other vascular 
events. Especially patients with a cardio-embolic stroke or large artery as a cause of their 
stroke have a very high cumulative risk of vascular events of more than 60% after 25 years. 
Risk factors independently associated with the risk of recurrent vascular events were poor 
kidney function, smoking, history of peripheral arterial disease and a history of myocardial 
infarction. Although the developed prediction model only had a moderate predictive 
performance, it became clear that traditional vascular risk factors play an important role in 
the risk of recurrent vascular disease.
In chapter 8 the prevalence of cerebral small vessel disease (SVD) after a stroke at young age 
was assessed and compared with healthy controls. After mean follow-up of 10 years, 24% of 
the patients had developed at least one lacune, 13% had developed at least one microbleeds 
and median white matter hyperintensity (WMH)-volume was 1.5 ML. Patients had an almost 
7 times higher risk of developing lacunes, after adjusting for traditional vascular risk factors 
(age, sex, smoking, diabetes mellitus and hypertension) than healthy controls. Moreover, 
patients had the same volume of WMHs on average 10-20 years earlier in life compared with 
healthy controls. Traditional vascular risk factors age, hypertension and smoking at the time 
of the initial stroke, were independently associated with WMH-volume at follow-up in these 
patients. 
Future perspective
Part IV of this thesis describes the design and rational of the ODYSSEY study (Observational 
Dutch Symptomatic StrokE study) (chapter 9). This ongoing multicenter cohort study is 
designed to prospectively determine prognosis after a stroke at young age and get more 
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insight in aetiology of TIA, ischemic stroke and ICH in patients aged 18-49 years old. The aim 
is to include 1500 patients and patients will be followed every 6 months for at least 3 years. 
Primary outcome will be all cause mortality and risk of recurrent vascular events. Secondary 
outcome will be the risk of post-stroke epilepsy and cognitive impairment. In addition well-
documented and less well-documented risk factors and potentially acute trigger factors 
will be investigated. Moreover, the use and (dis)continuation of secondary prevention will 
be documented. The risk estimates of recurrent vascular events may be used to design 
future intervention studies on start and withdrawal of secondary prevention in these young 
patients.
Conclusion
The studies in this thesis show that post-stroke epilepsy after a stroke at young age is a 
common problem and in addition is associated with a poor outcome in terms of mortality, 
functional outcome and cognitive performance.
In addition we have shown that patients remain at a lifelong risk of developing recurrent 
vascular events, especially patients with traditional vascular risk factors. The chronic 
consequences of a young stroke are also shown by the high proportion of patients who 
develop SVD compared to control subjects. Future studies should investigate the role of 
secondary prevention in this specific age group.
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De incidentie van een beroerte op jonge leeftijd neemt toe over de jaren heen. Dit lijkt met 
name verklaard te worden door een toename van traditionele vasculaire risicofactoren, 
zoals roken en een hoge bloeddruk. Vooral op deze jongere leeftijd is het belangrijk om de 
lange termijn kennis over de jaren na de beroerte te vergroten, omdat deze mensen over 
het algemeen nog een heel leven voor zich hebben.  Er is echter weinig bekend over de 
lange termijn complicaties bij patiënten die op jongere leeftijd een beroerte doormaken. 
In dit proefschrift wordt het lange termijn risico op epilepsie en het lange termijn risico op 
vasculaire ziekten na een beroerte op jonge leeftijd onderzocht.
De hoofdstukken in dit proefschrift zijn gebaseerd op het  FUTURE-onderzoek. Dit is een 
prospectieve studie naar oorzaken en gevolgen van patiënten met een transient ischemic 
attack (TIA), herseninfarct of hersenbloeding op jongere leeftijd (18 – 50 jaar). Alle patiënten 
die hiervoor tussen 1980 en 2010 in het Radboudumc zijn geweest, zijn geïncludeerd. Een 
uitgebreid follow-up onderzoek vond plaats tussen 2010 en 2012 en tussen 2014 en 2015. De 
opzet van het FUTURE-onderzoek staat beschreven in hoofdstuk 2.
Post-stroke epilepsie na een beroerte op jonge leeftijd
In deel II is het risico op post-stroke epilepsie na een beroerte op jonge leeftijd beschreven 
en de relatie tussen post-stroke epilepsie en prognose. Hoofdstuk 3 beschrijft de incidentie 
van post-stroke epilepsie. Na 30 jaar was het cumulatieve risico op post-stroke epilepsie 
14% en het cumulatieve risico op het optreden van herhaaldelijke insulten was 7%. 
Patiënten waarbij het eerste insult later dan 2 weken na de beroerte optrad, hadden vaker 
herhaaldelijke insulten dan patiënten waarbij het eerste insult binnen 2 weken na de beroerte 
optrad. Patiënten met een hersenbloeding of herseninfarct hadden een 4 keer hoger risico 
op het ontwikkelen van epilepsie dan patiënten met een TIA. Daarnaast was de ernst van de 
beroerte geassocieerd met het optreden van post-stroke epilepsie.
In hoofdstuk 4 hebben we de associatie tussen post-stroke epilepsie en algemeen 
functioneren onderzocht onder patiënten die nog in leven waren na een beroerte op jonge 
leeftijd. Patiënten met een herseninfarct die post-stroke epilepsie hadden ontwikkeld, 
functioneerden minder vaak zelfstandig dan patiënten die geen epilepsie hadden 
ontwikkeld. Zelfs 10 jaar na de beroerte functioneerde bijna 30% van de patiënten met post-
stroke epilepsie niet zelfstandig tegenover 10% van de patiënten die geen epilepsie hadden 
ontwikkeld. Dit was onafhankelijk van leeftijd, geslacht, ernst van de beroerte, follow-up duur 
en recidief beroertes. Voor patiënten met een TIA of hersenbloeding bestond deze associatie 
niet.
Hoofdstuk 5 beschrijft de associatie tussen post-stroke epilepsie en cognitief functioneren 
na een TIA of herseninfarct. Hiervoor zijn 7 verschillende cognitieve domeinen gemiddeld 
10 jaar na de beroerte onderzocht. Patiënten met post-stroke epilepsie hadden een slechter 
algemeen cognitief functioneren dan patiënten zonder post-stroke epilepsie, onafhankelijk 
van leeftijd, opleidingsniveau, ernst van de beroerte en recidief beroertes. Met name 
de domeinen verwerkingssnelheid en werkgeheugen waren meer aangedaan bij deze 
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patiënten. Daarnaast had 46% van de patiënten met post-stroke epilepsie een cognitieve 
stoornis ten opzichte van 25% van de patiënten zonder epilepsie. Er was geen verschil in 
cognitief functioneren tussen patiënten die antiepileptica gebruikten en patiënten die dit 
niet gebruikten. Echter, het stoppen en wisselen van epileptica gedurende de follow-up 
hebben we niet mee kunnen nemen in onze analyses.
In hoofdstuk 6 beschrijven we de associatie tussen post-stroke epilepsie en overlijden na 
een TIA of herseninfarct op jonge leeftijd. Patiënten met post-stroke epilepsie hadden een 
hoger cumulatief overlijdensrisico binnen 30 dagen na de beroerte dan patiënten zonder 
epilepsie (27% en 2% respectievelijk), onafhankelijk van leeftijd, geslacht en ernst van de 
beroerte. Na 20 jaar was het cumulatief risico op overlijden 57% voor patiënten met post-
stroke epilepsie en  33% voor patiënten zonder epilepsie. Dit verschil was onafhankelijk 
van leeftijd, geslacht, etiologie van de beroerte, diabetes mellitus, hypertensie of recidief 
beroerte. Er was geen verschil in doodsoorzaak tussen de twee groepen.
Lange termijn vasculaire gevolgen na een beroerte op jonge leeftijd
Deel III beschrijft de lange termijn vasculaire gevolgen na een TIA of herseninfarct op jonge 
leeftijd. In hoofdstuk 7 hebben we het lange termijn risico op recidief (hart- en) vaatziekten 
en de risicofactoren die hiermee geassocieerd zijn onderzocht. Patiënten met een beroerte 
op jonge leeftijd bleven een hoog risico op nieuwe (hart- en) vaatziekten houden in de jaren 
na hun beroerte. Na 25 jaar was het cumulatief risico op een willekeurig arteriële vasculaire 
ziekte 45%; 30% voor een recidief beroerte of TIA en 27% voor andere arteriële vasculaire 
ziekten. Met name patiënten die als etiologische oorzaak van hun beroerte ‘large artery 
atherosclerose’ of ‘cardio-embolie’  hadden, bleken een erg hoog cumulatief risico te hebben 
van meer dan 60%. Slechte nierfunctie, roken, voorgeschiedenis van perifeer vaatlijden 
en een voorgeschiedenis van een hartinfarct waren onafhankelijk geassocieerd met het 
optreden van recidief vasculaire ziekten. Ondanks dat het ontwikkelde predicitiemodel 
slechts een matige voorspellende waarde had, werd wel duidelijk dat traditionele vasculaire 
risicofactoren een belangrijke rol spelen in het risico op recidief vasculaire ziekten.
In hoofdstuk 8 is de prevalentie van cerebrale micro-angiopathie na een beroerte op jonge 
leeftijd bepaald en vergeleken met gezonde controle personen. Na een gemiddelde follow-
up van 10 jaar, had 24% van de patiënten tenminste 1 lacune ontwikkeld, 13% had tenminste 
1 microbloeding en het gemiddeld volume van wittes stofafwijkingen was 1.5 mL. Patiënten 
hadden bijna 7 keer zo hoog risico op het ontwikkelen van lacunes ten opzichte van controle 
personen, onafhankelijk van de aanwezigheid traditionele vasculaire risicofactoren (leeftijd, 
geslacht, roken, diabetes mellitus en hypertensie). Daarnaast hadden patiënten hetzelfde 
volume van witte stof afwijkingen gemiddeld 10-20 jaar eerder in hun leven dan controle 
personen. De vasculaire risicofactoren leeftijd, hypertensie en roken ten tijde van de initiële 
beroerte waren onafhankelijk geassocieerd met het volume van  witte stof afwijkingen ten 
tijde van follow-up.
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Lange termijn perspectief
Deel IV van deze thesis beschrijft de opzet en achtergrond van het ODYSSEY-onderzoek 
(Observational Dutch Symptomatic StrokE study) (hoofdstuk 9). Dit is een multicenter 
cohort onderzoek en is ontworpen om prospectief de prognose na een beroerte op jonge 
leeftijd te bepalen en meer inzicht te geven in de etiologie van een TIA, herseninfarct en 
hersenbloeding bij patiënten tussen 18 en 49 jaar oud. Er wordt beoogd 1500 patiënten te 
includeren, welke elke 6 maanden gevolgd zullen worden voor tenminste 3 jaar.
De primaire uitkomstmaten zijn overlijden en het risico op nieuwe vasculaire ziekten. 
Secundaire uitkomstmaten zijn het risico op post-stroke epilepsie en cognitieve stoornissen. 
Daarnaast zullen bekende en minder bekende risicofactoren en potentiele acute trigger 
factoren onderzocht worden. Tevens zal het gebruik en continueren van secundaire preventie 
worden gedocumenteerd. De risico schattingen op nieuwe vasculaire events zouden gebruikt 
kunnen worden voor het ontwikkelen van een toekomstige interventie studie naar het starten 
en stoppen van secundaire preventie.
Conclusie 
De studies in deze thesis tonen aan de post-stroke epilepsie na een beroerte op jonge leeftijd 
een veel voorkomend probleem is en daarnaast is geassocieerd met een slechtere prognose 
in de zin van overlijden, functioneren en cognitief functioneren.
Daarnaast hebben we laten zien dat patiënten een levenslang risico houden op het 
ontwikkelen van nieuwe vasculaire ziekten, met name patiënten met traditionele vasculaire 
risicofactoren hebben dit hoge risico. Deze chronische vasculaire gevolgen van een beroerte 
op jonge leeftijd worden verder benadrukt door de hogere proportie patiënten  die cerebrale 
micro-angiopathieën ontwikkeld in vergelijking met controlepersonen. Toekomstig 
onderzoek zou gericht moeten zijn op de rol van secundaire preventie bij patiënten die op 
jongere leeftijd een beroerte doormaken.
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List of abbreviations
A1 List of abbreviations
AED = anti-epileptic drug
ANOVA = analysis of variance
ANCOVA = analysis of covariance
CI = confidence interval 
CT = computed tomography
ECG = electrocardiogram
FUTURE = Follow-up of Transient ischemic attack and stroke patients and Unelucidated Risk 
factor Evaluation
HR = hazard ratio
ICH = intracerebral haemorrhage
ILAE = International League Against Epilepsy
IQR = interquartile range
IS = ischemic stroke
MRI = magnetic resonance imaging
mRS = modified Rankin Scale
NIHSS = National Institutes of Health Stroke Scale
ODYSSEY = Observational Dutch Young Symptomatic StrokE studY
OR = odds ratio
SD = standard deviation
SPSS = statistical package for the social sciences
SVD = small vessel disease
TIA = transient ischemic attack
TOAST = Trial of Org 10172 in Acute Stroke Treatment
WMH = white matter hyperintensity
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Ik ben blij dat ik in jullie een gelijke heb gevonden in de liefde voor lekker borrelen. Bedankt 
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ben erg blij met jullie en kijk alweer uit naar ons volgende etentje.
Lieve Ellen en Daphne, wat ben ik trots dat jullie vandaag naast mij willen staan als mijn 
paranimfen. Ellen, al vanaf groep 3 van de basisschool dikke vriendinnen. Ondanks dat 
we allebei een totaal andere richting op zijn gegaan, wordt onze vriendschap alleen maar 
hechter. Ik waardeer onze goede gesprekken en je oprechte interesse enorm. Wat is het 
genieten om samen met onze Jaspers en kinderen te gaan kamperen of gewoon lekker te 
borrelen. Dankjewel voor je vriendschap.
Daphne al vanaf de middelbare school vriendinnen, maar in de jaren daarna is onze 
vriendschap alleen maar hechter geworden. Een studententijd zonder jou kan ik mij eigenlijk 
niet voorstellen. Ook al wonen we niet meer bij elkaar om de hoek, het is fijn om te weten dat 
je er altijd voor me bent. Bedankt voor je vriendschap.
Lieve schoonfamilie, wat fijn dat jullie er altijd voor ons zijn. Bedankt voor jullie steun, maar 
vooral ook voor de gezellige afleiding en de heerlijke zondagse wandelingen. Antonio en 
Marlies wat is het heerlijk om jullie te zien genieten van de kinderen. Teun en Morijntje, ik 
bewonder hoe jullie je dromen naleven, hopelijk kunnen we jullie volgend jaar komen 
opzoeken in Nieuw Zeeland. Jelle en Mirthe, wat is het leuk om jullie te hebben zien 
opgroeien, geniet van jullie studententijd.
Lieve Petra en Linda, mijn zusjes, wat ben ik trots op jullie. Petra ik bewonder jouw 
optimistische en nuchtere houding enorm. Wat vind ik het heerlijk om samen met Roy, 
Jasper en de kinderen te genieten van de leuke dingen in het leven. Linda jouw enthousiaste 
houding maakt mij altijd vrolijk. Helaas woon je nu wat verder weg en zien we elkaar niet zo 
vaak als ik zou willen. Een spelletjesmiddag samen met Roy en Chris is altijd genieten.
Lieve papa en mama, bedankt dat jullie er altijd voor mij zijn. Jullie hebben mij altijd de 
vrijheid en mogelijkheid gegeven me te ontwikkelen. Dankzij jullie ben ik geworden wie ik nu 
ben. Het is heerlijk om jullie te zien genieten van de kinderen en ik waardeer het heel erg dat 
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jullie altijd voor ons klaar staan. Mama dat jij de voorkant van dit boekje wilde ontwikkelen, 
was extra speciaal voor mij. Ik zeg het misschien niet vaak, maar ik hou van jullie.
Lieve Jasper, mijn maatje, mijn alles en de allerliefste papa voor onze kinderen. Bedankt 
dat jij er altijd voor mij bent; als ik het koud heb, zorg jij voor warme sokken, als ik me rot 
voel ben jij een luisterend oor. Ik waardeer je pragmatische oplossingen en bewonder je 
ondernemende karakter enorm. Een dag samen met jou en de kinderen, voelt als een dag 
vakantie. Ik hou van jou.
Lieve Daan en Lotte, met jullie is alles nog zoveel leuker. Ik kijk er naar uit om samen nog heel 
veel avonturen te gaan beleven.
Jasper, Daan en Lotte: 
‘it’s always better when we’re together’ (Jack Johnson)
191
Ap
pe
nd
ic
es
acknowLedgements / dankwoord
Appendices
192
193
Ap
pe
nd
ic
es
curricuLum vitae
A4 Curriculum Vitae
Renate Arntz was born on July 13th 1983 in Hengelo (Gld), the Netherlands. She graduated 
from secondary school at the Ludger College in Doetinchem in 2001. After passing her 
propaedeutic exam in ‘Pedagogische Wetenschappen’, she started medical school at the 
Radboud University Nijmegen in 2003. She performed a research internship under the 
supervision of Prof Dr. de Leeuw  entitled: ‘very long-term survival and vascular risk in patients 
with a previous young stroke’, which became a pilot study of the FUTURE study described 
in this thesis. Renate obtained her medical degree in February 2009. After this she started 
working as a resident in Neurology at the Neurology department of the Radboudumc and in 
September 2009 she started her specialization.  
In 2010 she started a PhD-traject on the prognosis of patients with a stroke at young age 
under the supervision of Prof Dr. de Leeuw, resulting in this thesis . In 2019 Renate hopes to 
finish her specialization.  Renate is married with Jasper en has 2 children Daan en Lotte.
Appendices
194
195
Ap
pe
nd
ic
es
List of pubLications 
A5 List of publications
1. Roy P.C. Kessels, Willem Sake Eikelboom, Pauline Schaapsmeerders, Noortje A.M.M. Maaijwee, 
Renate M. Arntz, Ewoud J. van Dijk, Frank-Erik de Leeuw. The effect of formal education on vascular 
cognitive impairment after stroke: A meta-analysis and study in young-stroke patients. Journal of 
the International Neuropsychological Society. 2016; in press
2. Renate M. Arntz, Mayte E. van Alebeek, Nathalie E. Synhaeve, Jeske van Pamelen, Noortje A.M.M. 
Maaijwee, Hennie Schoonderwaldt, Maureen J. van der Vlugt, Ewoud J. van Dijk, Loes c.A. Rutten-
Jacobs, Frank-Erik de Leeuw. The very long-term risk and predictors of recurrent ischaemic events 
after a stroke at a young age: The FUTURE study. European Stroke Journal. 2016; 1(4):337-345
3. Pauline Schaapsmeerders, Anil M. Tuladhar, Renate M. Arntz, Sieske Franssen, Noortje A.M.M. 
Maaijwee, Loes C. Rutten-Jacobs, Hennie C. Schoonderwaldt, Lucille D. Dorresteijn, Ewoud J. van 
Dijk, Roy P. Kessels, Frank-Erik de Leeuw. Remote lower white matter integrity increases the risk 
of long-term cognitive impairment after stroke in young adults. Stroke. 2016; 47(10):2517-2525
4. Renate M. Arntz, Steffen M.A. van den Broek, Inge W.M. van Uden, Mohsen Ghafoorian, Bram 
Platel, Loes C.A. Rutten-Jacobs, Noortje A.M.M. Maaijwee, Pauline Schaapsmeerders, Hennie C. 
Schoonderwaldt, Ewoud J. van Dijk, Frank-Erik de Leeuw. Accelerated development of cerebral 
small vessel disease in young stroke patients. Neurology. 2016; 87(12):1212-1219 
5. Nathalie E. Synhaeve, Mayte E. van Alebeek, Renate M. Arntz, Noortje A.M.M. Maaijwee, Loes C. 
Rutten-Jacobs, Hennie C. Schoonderwaldt, Paul L. de Kort, Maureen J. van der Vlugt, Ewoud J. van 
Dijk, Jack F. Wetzels, Frank-Erik de Leeuw. Kidney dysfunction increases mortality and incident 
events after young stroke: The FUTURE study. Cerebrovasc Dis. 2016; 42(3-4):224-31
6. Noortje A.M.M. Maaijwee, Indira tendolkar, Loes C. Rutten-Jacobs, Renate M. Arntz, Pauline 
Schaapsmeerders, Lucille D. Dorresteijn, Hennie C. Schoonderwaldt, Ewoud J. van Dijk, Frank-
Erik de Leeuw. Long-term depressive symptoms and anxiety after transiet ischaemic attack or 
ischaemic stroke in young adults. Euro J Neurol. 2016; 23(8):1262-1268
7. Nathalie E. Synhaeve, Renate M. Arntz, Mayte E. van Alebeek, Jeske van Pamelen, Noortje A.M.M. 
Maaijwee, Loes C. Rutten-Jacobs, Hennie C. Schoonderwaldt, Paul L. de Kort, Ewoud J. van Dijk, 
Frank-Erik de Leeuw. Women have a poorer very long-term functional outcome after stroke among 
adults aged 18-50 years: the FUTURE study. J Neurol. 2016; 23(6):1099-11105
Appendices
196
8. Pauline Schaapsmeerders, Anil M. Tuladhar, Noortje A.M.M. Maaijwee, Loes C. Rutten-Jacobs, 
Renate M. Arntz, Hennie C. Schoonderwaldt, Lucille D. Dorresteijn, Ewoud J. van Dijk, Roy P. 
Kessels, Frank-Erik de Leeuw. Lower ipsilateral hippocampal integrity after ischemic stroke in 
young adults: a long-term follow-up study. PloS One. 2015; 10(10):e0139772
9. Nathalie E. Synhaeve, Pauline Schaapsmeerders, Renate M. Arntz, Noortje A.M.M. Maaijwee, Loes 
C. Rutten-Jacobs, Hennie C. Schoonderwaldt, Lucille D. Dorresteijn, Paul L. de Kort, Ewoud J. van 
Dijk, Ro P. Kessels, Frank-Erik de Leeuw. Cognitive performance and poor long-term functional 
outcome after young stroke. Neurology. 2015; 85(9):776-782
10. Renate M. Arntz, Loes C. Rutten-Jacobs, Noortje A.M.M. Maaijwee, Hennie C. Schoonderwaldt, 
Lucille D. Dorresteijn, Ewoud J. van Dijk, Frank-Erik de Leeuw. Poststroke epilepsy is associated 
with a high mortality after a stroke at young age: follow-p of transient ischemic attack and stroke 
patients and unelucidated risk factor evaluation study. Stroke.2015; 46(8):2309-2311
11. Pauline Schaapsmeerders, Inge W.M. van Uden, Anil A.M. Tuladhar, Noortje A.M.M. Maaijwee, 
Ewoud J. van Dijk, Loes C.A. Rutten-Jacobs, Renate M. Arntz, Hennie C. Schoonderwaldt, Lucille 
D. Dorresteijn, Frank-Erik de Leeuw, Roy P.C. Kessels. Ipsilateral hippocampal atrophy is associated 
with long-term memory dysfunction after ischemic stroke in young adults. Hum Brain Mapp. 2015; 
36(7):2432-42
12. Loes C.A. Rutten-Jacobs, Renate M. Arntz, Noortje A.M.M. Maaijwee, Hennie C. Schoonderwaldt, 
Lucille D. Dorresteijn, Ewoud J. van Dijk, Frank-Erik de Leeuw. Cardiovascular disease is the main 
cause of long-term excess mortality after ischemic stroke in Young adults. Hypertension. 2015; 
65(3):670-675
13. Noortje A.M.M. Maaijwee, Renate M. Arntz, Loes C.A. Rutten-Jacobs, Pauline Schaapsmeerders, 
Hennie C. Schoonderwaldt, Ewoud J. van Dijk, Frank-Erik de Leeuw. Post-stroke fatigue and its 
association with poor functional outcome after stroke in young adults. J Neurol Neurosurg 
Psychiatry. 2015; 86(10):1120-1126
14. Loes C.A. Rutten-Jacobs, Noortje A.M.M. Maaijwee, Renate M. Arntz, Hennie C. Schoonderwaldt, 
Lucille D. Dorresteijn, Ewoud J. van Dijk, Frank-Erik de Leeuw. Clinical characteristics and 
outcome of intracerebral hemorrhage in young adults. J Neurol. 2014; 261(11):2143-2149
15. Noortje A.M.M. Maaijwee, Loes C.A. Rutten-Jacobs, Renate M. Arntz, Pauline Schaapsmeerders, 
Hennie C. Schoonderwaldt, Ewoud J. van Dijk, Frank-Erik de Leeuw. Long-term increased risk of 
unemployement after Young stroke: a long-term follow-up study. Neurology. 2014; 83(13):1132-1138
197
Ap
pe
nd
ic
es
List of pubLications 
16. Noortje A.M.M. Maaijwee, Pauline Schaapsmeerders, Loes C.A. Rutten-Jacobs, Renate M. Arntz, 
Hennie C. Schoonderwaldt, Ewoud J. van Dijk, Roy P.C. Kessels, Frank-Erik de Leeuw. Subjective 
cognitive failures after stroke in Young adults: prevalent but not related to cognitive impairment. J 
Neurol. 2014; 261(7)1300-1308
17. Renate M. Arntz, Mayte E. van Alebeek, Nathalie E. Synhaeve, Paul J. Brouwers, Gert W. van 
Dijk, Rob A. Gons, Tom den Heijer, Paul L. de Kort, Karlijn F. de Laat, Anouk G. van Norden, Sarah 
E. Vermeer, Maureen J. van der Vlugt, Roy P.C. Kessels, Ewoud J. van Dijk, Frank-Erik de Leeuw. 
Observational Dutch Young Symptomatic StrokEstudY (ODYSSEY): study rationale and protocol of 
a multicentre prospective cohort study. BMC Neurol. 2014; 14:55
18. Nathalie E. Synhaeve, Renate M. Arntz, Noortje A.M.M. Maaijwee, Loes C.A. Rutten-Jacobs, Hennie 
C. Schoonderwaldt, Lucille D. Dorresteijn, Paul L. de Kort, Ewoud J. van Dijk, Frank-Erik de Leeuw. 
Poor long-term functional outcome after stroke among adults aged 18-50 years: Follow-Up of 
Transient Ischemic Attack and Stroke Patients and Unelucidated Risk Factor Evaluation (FUTURE) 
study. Stroke. 2014; 45(4):1157-1160
19. Loes C.A. Rutten-Jacobs, Pim A. Keurlings, Renate M. Arntz, Noortje A.M.M. Maaijwee, Hennie C. 
Schoonderwaldt, Lucille D. Dorresteijn, Maureen J. van der Vlugt, Ewoud J. van Dijk, Frank-Erik 
de Leeuw. High incidence of diabetes after stroke in Young adults and risk of recurrent vascular 
events: the FUTURE study. PLoS One. 2014; 9(1):e87171
20. Renate M. Arntz, Noortje A.M.M. Maaijwee, Loes C.A. Rutten-Jacobs, Hennie C. Schoonderwaldt, 
Lucillie D. Dorresteijn, Ewoud J. van Dijk, Frank-Erik de Leeuw. Epilepsy after TIA or stroke in young 
patients impairs long-term functional outcome: the FUTURE Study. Neurology. 2013; 81(22):1907-1913
21. Loes C.A. Rutten-Jacobs, Noortje A.M.M. Maaijwee, Renate M. Arntz, Hennie C. Schoonderwaldt, 
Lucille D. Dorresteijn, Maureen J. van der Vlugt, Ewoud J. van Dijk, Frank-Erik de Leeuw. Ann Neurol. 
2013; 74(4):592-601
22. Pauline Schaapsmeerders, Noortje A.M.M. Maaijwee, Ewoud J. van Dijk, Loes C.A. Rutten-Jacobs, 
Renate M. Arntz, Hennie C. Schoonderwaldt, Lucille D. Dorresteijn, Roy P.C. Kessels, Frank-Erik de 
Leeuw. Stroke. 213; 44(6):1621-1628
23. Loes C.A. Rutten-Jacobs, Renate M. Arntz, Noortje A.M.M. Maaijwee, Hennie C. Schoonderwaldt, 
Lucille D. Dorresteijn, Ewoud J. van Dijk, Frank-Erik de Leeuw. Long-term mortality after stroke 
among adults aged 18-50 years. JAMA. 2013; 309(11):1136-1144
Appendices
198
24. Renate M. Arntz, Loes C.A. Rutten-Jacobs, Noortje A.M.M. Maaijwee, Hennie C. Schoonderwaldt, 
Lucille D. Dorresteijn, Ewoud J. van Dijk, Frank-Erik de Leeuw. Post-stroke epilepsy in young adults: 
a long-term follow-up study. PLoS One. 2013; 8(2):e55498
25. Loes C.A. Rutten-Jacobs, Noortje A.M.M. Maaijwee, Renate M. Arntz, Mayte E. van Alebeek, Pauline 
Schaapsmeerders, Hennie C. Schoonderwaldt, Lucille D. Dorresteijn, Sebastiaan Overeem, Gea 
Drost, Mirian C. Janssen, Waander L. Van Heerde, Roy P.C. Kessels, Marcel P. Zwiers, David G. Norris, 
Maureen J. van der Vlugt, Ewoud J. van Dijk, Frank-Erik de Leeuw. Risk factors and prognosis of 
Young stroke. The FUTURE study: a prospective cohort study. Study rationale and protocol. BMC 
Neurol. 2011; 11:109
Submitted
1. Renate M. Arntz, Pauline Schaapsmeerders, Noortje A.M.M. Maaijwee, Loes C.A. Rutten-Jacobs, 
Hennie C. Schoonderwaldt, Lucille D. Dorresteijn, Roy P.C. Kessels, Ewoud J. van Dijk, Frank-Erik de 
Leeuw. Post-stroke epilepsy after a stroke at young age is associated with cognitive performance. 
The FUTURE study. Submitted
2. Mayte E. van Alebeek, Renate M. Arntz, Nathalie E. Synhaeve, Noortje A.M.M. Maaijwee, Hennie C. 
Schoonderwaldt, Maureen J. van der Vlugt, Ewoud J. van dijk, Loes C.A. Rutten-Jacobs, Frank-eErik 
de Leeuw. Risk factors and mechanisms of stroke in Young Adults: The FUTURE-study. Submitted
3. Mayte E. van Alebeek, Myrthe de Vrijer, Loes C.A. Rutten-Jacobs, Renate M. Arntz, Noortje A.M.M. 
Maaijwee, Nathalie E. Synhaeve, Hennie C. Schoonderwaldt, Ewoud J. van Dijk, Roel de Heus, 
Frank-Erik de Leeuw. Pregnancy complications after stroke in young women: the FUTURE-study. 
Submitted
199
Ap
pe
nd
ic
es
List of pubLications 
Appendices
200
201
Ap
pe
nd
ic
es
dissertations of the disorders of movement research group, nijmegen
A6 Dissertations of the disorders of movement research group, Nijmegen 
 
Parkinson Center Nijmegen (ParC)
•   Jasper E. Visser. The basal ganglia and postural control. Radboud University Nijmegen, 17 
June 2008
•   Maaike Bakker. Supraspinal control of walking: lessons from motor imagery. Radboud 
University Nijmegen, 27 May 2009
•   W. Farid Abdo. Parkinsonism: possible solutions to a diagnostic challenge. Radboud 
University Nijmegen, 7 October 2009
•   Samyra H.J. Keus. Physiotherapy in Parkinson’s disease. Towards evidence-based practice. 
Leiden University, 29 April 2010
•   Lars B. Oude Nijhuis. Modulation of human balance reactions. Radboud University 
Nijmegen, 29 November 2010
•   Maarten J. Nijkrake. Improving the quality of allied health care in Parkinson’s disease 
through community-based networks: the ParkinsonNet health care concept. Radboud 
University Nijmegen, 29 November 2010
•   Rick C.G. Helmich. Cerebral reorganization in Parkinson’s disease. Radboud University 
Nijmegen, 24 May 2011
•   Charlotte A. Haaxma. New perspectives on preclinical and early stage Parkinson’s disease. 
Radboud University Nijmegen, 6 December 2011
•   Johanna G. Kalf. Drooling and dysphagia in Parkinson’s disease. Radboud University 
Nijmegen, 22 December 2011
•   Anke H. Snijders. Tackling freezing of gait in Parkinson’s disease. Radboud University 
Nijmegen,4 June 2012
•   Bart F.L. van Nuenen. Cerebral reorganization in premotor parkinsonism. Radboud 
University Nijmegen, 22 November 2012
•   Wandana Nanhoe-Mahabier. Freezing of physical activity in Parkinson’s disease, the 
challenge to change behavior. Radboud University Nijmegen, 13 February 2013
•   Marlies van Nimwegen. Promotion of physical activity in Parkinson’s disease, the challenge 
to change behavior. Radboud University Nijmegen, 6 March 2013
•   Arlène D. Speelman. Promotion of physical activity in Parkinson’s disease, feasibility and 
effectiveness. Radboud University Nijmegen, 6 March 2013
•   Tjitske Boonstra. The contribution of each leg to bipedal balance control. University Twente, 
6 June 2013
•   Marjolein A van der Marck. The Many faces of Parkinson’s disease: towards a multifaceted 
approach? Radboud University Nijmegen, 10 January 2014
•   Katrijn Smulders. Cognitive control of gait and balance in patients with chronic stroke and 
Parkinson’s disease. Radboud University Nijmegen, 21 May 2014
•   Marjolein B. Aerts. Improving diagnostic accuracy in parkinsonism. Radboud University 
Nijmegen, 27 June 2014 
Appendices
202
•   Maartje Louter. Sleep in Parkinson’s disease. A focus on nocturnal movements. Radboud 
University Nijmegen, 13 February 2015
•   Frederick Anton Meijer. Clinical Application of Brain MRI in Parkinsonism: From Basic to 
Advanced Imaging, Radboud University Nijmegen, 23 June 2015
•   Jorik Nonnekes. Balance and gait in neurodegenerative disease: what startle tells us about 
motor control, Radboud University Nijmegen, 2 September 2015
•   Martijn van der Eijk. Patient-centered care in Parkinson’s disease. Radboud University 
Nijmegen, 1 December 2015
•   Ingrid Sturkenboom. Occupational therapy for people with Parkinson’s disease: towards 
evidence-informed care. Radboud University Nijmegen, 11 February 2016
•   Merel M. van Gilst. Sleep benefit in Parkinson’s disease. Radboud University Nijmegen, 13 
April 2016
•   Arno M. Janssen. Transcranial magnetic stimulation - measuring and modeling in health 
and disease. Radboud University Nijmegen, 2 June 2016
Non-Parkinsonian disorders of movement
•   Sacha Vermeer. Clinical and genetic characterization of autosomal recessive 
cerebellarataxias. Radboud University Nijmegen, 5 April 2012
•   Susanne T. de Bot. Hereditary spastic paraplegias in the Netherlands. Radboud University 
Nijmegen, 20 December 2013
•   Catherine C.S. Delnooz. Unraveling primary focal dystonia. A treatment update and new 
pathophysiological insights. Radboud University Nijmegen, 7 January 2014
•   Ella M.R. Fonteyn. Falls, physiotherapy, and training in patients with degenerative ataxias. 
Radboud University Nijmegen, 29 June 2016.
Vascular disorders of movement – The Radboud Stroke centre
•   Liselore Snaphaan. Epidemiology of post stroke behavioral consequences. Radboud 
University Nijmegen, 12 March 2010
•   Karlijn F. de Laat. Motor performance in individuals with cerebral small vessel disease: an 
MRI study. Radboud University Nijmegen, 29 November 2011
•   Anouk G.W. van Norden. Cognitive function in elderly individuals with cerebral small vessel 
disease. An MRI study. Radboud University Nijmegen, 30 November 2011
•   Rob Gons. Vascular risk factors in cerebral small vessel disease. A diffusion tensor imaging 
study. Radboud University Nijmegen, 10 December 2012
•   Loes C.A. Rutten-Jacobs. Long-term prognosis after stroke in young adults. Radboud 
University Nijmegen, 14 April 2014 
•   Noortje A.M.M. Maaijwee. Long-term neuropsychological and social consequences after 
stroke in young adults. Radboud University Nijmegen, 12 June 2015
•   Nathalie E. Synhaeve. Determinants of long-term functional prognosis after stroke in young 
adults. Radboud University Nijmegen, 28 September 2016
203
Ap
pe
nd
ic
es
dissertations of the disorders of movement research group, nijmegen
•   Anil M. Tuladhar. The disconnected brain: mechanisms of clinical symptoms in small vessel 
disease. Radboud University Nijmegen, 4 October 2016.
•   Pauline Schaapsmeerders. Long-term cognitive impairment after first-ever ischemic stroke 
in young adults: a neuroimaging study. Radboud University Nijmegen, 24 January 2017
•   Ingeborg W.M. van Uden. Behavioural consequences of cerebral small vessel disease; an 
MRI approach. Radboud University Nijmegen, 14 February 2017
Neuromuscular disorders of movement
•   Mireille van Beekvelt. Quantitative near infrared spectroscopy (NIRS) in human skeletal 
muscle. Radboud University Nijmegen, 24 April 2002
•   Johan Hiel. Ataxia telangiectasia and Nijmegen Breakage syndrome, neurological, 
immunological and genetic aspects. Radboud University Nijmegen, 23 April 2004
•   Gerald JD Hengstman. Myositis specific autoantibodies, specificity and clinical applications. 
Radboud University Nijmegen, 21 September 2005
•   M. Schillings. Fatigue in neuromuscular disorders and chronic fatigue syndrome, a 
neurophysiological approach. Radboud University Nijmegen, 23 November 2005
•   Bert de Swart. Speech therapy in patients with neuromuscular disorders and Parkinson’s 
disease. Diagnosis and treatment of dysarthria and dysphagia. Radboud University 
Nijmegen, 24 march 2006
•   J. Kalkman. From prevalence to predictors of fatigue in neuromuscular disorders. The 
building of a model. Radboud University Nijmegen, 31 October 2006
•   Nens van Alfen. Neuralgic amyotrophy. Radboud University Nijmegen, 1 November 2006
•   Gea Drost. High-density surface EMG, pathophysiological insights and clinical applications. 
Radboud University Nijmegen, 9 March 2007
•   Maria Helena van der Linden. Pertubations of gait and balance: a new experimental setup 
applied to patients with CMT type 1a. Radboud University Nijmegen, 6 October 2009
•   Jeroen Trip. Redefining the non-dystrophic myotonic syndromes. Radboud University 
Nijmegen, 22 January 2010
•   Corinne G.C. Horlings. A weak balance: balance and falls in patients with neuromuscular 
disorders. Radboud University Nijmegen, 1 April 2010
•   E. Cup. Occupational therapy, physical therapy and speech therapy for persons with 
neuromuscular diseases, an evidence based orientation. Radboud University Nijmegen, 5 
July 2011
•   Alide Tieleman. Myotonic dystrophy type 2, a newly diagnosed disease in the Netherlands. 
Radboud University Nijmegen, 15 July 2011
•   Nicol Voermans. Neuromuscular features of Ehlers-Danlos syndrome and Marfan syndrome. 
Radboud University Nijmegen, 2 September 2011
•   Allan Pieterse. Referral and indication for occupational therapy, physical therapy and 
speech- language therapy for persons with neuromuscular disorders. Radboud University 
Nijmegen, 13 February 2012
Appendices
204
•   Bart Smits. Chronic Progressive External Ophthalmoplegia more than meets the eye. 
Radboud University Nijmegen, 5 June 2012
•   Ilse Arts. Muscle ultrasonography in ALS. Radboud University Nijmegen, 31 October 2012
•   M. Minis. Sustainability of work for persons with neuromuscular diseases. Radboud 
University Nijmegen, 13 November 2013
•   Willemijn Leen. Glucose transporter – 1 deficiency syndrome. Radboud University Nijmegen, 
26 June 2014
•   Femke Seesing. Shared Medical appointments for neuromuscular patients and their 
partners. Radboud University Nijmegen, 2 September 2016
•   Nicole Voet. Aerobic exercise and cognitive behavioral therapy in fascioscapulohumeral 
dystrophy: a model based approach. Radboud University Nijmegen , 14 October 2016. 
•   Barbara Jansen. Magnetic Resonance Imaging signature of fascioscapulohumeral muscular 
dystrophy. Radboud University Nijmegen, 14 September 2016
•   Noortje Rijken. Balance and gait in FSHD relations with individual muscle involvement. 
Radboud University Nijmegen, 8 December 2015.
205
Ap
pe
nd
ic
es
dissertations of the disorders of movement research group, nijmegen
Appendices
206
207
Ap
pe
nd
ic
es
donders graduate schooL for cognitive neuroscience
A7 Donders Graduate School for Cognitive Neuroscience
For a successful research Institute, it is vital to train the next generation of young scientists. 
To achieve this goal, the Donders Institute for Brain, Cognition and Behaviour established the 
Donders Graduate School for Cognitive Neuroscience (DGCN), which was officially recognised 
as a national graduate school in 2009. The Graduate School covers training at both Master’s 
and PhD level and provides an excellent educational context fully aligned with the research 
programme of the Donders Institute. 
The school successfully attracts highly talented national and international students in 
biology, physics, psycholinguistics, psychology, behavioral science, medicine and related 
disciplines. Selective admission and assessment centers guarantee the enrolment of the 
best and most motivated students.
The DGCN tracks the career of PhD graduates carefully. More than 50% of PhD alumni show 
a continuation in academia with postdoc positions at top institutes worldwide, e.g. Stanford 
University, University of Oxford, University of Cambridge, UCL London, MPI Leipzig, Hanyang 
University in South Korea, NTNU Norway, University of Illinois, North Western University, 
Northeastern University in Boston, ETH Zürich, University of Vienna etc.. Positions outside 
academia spread among the following sectors: specialists in a medical environment, 
mainly in genetics, geriatrics, psychiatry and neurology. Specialists in a psychological 
environment, e.g. as specialist in neuropsychology, psychological diagnostics or therapy. 
Positions in higher education as coordinators or lecturers. A smaller percentage enters 
business as research consultants, analysts or head of research and development. Fewer 
graduates  stay in a research environment as lab coordinators, technical support or policy 
advisors. Upcoming possibilities are positions in the IT sector and management position 
in pharmaceutical industry. In general, the PhDs graduates almost invariably continue with 
high-quality positions that play an important role in our knowledge economy.
For more information on the DGCN as well as past and upcoming defenses please visit:
http://www.ru.nl/donders/graduate-school/donders-graduate/ 

